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 This dissertation uses two different approaches to the identification of inhibitors 
of Mycobacterium tuberculosis (Mtb) - a structure-based drug discovery approach and a 
high-throughput screening of natural product libraries based approach. In the structure-
based approach the structural characterization of Mtb s-adenosylhomocysteine hydrolase 
(SAHH) enzyme as a drug target using x-ray crystallography is described. Crystal 
structure of Mtb SAHH protein was solved in complex with the substrate adenosine and 
the product s-adenosylhomocysteine at 1.6 Å and 2.0 Å resolutions respectively. 
Additionally, crystal structures of Mtb SAHH in complex with inhibitors, aristeromycine 
(ARI), deazaadenosine and 2-fluoroadenosine were also solved at 2.1 Å, 2.2 Å and 2.4 Å 
resolutions respectively. The complex structure with ARI is the first structure reported 
and confirms the proposed type-I mechanism based inhibition of Mtb SAHH. 
Differences in the active site of Mtb SAHH and human SAHH are identified and the 
design of lead molecules selective towards the Mtb SAHH is described using the 
fragment-based lead identification method. The structural characterization of a nitrogen 
regulatory Mtb PII protein is also described. The crystal structure of Mtb PII protein in 
the apo form and adenosine triphosphate bound form was solved to 1.4 Å and 2.4 Å 
resolutions respectively. The crystal structures suggest an alternate annotation of the 
protein as GlnK and also provide insights into the mechanism of action of the Mtb PII 
protein. The Mtb PII protein plays a versatile role in the nitrogen regulatory pathway of 




Through the alternate approach to drug discovery involving the screening of 
natural products for whole-cell bactericidal activity a novel natural product inhibitor of 
Mycobacterium tuberculosis and Mycobacterium smegmatis was isolated, purified and 
characterized. Challenges encountered in the large scale data processing involving high-
throughput screening and high performance liquid chromatography (HPLC) / mass 
spectrometric analysis in terms of prioritizing the crude extracts, the HPLC fractions and 
the masses corresponding to the compounds of interest are listed and methods for data 
reduction and efficient data analysis are presented. The successful identification of a 
novel natural product with inhibitory activity towards the human and yeast proteasome 
in an in-vitro enzyme assay is also described. The novel polyphenolic natural product 
was discovered through the screening of crude extracts in a proteasome targeted in vitro 
enzyme assay followed by activity based fractionation, isolation, purification and 
structure elucidation using analytical techniques. A technique for the chemical 
derivatization of a mixture of unknown secondary metabolites in crude extracts is also 
described, which can potentially increase the existing diversity of natural product 
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INTRODUCTION AND LITERATURE REVIEW 
  
The History of Tuberculosis 
Tuberculosis (TB) is the most widely recognized and mortal diseases known to 
mankind. Throughout history TB has been responsible for more deaths than the plague, 
leprosy or HIV with an estimated 1 billion fatalities due to TB in the past two centuries 
1. TB has aptly been labeled as the “Captain of all these men of death” 2. TB is also one 
of the most ancient diseases known to affect humans. Lesions characteristic of TB in the 
skeletal remains of humans in the eastern Mediterranean from 7000 BC showed that 
prehistoric humans suffered from the disease. Many early Egyptian mummies from 3000 
– 2400 BCE have been found with spinal lesions that are characteristic of spinal 
tuberculosis (also called Pott’s disease) 3. Hence it is certain that tuberculosis was widely 
prevalent in predynastic and early dynastic Egypt. Ancient Indians, in 2000 BCE 
described a disease called “Yakshma”, the causes of which included over-fatigue, 
sorrow, fasting and pregnancy. Today we know that fatigue, depression and pregnancy 
can all lead to a weakening of the immune system thus making an individual more 
susceptible to active tuberculosis infection. Symptoms of the disease were similar to 
those found in consumptive patients in modern times.  
Throughout the middle ages the disease continued to wreak havoc in the 
European countries. According to John Locke, a well-known physician, twenty percent 




cases of TB per 100,000 people were reported every year in London in the seventeenth 
century 5. Early European explorers to Africa, Americas and the Arctic are believed to 
have carried the disease with them and infected the indigenous population who had very 
little natural resistance to the disease. South East Asia was also not left untouched as TB 
followed the European colonizers. By 1900 approximately 10 % of all the deaths 
reported in Indian cities were due to TB. 
Over the centuries, before the real cause of TB was yet to be discovered, the 
disease was known by many different names, like scrofula (tuberculosis of the lymph 
glands of the neck), tabes, consumption or phthisis (Greek for consumption), because the 
patients displayed characteristic traits of TB like losing excessive body weight and 
getting wasted. It has been called the white plague due of the pale appearance of the 
patient and the scale of the epidemic. Symptoms of the disease have been well 
documented in medical literature since the time of Hippocrates in 460 BCE. Fever, night 
sweats, shortness of breath, pain in the side or shoulder, excessive coughing with blood 
stained sputum are common symptoms associated with pulmonary TB. 
Franciscus Delaboe Sylvius coined the word “tubercles” for the first time in 1679 
in his book Opera medica, due to the presence of characteristic nodules that were found 
in the bodily organs, especially the lungs, of the victims of consumption. These tubercles 
were described to resemble millet seeds and would sometimes be hard as bones and at 
other times soft with a cheese like appearance. This similarity with millet seeds would 
later lead to the term ‘miliary’ tuberculosis, to describe a generalized infection 




the body, like the membranes surrounding the brain (meningeal tuberculosis), kidney 
tissues (renal tuberculosis), the spine (Pott’s disease or spinal tuberculosis) and lupus 
(tuberculosis of the skin). Since the disease could infect virtually any part of the body, 
physicians of the seventeenth and eighteenth century were inclined to regard these 
symptoms as signs of unrelated diseases and even went to the extent of separating one 
type of infection from the other. For example, it was hard to imagine that the scrofulous 
glands in the neck were caused due to the same pathological condition that also caused 
the ulcerations in the lungs. The famous French physician Laënnec, through his studies 
on hundreds of consumptive cadavers, was able to postulate that the infiltrations, 
tubercles and cavities caused by the ulcers were all expressions of a single disease.  
Shortly, in 1839, J.L. Schönlein suggested that the disease officially be called as 
tuberculosis and used to cover all forms of phthisis. 
The cause of the disease, however, was still unknown and debated until the 
eighteenth century. Indeed many prominent physicians of the time discounted the very 
contagious nature of phthisis. This was attributed to the fact that a person exposed to the 
sputum or infected tissue of another tuberculous patient did not always immediately 
develop the symptoms characteristic of the disease. We now know that the disease 
causing organisms may lay dormant inside a person’s macrophages for many years 
before flaring up into its active form. Not surprisingly the more popular belief of the 
time was that the disease was passed on genetically from parents to their offspring, 
making some population predisposed to it. This was derived by the observation that if 




develop the disease in their lifetimes. Indeed successive generations of a tuberculous 
person have been found to be particularly vulnerable to the disease given credence to the 
theory that TB must be hereditary. It took many years and much effort by physicians like 
William Budd, Thomas Young and Jean-Antoine Villemin to establish the contagion 
theory of tuberculosis among the medical professionals. Jean-Antoine Villemin, a 
French army surgeon, is credited for being able to demonstrate for the first time that 
phthisis could be transmitted from human to cattle and other animals. Villemin went on 
to show that the material taken from the scrofula could be used to induce ulceration and 
cavity formation in the lungs of another animal, thus proving that scrofula and 
tuberculosis were etiologically the same. With advances in microbiological techniques 
the germ theory slowly gained prominence in the world of medicine. It was back in 1722 
that the English physician, Benjamin Marten had for the first time proposed the germ 
theory when he said that diseases were caused by … “some certain species of 
Animalculae or wonderfully minute living creatures that, by their peculiar shape or 
disagreeable parts are inimicable to our nature;” But limited by the insufficient 
technological advancement of his time, Marten was unable to experimentally 
demonstrate the relevance of his germ theory and wisely left it to the future generation of 
scientists to “… carry the theory much farther than I have done and … bring it to 
absolute demonstration in an extensive degree” . It was not until one hundred and sixty 
years later in 1862 that Robert Koch used the germ theory to actually demonstrate the 
constant presence of bacteria in the tuberculous tissues of human as well as livestock.  




the disease in other normal animals by inoculating the culture into them. Koch’s work 
was of great significance because man was finally able to confront the real enemy he 
was up against.  
The next big step was to detect the presence of the infection in patients. Since the 
symptoms of TB appear only when the disease has progressed to an advanced stage, 
detecting the infection early was crucial to treatment. Incidentally all the currently 
available detection methods were discovered more or less by accident. In attempting to 
find a cure against TB, Koch derived a glycerine extract of the tubercle bacillus and 
named it tuberculin. While this discovery was widely publicized, it was immediately 
evident that tuberculin was not a cure against TB. However it found use as a test to 
determine the presence of tuberculosis infection in patients. Today the Mantoux skin test 
used worldwide for the detection of tuberculosis infection consists of a purified protein 
derivative (ppd) of the tuberculin. The accidental discovery of X rays by Roentgen in 
1895 also provided a way to look directly into the lungs of a patient to detect the 
tuberculous lesions long before the symptoms appear in the patient. 
 
Cause of TB and Early Treatment Methods 
After it was identified as a single disease in the 1820s, the disease got its name as 
‘tuberculosis’ in 1839 by Dr. J. L. SchÖnlein. The bacillus causing TB was first 
identified by Robert Koch in 1882 as tubercle bacillus and later termed Mycobacterium 




infection site in the human body; however Mtb can infect virtually any part of the body 
including the spine, brain and skin. 
Consumptives were recommended a healthy diet, lots of fluid, physical exercise 
and fresh air. During the Middle Ages many European consumptives found relief when 
they removed themselves from the cold and damp English weather to warm, bright and 
sunny climate of the Mediterranean countries. One superstitious yet popular treatment 
method in the Middle Ages was to be touched by a king. The French and English Kings 
were believed to possess a divine healing power to cure people with scrofulous glands in 
the neck. This ritualistic healing process was performed in large ceremonies, where the 
kings touched the patients mostly suffering from scrofula. While the ritual was started in 
the fifth century, it continued till as late as the eighteenth century by Queen Anne. 
Scrofula, being an indolent form of the disease, usually resolved by itself, leading 
credence to the popularity of the phrase - “royal touch”. Cod-liver oil was first 
prescribed by Dr. C. J. Blasius Williams and since then has been widely recommended 
by physicians as a dietary supplement of tuberculosis patients 6. The patients frequently 
sought opium to calm the continuous coughing and to ease the diarrhea and pain caused 
by intestinal tuberculosis. Studies conducted in the early twentieth century showed that 
animal protein consumed in the form of meat offered enhanced resistance against active 
tuberculosis 7. While this claim has not been substantially proved or disproved, it is 
generally agreed upon that poor nutrition contributes to greater susceptibility to 
tuberculosis. In 1822, a physician named James Carson suggested the use of artificial 




involved introducing air into the chest cavity by making incisions into the thorax on the 
infected side of the lungs. This allowed the collapse of the affected lobes thereby healing 
the patient. Other similar methods like thoracoplasty 8 and pneumoperitoneum 9 were 
soon developed based on the same principle of collapsing the infected lungs. 
Many physicians in the eighteenth and early nineteenth century believed in the 
doctrine that pure air, pure water and pure food that are essential for a healthy living 
were somehow also curative to consumptive patients. Doctors were recommending long 
walks and horse rides in the open air to patients suffering from consumption. However, 
it was not until 1854 that a German physician Hermann Brehmer started and popularized 
the concept of sanatorium. Brehmer, a student of J. L. Schönlein opened the first 
sanatorium in Görbersdorf for treating tuberculous patients. Others were soon 
established all over Europe. Edward Livingston Trudeau, a physician and himself a 
tuberculosis patient established the first sanatoriums in America in 1882 after he read 
about the success of Brehmer’s sanatorium treatment in Germany. Treatment methods in 
these sanatoriums consisted of nothing more than good food, fresh air and plenty of rest. 
Other prevention and treatment methods of tuberculosis included quarantine, good 
sanitary practices and exposure to fresh air.  
 
Modern Treatment Methods 
Based on the success of vaccines against the small pox and rabies virus, it was 
believed that a similar vaccine could be developed to immunize people against 




to inject into guinea pigs and people, including himself. The extract, which he called 
“tuberculin”, was tolerated well by individuals who were not previously infected by the 
tubercle bacilli but elicited a strong allergic reaction in people who were previously 
exposed to infection. Although tuberculin was heralded as a breakthrough in the fight 
against tuberculosis by the scientific community, it was soon evident that tuberculin was 
not the ‘magic bullet’ that everyone was looking for. It killed more people than it cured.  
Moreover it did not immunize against a future infection. Although Koch’s work fell into 
discredit as a touted cure for tuberculosis, tuberculin is still in use in a modified form as 
a method for the early diagnosis of tuberculosis infection. Undaunted by the failure of 
tuberculin to cure or immunize against TB, other microbiologists continued their work 
on developing a vaccine against TB. Leon Charles Albert Calmette and his assistant Jean 
Marie Camille Guérin started working on a tuberculosis vaccine in 1900. They isolated a 
strain of bovine tubercle bacilli and cultured it in a medium containing ox bile. After 
many subsequent cultures in the media a change in the morphology of the bacillus was 
noted. The colonies containing the microorganism were smoother and smaller than those 
containing the virulent strains of the same microorganisms. When they inoculated guinea 
pigs and rabbits with this culture, the animals did not get sick. Therefore Calmette and 
Guérin concluded that they had achieved a strain of the tubercle bacilli of low virulence. 
After reculturing the vaccine strain over two hundred times they observed that the 
bacillus was unable to produce the disease in cows, horses and monkeys. They called it 
the Bacilli Bilié Calmette-Guérin strain which later became the BCG vaccine. On July 




charité in Paris. The child did not develop any signs of TB and was healthy for the rest 
of its life. This event marked the beginning of man’s first successful attempt to bring the 
spread of TB under control. Although the effectiveness of TB varied from country to 
country, BCG gained increasing acceptance in the world and today it is generally 
accepted as a good immunization technique against TB. Back in the twentieth century, in 
the absence of any other known cure against TB, BCG stood out as mankind’s only 
weapon against the onslaught of a growing TB epidemic. 
Since the beginning of the twentieth century investigations had started into the 
discovery and development of antibacterial chemotherapeutic agents. Arsphenamine, an 
arsenic containing small molecule synthesized in 1909 was the first antibacterial drug, 
and was used in the treatment of syphilis. Promin, a sulfur containing drug, synthesized 
in 1940 by W. H. Feldman was reported to have a mild activity against tuberculosis in 
guinea pigs 10,11. Another compound called promizole was also synthesized and had 
similar activity but less toxicity than promin 12. While synthetic molecules have been 
used in antibacterial chemotherapy, nature has provided us with some of the best 
antimicrobials known. So it was also in the case of tuberculosis that nature came to the 
rescue. Streptomycin, a natural product isolated from soil bacteria that belongs to the 
genus Actinomycetes, ultimately proved to be highly effective in killing the pathogen. 
Albert Schatz, a graduate student and his mentor, Selman Abraham Waksman spent 
many years isolating secondary metabolites from actinomycetes and studying their 
antitubercular activities. Streptomycin was isolated from a strain of actinomyces griseus 




activity against tubercle bacilli, it was also much less toxic compared to other known 
antitubercular drugs. Soon other antibiotics like oxytetracycline 14, viomycin 15 and 
cycloserine 16, derived from different species of Streptomyces were found to be active 
against tuberculosis. On the other hand, research on the development of synthetic 
antibiotics continued and a number of drugs like, para aminosalicylic acid 17, isonicotinic 
acid hydrazide (isoniazid) 18,19 and pyrazinamide, with good antitubercular activities 
were reported. Other drugs like rifampin, kanamycin and ethambutol were subsequently 
discovered. It was also observed that different TB drugs taken together were more 
effective than single drugs by themselves due to synergy 20,21. 
Today drug treatment against TB consists of a cocktail of drugs taken over a 
period of time ranging from six months to one year. Ethambutol, isoniazid, pyrazinamide 
and rifampin are considered as first line of drugs as these are the most effective against 
TB (Source – National Institute of Allergy and Infectious Diseases (NIAID)). In many 
countries a second and third line of drugs are also administered to TB patients. The 
second-line drugs include aminoglycosides like amikacin and kanamycin, polypeptides 
like capreomycin, viomycin and enviomycin, fluoroquinolones like ciprofloxacin, 
levofloxacin and moxifloxacin, and thioamides like ethionamide and prothionamide. A 
third-line of drugs may consist of rifabutin, macrolides like clarithromycin, linezolid, 
thioacetazone, thioridazine, arginine, vitamin D and R207910. The second and third-line 
drugs are used either because these drugs are not as effective as the first line of drugs 
against Mtb, they are more toxic compared to the first line of drugs or because the first 




tuberculosis to the first line drugs may also prompt the usage of second-line or third-line 
of drugs (NIAID). 
Even though drug treatment exists, eradication of this ‘curable disease’ has been 
like a ‘mirage’. The disease has proved to be more than a match for all the drugs 
approved for treatment for various reasons. There are several reasons for the failure of 
drug treatment regimens. One of the reasons is the resurgence of drug resistant strains of 
the bacteria. Natural mutations exist in any random population of microorganisms that 
render a small population of the same resistant to the drugs. This is especially true with 
Mtb, which is known for its high mutation rate. Some drugs were more prone to develop 
drug resistance in the patients than others. For example, streptomycin, when it was 
discovered, was the best form of treatment against TB, however resistance to 
streptomycin soon began to appear and it had to be taken out of the first-line of preferred 
drugs. Poor patient compliance is another factor that has contributed to the rise in drug 
resistant strains of the bacteria. TB chemotherapy involves lengthy treatment regimens 
of six to twelve months. A lack of education about the mode of action of the antibiotics 
leads the patients to stop their treatment as soon as they start feeling better. High costs 
associated with the treatment also lead to a failure to comply with the treatment regimen 
in poor and developing countries. Since the antibiotic course is stopped abruptly, the 
pathogenic microorganisms see a suboptimal dose of the drugs and the treatment is 
unsuccessful in killing off the entire population of the microorganism. The surviving 
drug resistant pathogens begin to multiply in number and cause a drug resistant form of 




replicating Mtb cells, but are unable to reach and kill the persistent Mtb that survives in 
the macrophages. From a drug development perspective it is difficult to design drugs 
that can enter the macrophages as well as penetrate the thick lipid layers of Mtb. 
Today, the Center for Disease Control (CDC) lists TB as one of the world’s most 
deadly diseases with about 1.4 million TB related deaths per year worldwide. About 9 
million people get infected with the tubercle bacillus every year (Source – CDC). There 
are two forms of the infection – a latent infection and an active disease state. When an 
individual gets infected with Mtb, there is about one in ten chance that the person will 
develop the active form of the disease over the course of his lifetime. Nine times out of 
ten, the person carries a latent form of the infection showing no symptoms of the disease. 
What causes some people to remain symptom free while others to develop the disease is 
still not clearly understood. The change from the latent form to the active form has to do 
with the lifecycle of the bacillus inside a human body. Once inside the body, the tubercle 
bacilli are immediately attacked by the natural immune response of the individual and 
get engulfed by macrophages. Inside the macrophages the bacillus encounters a 
completely different and hostile environment, which leads to a drastic altering of the 
bacteria’s metabolic processes. The mycobacterium goes into a dormant state where it 
doesn’t grow actively but remains nested in macrophages. When external conditions lead 
to a weakening of the immune system, the bacteria seizes the opportunity and bursts out 
of the macrophage to begin its active life cycle. This is when the bacteria begin to divide 




leading causes of death by infectious diseases in immune-compromised people such as 
those with certain types of cancer or people infected with HIV. 
The Tuberculosis Structural Genomics Consortium (TBSGC) was initiated to 
streamline the process of drug discovery against Mtb 22. The goal of the consortium was 
to solve the three dimensional structures of proteins from Mtb that are considered 
important drug targets. The important drug targets could include those proteins found to 
be essential to the survival and growth of Mtb through gene knock-out studies, or the 
genes that are identified through comparisons of the whole genome sequencing of wild 
type and the drug resistant strains of Mtb genome. With the rapid improvements in 
technologies pertaining to gene cloning, protein expression, purification, crystallization 
and x- ray crystal structure determination, the consortium also aimed to solve the protein 
crystal structures in a high-throughput manner. Members of the consortium could apply 
their areas of technological expertise to collaborate with other members specializing in 
other areas of the protein structure determination process. Solving the crystal structure of 
proteins or enzymes that are known drug targets with known inhibitors, could help in 
understanding the mechanisms of inhibition and design new inhibitors or modify 
existing inhibitors that exhibit higher binding affinities by efficiently exploiting the 
hydrophobic, polar and electrostatic interactions in the active site. Nearly half of the 
approximately 4000 open-reading frames (ORFs) remain unannotated or wrongly 
annotated in the Mtb genome 23. Thus, apart from providing a structural basis for the 
drug discovery efforts, a secondary goal of the consortium was to identify the function of 




of important biochemical pathways in Mtb that can further fuel the drug discovery 
process by identifying new protein structures that may be of biological relevance in Mtb. 
Thus the defined goals of the consortium were; 
1. To construct a knowledge base to contribute to the understanding of Mtb 
pathogenesis and aid in drug design, 
2. To develop scalable technologies to make structural genomics research 
accessible to a larger number of researchers, 
3. To solve the structures of biologically important proteins as a basis for drug 
discovery efforts, and 
4. To demonstrate the benefits of a distributed consortium approach for large-
scale research 24. 
 
Strategies for Drug Discovery 
This dissertation uses two traditionally different but complementary drug 
development strategies to find inhibitors of Mycobacterium tuberculosis (Mtb), the cause 
of TB. TB, called the scourge of mankind, has gone from being completely untreatable 
to being on the verge of absolute control by the use of chemotherapy. For various 
reasons discussed above and in spite of numerous attempts made by the scientific and 
medical establishment to find a lasting cure, the eradication of TB has been out of reach. 
TB has reemerged as a major health concern in the twenty first century, especially in the 
developing countries but also in the countries of America and Europe. It is now again 




treatment regime against this opportunistic pathogen and also due to the unusually high 
mutation rate observed in Mtb that allows Mtb to develop resistance rapidly against drug 
therapy. New drugs are urgently needed to combat TB. 
In order to design and develop an effective and lasting therapy for the elimination 
of TB the drug discovery approach needs to be designed rationally rather than through 
random discoveries that have dominated the past century. A planned research results in a 
reduced amount of risk and serendipity in the discovery process. As Henderson points 
out that drug discovery process is no longer a ‘… random procedure in which inspired 
scientists, working around the clock, come upon breakthroughs in the middle of the 
night’ 25. Given the imminent threat posed by rapidly spreading XDR strains of TB, it is 
imperative that a rational drug discovery approach be employed to hasten the process of 
identifying good inhibitors and lead molecules. This dissertation will explore two 
fundamentally different but complimentary approaches to drug discovery. These are; 
1. Structure – based drug design approach and 
2. Screening of natural products extract libraries for inhibition 
 
The structure–based drug design approach, also called a target based approach, 
begins with the identification of a druggable target enzyme in the pathogen. Accurate 
knowledge of the three dimensional structure of the target enzyme and its catalytic active 
site is used to design small molecule ligands that can bind the target with high affinity 26. 
X-ray crystallography or NMR spectroscopic methods are typically used to elucidate the 




decade in the instrumentation and methods of macromolecular structure determination 
have resulted in an exponential growth in the availability of the structures of target 
proteins in the available databases 27,28. A structure guided medicinal chemistry approach 
is used to design the small molecule inhibitors of the target enzyme based on the 
knowledge of the active site architecture. Such inhibitors are predicted to be highly 
selective to the active site of the target of interest. 
The target enzymes are selected based on their essentiality to the survival of the 
microorganism in different growth conditions. Enzymes considered as virulence factors 
make an interesting drug target in this perspective as these are not essential to the 
microorganisms under normal growth conditions but are required to establish an 
infection in the host organism. Many enzymes involved in different metabolic and 
biosynthetic pathways have been successfully targeted for inhibition studies 29. The 
complete genome of Mtb has been sequenced and is available 30. The TB structural 
genomics consortium (TBSGC) pipeline was established to solve the crystal structures of 
as many proteins from the TB genome as possible in a high-throughput manner 22. The 
goal of the consortium is to have the structural information on all the potential protein 
targets available in a database 31. The three dimensional structure of the protein in its apo 
form and substrate / product bound form helps to identify the presence and orientation of 
the different domains, the active sites and the preferred oligomeric state of the protein. 
With a detailed knowledge of the enzyme activity, its active site architecture, the 
chemical environment afforded by the active site residues and using the structural 




inhibitors that can potentially bind in the enzyme’s active site and inhibit or alter its 
function. Based on the importance of an enzyme to the survival of the microorganism a 
loss of enzyme function can have a potentially detrimental cascading effect on one or 
more metabolic pathways of the organism ultimately resulting in cell death or cell 
growth arrest. As enzyme inhibitors are typically analogs of the substrate or product of 
the enzyme an effective inhibitor is one that binds with greater affinity than the 
enzyme’s natural substrates and is both specific and selective towards the targeted 
enzyme. 
Selectivity of an inhibitor to an enzyme arises when the designed inhibitor is 
unique to the active site of the targeted enzyme. For example, when developing 
inhibitors against protein kinases, it is important to consider the fact that there are many 
different types of kinases in an organism and that the active sites of most kinases are 
identical. Hence substrate analogs designed to inhibit one type of kinase may very well 
inhibit another kinase, making it a promiscuous inhibitor. 
The concern over inhibitor specificity arises when the host organism encodes a 
protein or an enzyme that is homologous to the enzyme being targeted in the pathogen. 
If the host’s as well as the pathogen’s enzyme are conserved through evolution, the 
architecture of the active site would also have evolved to encode similar amino acids to 
perform the enzymatic reaction. Thus an inhibitor designed to inhibit the reactive site of 
the pathogenic enzyme would follow the same mechanism to bind the host enzyme 
resulting in cytotoxicity issues. Essential enzymes in the pathogens that do not have a 




enzymes competing for specificity of the potential enzyme inhibitor. In the absence of 
such a scenario, differences are sought between the host and the pathogen enzymes. 
Such differences in the architecture of the active site or the amino acids involved in the 
activity are exploited to develop the inhibitors so that they have high affinity for the 
target enzyme in the pathogen while having the least possible affinity for the host 
enzyme. A series of inhibitors designed in this manner are typically tested in an in vitro 
assay with the host and pathogen enzymes and the minimum fifty percent inhibitory 
concentrations (IC50 values) are calculated for both enzymes. Minimum in vivo 
inhibitory concentrations (MIC) are also measured wherever appropriate. However a 
problem with the target based approach to drug design is that, while the inhibitors are 
designed based on the thermodynamic parameters affecting their interaction with the 
enzyme’s active site, not much consideration is given to the permeability of the 
inhibitors through the complex cell wall of the pathogenic organism. This is an inherent 
problem with the target based approach to drug design, where many potentially good 
inhibitor candidates are rendered useless due to their poor cell permeability. Chemical 
modifications carried out to increase cell permeability may also increase the in vitro IC50 
values, thus affecting the selectivity and specificity of the inhibitors. 
In the current research two key proteins functioning in different essential 
metabolic pathways of Mtb are described. The two pathways are; 
1. Methylation pathway and 




A brief introduction is provided for each pathway and the role of the selected 
target protein is described. 
 
The Methylation Pathway 
Methylation is central to the survival of a cell 32. Simply explained, methylation 
is the addition of a methyl group to a biomolecule. The biomolecule, called the acceptor, 
could be DNA, proteins or other biomolecules like phospholipids and secondary 
metabolites. S-adenosyl methionine (SAM) is the most common methyl donor used in 
methylation reactions. The reaction is also referred to as transmethylation. SAM is thus 
ubiquitous in the cell and is the second most frequently used cellular substrate of an 
enzyme after ATP 33. The methylation reactions are carried out enzymatically by methyl 
transferase enzymes. Numerous methyltransferases such as lysine methyltransferases, 
histone methyltransferases and DNA methyltransferases perform the methylation 
reactions in the cell to perform various cellular functions including quorum sensing 34, 
phospholipid biosynthesis 35 and DNA replication and repair 32.  
Methyl transferases play the central role in methylation pathway. As a methyl 
group from SAM is transferred on to the acceptor biomolecule, SAM is converted to s-
adenosyl homocysteine (SAH). SAH has a higher binding affinity for methyl 
transferases and is shown to be a potent feedback inhibitor of the transmethylation 
reaction. Thus, SAH needs to be eliminated from the cellular environment in order to 
facilitate continuation of the transmethylation process. An intracellular ratio of SAM to 




is processed by different methods. SAH can be hydrolysed by nucleoside phosphorylase 
into adenine and ribosyl homocysteine, or it is converted to s-inosyl homocysteine by 
methyl thioadenosine (MTA) / SAH deaminase (also called SAH aminohydrolase) 37, or 
it is hydrolysed to adenosine and homocysteine by SAH hydrolase (SAHH). Hydrolysis 
by SAHH leads to the formation of adenosine and homocysteine. The methylation 
pathway generates essential byproducts as each of the products mentioned above are fed 
back into other pathways like the purine salvage pathway, methionine biosynthesis, 
cysteine biosynthesis, taurine biosynthesis and α-ketobutyrate biosynthesis. 
Since methylation reactions are central to the survival of bacterial cells, enzymes 
involved in this pathway have been targeted for inhibition studies 38. For example, DNA 
methylation has been recognized as the driving force behind epigenetics with the 
methylation pattern often profoundly altered in cancer cells. Hence DNA methylation 
has been targeted for cancer chemotherapy 39. Enzymes of the purine salvage pathway 
have been targeted in plasmodium falciparum for the treatment of malaria 40. 
Methylenetetrahydrofolate reductase, a key enzyme in the methionine biosynthesis has 
also been targeted for cancer therapy 41. Similarly, inhibitors of SAHH have also been 
investigated for antiviral chemotherapy 42 and human coronary artery disease 43.  
SAHH represent a particularly good target in the methylation pathway because 
the enzyme is crucial to the maintenance of the intracellular SAM to SAH concentration. 
Inhibition of SAHH results in the accumulation of intracellular SAH, which in turn 
inhibits the methyltransferases, affecting the entire transmethylation pathway. 




deletion of the gene encoding SAHH caused embryonic lethality in mice 44. SAHH is 
also the only source of homocysteine (Hcy) in the cell and as Hcy is the precursor to the 
formation of cystathione, cycteine and taurine in the transsulfuration pathway, SAHH 
becomes an important checkpoint in the biosynthesis of these important metabolites. Mtb 
has no homologs of SAH deaminase or SAH halogenase. Mtb encodes for a putative 
SAH nucleosidase, which has 30 % protein sequence identity with the E. coli SAH 
nucleosidase. Mtb SAHH was also shown to be essential for growth in vitro and thus it 
represents a potential drug target in Mtb 45. 
 
The Pathway of Nitrogen Control 
 Nitrogen is essential to life regardless of the type of organism or the environment 
they grow in. Nitrogen is a component in some of the most basic molecules in the living 
cell such as nucleic acids, amino acids, cell wall constituents and other secondary 
metabolites. Microorganisms are constantly challenged for survival by a changing 
nitrogen environment. Thus microorganisms have developed complex and failsafe 
pathways for the regulation of nitrogen 46. E. coli is considered a model organism among 
prokaryotes whose nitrogen regulation system has been studied extensively 47. It is 
widely established that E. coli uses glutamine (Gln) levels as the nitrogen status and 2-
Oxoglutarate (2OG) levels as the carbon status of the cell 48. A drop in the Gln level or 
an increase in the 2OG level is perceived as a nitrogen deficient condition and 
mechanisms are immediately kicked into action to allow nitrogen to be taken up from 




Conversely, drop in 2OG levels or increase in Gln levels signal nitrogen excess. 
Consequently, the 2OG and Gln concentrations are closely monitored in the cell using a 
highly conserved and ancient set of nitrogen sensing proteins called PII 49,50. The PII 
constitutes a family of small proteins that work in tandem with other nitrogen regulatory 
pathway enzymes to convey the nitrogen status of the cell, ultimately controlling the 
action of glutamine synthetase / glutamine: 2-Oxoglutarate aminotransferase enzymes 
(GS/GOGAT) 47,51. 
The GS/GOGAT system plays key role in the nitrogen regulation, converting 
2OG to glutamate (Glu) and further on to Gln, which is then utilized by downstream 
pathways that incorporate the nitrogen 52. The action of GS is controlled by post 
translational modification as well as at the transcriptional level 53. In E. coli both modes 
of regulation have been shown to be dependent on a PII family protein called GlnB 54. 
A second homolog of the PII protein, GlnK, controls the cellular nitrogen levels 
by directly modulating the activity of an ammonium transporter, AmtB 55,56. AmtB is a 
membrane bound channel that allows the direct influx of ammonium into the cell 57,58. 
GlnK forms a complex with AmtB through its T-loop and blocks the channel, while 
uridylylated GlnK is unable to form complex with AmtB 59. 
There is high sequence and structural homology between GlnB and GlnK 
proteins. However, there are differentiating factors between the PII proteins. For 
instance, GlnK proteins carry a 310 helix at their C-terminal ends, which is absent in the 
GlnB proteins. Further, GlnB proteins bear a lysine (Lys) residue at the third position 




gene is typically found next to the amtB gene forming an amtB-glnK or glnK-amtB 
operon, while the glnB gene typically lies in an operon with glnA. 
Curiously, Mtb is found to carry a single homolog of the PII protein 60. The Mtb 
PII gene is found in the glnD-PII-amtB operon. The protein sequence consists of a Leu 
at the third position and Thr at the fifth position, both consistent with the E. coli GlnK 
protein. The Mtb glnD-PII-amtB operon was upregulated under conditions of nitrogen 
starvation and found to work independent of the GlnE and Gs nitrogen regulatory 
enzymes suggesting that PII plays an important role in nitrogen control in the 
mycobacteria through interactions with the AmtB and GlnD 61.  
 
Screening of Natural Products Extract Libraries for Inhibition 
An alternate strategy for drug discovery uses a high-throughput screening (HTS) 
approach. In this method large libraries of synthetic / combinatorial compounds or 
natural products are screened to search for lead compounds or classes of compounds 
against a select protein target in an in vitro assay or tested for whole-cell growth 
inhibition of microorganisms in a cell culture. The key to such HTS approach are the 
size and quality of the library of compounds used. Big pharmaceutical companies 
possess large chemical collection of molecules that can range in their size from one 
hundred thousand to a million molecules. The molecules are sourced from diverse areas 
like randomly generated individual chemicals in the laboratory, or arrays of biased 
chemical libraries of compounds developed using combinatorial chemistry, or natural 




vitro assay where the target is well characterized and biophysical information about the 
target active site is known, such libraries do provide a source of diversity in the 
screening process, that can lead to a chance discovery of a novel structural class of lead 
compounds that can be further explored. Libraries of random chemical entities, if 
sufficiently large, are capable of sampling the ‘chemical space’ and are especially useful 
in HTS efforts where not much structural information is available going into the 
experiment. Combinatorial chemistry approach is used to generate analogs of a 
particular structural scaffold by exploiting the functionalities existing in the core 
molecule 62. For example, if the core molecule has three functionalities and if each 
functional position can be modified with ten different monomers then potentially a 
library of one thousand such analogs can be generated using the ten monomers. 
Combinatorial chemistry technique thus emerged in the nineties as an efficient way of 
feeding the high-throughput screening libraries by generating large volumes of 
compounds based on a structural scaffold 62. Such libraries are useful in a biased 
structure guided assay where the scaffold of a lead molecule is already known. Natural 
product libraries, on the other hand, represent the widest collection of molecules that can 
be generated as these are sourced from nature which has evolved and perfected its 
synthetic methodologies over millions of years. In terms of drug discovery natural 
product sources remain unrivaled as the number of approved drugs originating from 
natural products out compete those originating via synthetic methodologies 63,64. The 
different sources of natural products include microorganisms like bacteria and fungi 




This dissertation will provide examples of high-throughput screening approach 
applied to in vivo (whole cell bactericidal) activity specifically against Mtb and M. 
smegmatis cells as well as in vitro assays directed against selected targets from Mtb. One 
of the main advantages of HTS studies on in vivo systems is that the cell permeability of 
the inhibitor is taken care of at the outset of the screening experiment as compounds 
exhibiting poor cell permeability are automatically screened out of the library. All the 
first-line therapy drugs currently used for TB like rifampicin, isoniazid, pyrazinamide 
and ethambutol were identified by this method of screening 71. Other factors affecting 
drug development like cytotoxicity can also be taken care of by designing appropriate 
screens to eliminate the cytotoxic compounds. For example the collection of compounds 
can be screened simultaneously against a human cell line or other eukaryotic models to 
test for promiscuity and hence cytotoxic properties. Compound exhibiting in vivo 
activity against the mycobacterial cells as well as the eukaryotic cells are considered as 
likely cytotoxic agents and eliminated from the screen. Once a library is narrowed down 
to a list of prioritized hits, the target for the hits can be identified by a number of 
methods like growing resistant mutants for the hits and employing whole genome 
sequencing to pin point the target gene or genes in the microorganism 72. Other methods 
include supplementing the cell culture medium with various secondary metabolites to 
determine which metabolites can rescue the culture from the bactericidal effects of the 
drug. Identifying such secondary metabolites provide useful insights into the metabolic 
pathways that the drug candidate might be targeting. Success of the high-throughput 




this method and are currently undergoing clinical trials for TB therapy, namely, SQ-109, 
OPC-67583, LL3858, TMC 207 and PA -824 73,74. 
The structure-based drug discovery and the high-throughput screening methods 
have their advantages as valid drug development approaches to identify an inhibitor or a 
lead molecule in the shortest possible time. At the same time the challenges encountered 
in one type of approach seem to have a solution in the other approach. Thus it appears 
that a combined approach incorporating the structure–based and the high–throughput 
screening based methods has the potential to complement each other and work 
synergistically to significantly reduce both the cost and time of developing useful 
pharmacological agents 75. In the forthcoming chapters, examples will be provided for 
each of the drug discovery approach, including the various experimental challenges 






MTB S-ADENOSYL-L-HOMOCYSTEINE HYDROLASE  
 
Background and Introduction 
S-adenosylhomocysteine hydrolase (SAHH) is a ubiquitous enzyme that 
catalyzes the reversible hydrolysis of s-adenosylhomocysteine (SAH) to adenosine and 
homocysteine (Hcy) in the presence of a bound NAD+ as cofactor. The mechanism of 
SAH hydrolysis was first reported in 1979 by Palmer and Abeles and is represented in 
Figure 1 76. The first step involves the oxidation of hydroxyl group at C3’ position of 
SAH to form a 3’ keto intermediate. In the first step NAD+ is converted to NADH. This 
is followed by the abstraction of a labile proton at the C4’ position to form a carbanion 
intermediate. Then the thioether linkage breaks to eliminate the homocysteine moiety 
and a 4’, 5’ didehydro-3’ keto adenosine intermediate is left at the active site. Michael 
addition of a water molecule across the 4’, 5’ double bond results in the formation of 3’ 
keto adenosine. This is then followed by reduction at the C3’ keto position to yield 
adenosine and the simultaneous conversion back of NADH to NAD+. Thus NAD+ is 
regenerated during every turnover to catalyze the next batch of SAH hydrolysis. SAHH, 
through its function regulates the intracellular concentrations of SAH, adenosine and 
____________ 
* Part of this chapter is reproduced with permission from “Crystal structures of 
Mycobacterium tuberculosis S-adenosyl-L-homocysteine hydrolase in ternary complex 
with substrate and inhibitors.” Reddy MC, Kuppan G, Shetty ND, Owen JL, Ioerger TR, 






homocysteine. Inhibition of SAHH results in the accumulation SAH inside the cell 
which in turn increases the concentration of SAM due to feedback inhibition of the 
methyl transferases by SAH. Concentrations of adenosine and Hcy are also reduced 
upon the inhibition of SAH hydrolysis. Thus SAHH inhibition perturbs not only the 
methylation cycle but also the purine salvage pathway and the transsulfuration pathway.  
While the methyl transferases have many copies, there is a single copy of the 
SAHH enzyme in most organisms. Being unique and centrally located in important 
metabolic pathways SAHH has traditionally been a good target for inhibition. For 
example; SAHH has been targeted for inhibition in hypercholesterolemia 77, malaria 78, 
Chagas disease 79, Cryptosporidiosis 80 and cancer 81. 
Mtb SAHH is encoded by the gene Rv3248c. It is a 54 Kd protein that is essential 
for in vitro growth of Mtb 45. Although it is down-regulated two- to three fold during 
starvation conditions in vitro 82, and is not significantly up- or down-regulated in 
activated macrophages 83, it appears to be up-regulated in infected mouse lung tissue 
(determined using promoter-trap experiments) 84, a condition which also shows up-










considered ‘‘druggable,’’ given the large number of nucleoside analogs with 




other ADO analogs 87. However, these are not considered clinically relevant due to 
cytotoxicity issues 88 (Figure 2). 
The activity of ADO analogs as competitive inhibitors can be rationalized through 
similar recognition and affinity compared to substrate, but inability to complete the 
reaction 85. For example, 2’,3’-dihydroxy-cyclopent-4’-enyl adenine (DHCeA) inhibits 
SAHH via a type-I mechanism 85 by oxidation of the 3’ hydroxyl to a 3’ keto group, 
which reduces the bound NAD+ to NADH, thus inactivating the enzyme 89.  This 
compound represents a family of carbocyclic pyrimidine nucleosides, like neplanocin A 
90, that form similar chemically-abortive complexes 91. ARI is also expected to inhibit 
SAHH via a type-I mechanism 92. Attempts have also been made to synthesize 
compounds exhibiting type-II inhibition (activation followed by covalent attachment to 
active site) 85. For example, 5’-carboxyldehyde and vinyl-fluoride derivatives of ADO 
appear to react with a protein nucleophile at the 5’ position 92. There are also more 
conventional reversible inhibitors, including acyclic analogs such as D-eritadenine, 
whose affinity appears to be due to reorganized hydrogen bonding, which locks the 
enzyme into a closed conformation 93. 
While SAHH is an essential enzyme, it is not unique to Mtb. Copies of SAHH 
gene exists in the human genome as well. The protein sequence identity between the 











enzymes, there is a risk of cross reactivity of designed Mtb SAHH inhibitors, inhibiting 
the human SAHH, and hence causing cytotoxicity. Hence one challenge was to design 




selectivity of the inhibitor to the target protein of interest. As mentioned earlier, a good 
starting point for designing inhibitors is by making analogs of the natural substrates or 
products of the enzyme. SAHH is a nucleotide binding protein and a typical genome 
encodes for many nucleotide binding proteins in the cell such as kinases and 
phosphorylases. Therefore nucleotide and nucleoside analogs suffer from the 
disadvantage that they may have affinity towards other ADO binding proteins and hence 
lose selectivity. 
The first step was to crystallize and solve the crystal structure of the Mtb SAHH. 
The crystal structure for SAHH has been solved for three different organisms to date, all 
eukaryotic: human, rat (Rattus rattus), and malaria (Plasmodium falciparum) 77,89,91,93-98. 
The Mtb SAHH structure would then be compared with the human and any other 
available SAHH structure to identify differences in or near the active site between the 
different structures. Such differences can then be exploited to design specific inhibitors 
of Mtb SAHH.  
 
Methods 
Cloning and Expression of Mtb SAHH 
 A 1.49 kb DNA fragment containing the SAHH gene (Rv3248c) was amplified by 
PCR from Mtb H37Rv genomic DNA as a template, using the following oligonucleotides 
as the forward and reverse primers, respectively:  
5’- AGA TGA AGC CAT ATG ACC GGA AAT TTG GTG ACC 3’  




The amplified DNA fragment was digested with NdeI and HindIII and subcloned in the 
corresponding restriction sites in a pET28b vector to yield an N-terminal 6 X (His) tag.  
The kanamycin resistant SAHH-pET28b vector was transformed into E. coli BL21 (DE3) 
cells, and grown to the mid-log exponential phase at 37°C in LB media (Difco).  Cells 
were induced at 18°C at an O.D600 of 0.8 with 1 mM IPTG and grown for 16 hrs. 
 
Purification of Mtb SAHH and Preparation of the Apo Enzyme 
The harvested cell pellet was resuspended in buffer containing 20 mM Tris-HCl 
pH 8.0, 10 mM imidazole, 0.5 M NaCl and 10 % glycerol with 1 mM 
phenylmethanesulfonyl fluoride and DNAse. The cells were lysed using French press.  
SAHH was purified on a Hi-Trap Ni2+ chelating metal affinity chromatography column 
(GE Healthcare).  The peak fractions were pooled and dialysed against 20 mM Tris pH 
8.0, 50 mM NaCl, 10 % glycerol, 1 mM dithiothreitol (DTT) and concentrated to 18 
mg/mL in an Amicon Ultra Centrifugal filter device (MILLIPORE). The enzyme was 
found to be about 95 % pure as observed on SDS PAGE.  
The purified enzyme was stripped of both forms of the dinucleotide to prepare an 
apo-enzyme. The apo-enzyme was made as described for the preparation of rat liver apo-
SAHH 99. It involved an acidic (pH 3.3) ammonium sulfate precipitation of the enzyme 
followed by re-suspension in a potassium phosphate buffer (pH 7.2) containing 5 mM 
DTT and 1 mM EDTA. The step was repeated a second time followed by precipitation 
with a neutral saturated ammonium sulfate solution. The precipitate was re-dissolved in 




collected by centrifugation and discarded. The apo-enzyme was inactive and could not 
catalyze the hydrolysis reaction by itself. Activity was reconstituted by incubating it with 
2 µM NAD+ for 10 min before carrying out the activity assay. The reconstituted holo-
enzyme was used for the enzyme activity assays. 
 
Crystallization 
 Crystallization screening of Mtb SAHH was performed using the sitting drop and 
hanging drop methods with Crystal Screen I and II, Index (Hampton Research) and 
Wizard I and II (Emerald Biosystems), as well as random screening kits (Lawrence 
Livermore National Laboratory) using a crystallization robot (Robbins Scientific). Initial 
crystallization screening was carried out with SAHH alone, and pre-incubated with ADO 
or an analog inhibitor for 30 min at a molar ratio of ~1:15. Crystals for ADO-, DZA-, and 
ARI- bound SAHH were obtained at 18°C when 1:1 protein:reservoir solution drops 
were equilibrated within a hanging drop against 500 uL of mother liquor solution 
containing 20% w/v polyethylene glycol (PEG) 1000, 200 mM imidazole (pH 8.0), and 
100 mM Ca(OAc)2. Crystals for 2FA-bound SAHH were obtained in the presence of 
mother liquor solution containing 0.2 M MgCl2, 0.1 M Tris pH 8.5 and 25% w/v PEG 
3350. Diffraction quality crystals were obtained after 3-4 days. To determine the 
structure of SAHH in complex with SAH, 10 mM SAH was co-crystallized with SAHH 






Data Collection, Structure Determination and Refinement 
 Crystals from a droplet were transferred directly to a cryoprotectant, N-paratone 
(Hampton Research). The crystals were mounted on nylon loops and flash-frozen in a 
liquid nitrogen stream at 100 K before data collection. The high resolution data of the 
ternary complexes of SAHH:ADO:NAD, SAHH:DZA:NAD, SAHH:2FA:NAD and 
SAHH:ARI:NAD were collected at beamline 19-ID on an Area Detector Systems 
Corporation Q315 area detector at the Advanced Photon Source, Argonne National 
Laboratory, Chicago, IL. The data were reduced using DENZO, and intensities were 
scaled with SCALEPACK 100. Integrated and scaled data indicated that Mtb SAHH 
belongs to the P21 space group. The ternary SAHH:ARI:NAD, SAHH:DZA:NAD, and 
SAHH:2FA:NAD complexes were crystallized in the same space group with similar cell 
dimensions. Solvent content calculations indicated the presence of a tetramer in the 
asymmetric unit 101. Data for SAHH:SAH co-crystals were also collected at APS on 
beamline 19-ID. The crystallographic data collection statistics are summarized in Table 
1.  
The crystal structures of Mtb SAHH bound with ADO or its analogs, ARI, 2FA, 
and DZA, have been determined to 1.60, 2.01, 2.42, and 2.20 Å, respectively. Attempts 
to crystallize apo SAHH did not yield diffraction quality crystals. The structures of the 
SAHH:ADO:NAD ternary complex of Mtb was solved by molecular replacement 
method, EPMR, using the human SAHH model (PDB ID: 1LI4) as a search model for the 
extending data from 25 to 3.5 Å 91. Complexes with DZA, 2FA, and ARI were solved by 




performed using REFMAC (5.02) 102. NCS restraints were applied for each domain of the 
model. After model building and fitting, bias-minimized electron density maps were 
obtained using Shake&wARP protocol 103. Model building was done using the programs 
XTALVIEW 104 and Coot 105. After repeated cycles of refinement and manual model 
building, water molecules were added to the structure using Xfit 104. The refinement 
continued with structure factors measuring 1.0 or better within the resolution range 30 
to 2.48 Å to reduce the effects of poorly measured reflections. At the final stage of the 
refinement, the NCS restraints were removed for the entire model. The refinement 
statistics and the model stereochemistry are summarized in Table 1. 
The SAHH:SAH:NAD complex structure was determined to a resolution of 2.0 
Å. Our best data showed overall completeness of 82.5% in the resolution range of 30 – 
2.0 Å. The low completeness may be attributed to the high crystal mosaisity (3.42). The 
data was processed using d*TREK 106. After running Shake&wARP, clear density in the 
unbiased map was observed contiguous with the 5’ carbon of the ADO, showing covalent 
attachment of additional atoms. Although positive density was apparent for most of the 
expected atoms of the HCY appendage, the density was not defined well enough to 
model the terminal atoms (amino and carboxylate groups). Therefore coordinates were 
only built and refined for C, C, and S. The model was refined with Refmac5, and the 







In vitro Assay 
HCY production was monitored using a spectrophotometric assay. Ellman’s 
reagent (5,5’-dithiobis(2-nitrobenzoic acid), or DTNB), was used to convert HCY into a 
HCY-TNB complex 109,110 with an absorption maximum at 412 nm. The reaction mixture 
contained 0.5 M apo-SAHH, 250 M NAD+, 100 M DTNB, and 50 mM potassium 
phosphate (pH 7.2) for a total assay volume of 200 L. Readings were observed on a 
POLARstar OPTIMA plate reader from BMG LABTECH, using an absorbance filter of 
410 nm. 
The apo-enzyme was incubated with cofactor NAD+ and the inhibitors (where 
applicable) for 10 min. The reaction was initiated by addition of 100 μM SAH. The 
reaction progress was measured for approximately 2 min. The linear region of the curve 
was used for measuring the initial velocity parameters. Inhibition constants were 
determined by assaying 10 nM to 1 mM concentrations of the inhibitors in the presence 






Table 1: Crystallographic and refinement statistics for Mtb SAHH. 
a Deviations from restraint targets. 
b Estimated standard uncertainty, diffraction precision index (DPI) based on free R 107. 
c Real space correlation coefficient, maximum likelihood mFo–DFc map, reported by 
REFMAC (5.02) 108.  
SAHH:ADO:NADSAHH:ARJ:NAD SAHH:2FA:NAD SAHH:AD3:NAD SAHH:ETA
Ligand Name Adenosine Aristeromycin2-fluoroadenosine3-deazaadenosines-adenosyl-L-homocysteine
Space Group P21 P21 P21 P21 P21
Wavelength (Å) 0.964 0.964 0.964 0.964 0.979
Temperature (K) 120 120 120 120 120
a (Å) 97.04 94.85 96.25 95.74 94.2
b (Å) 112.13 111.85 112.08 112.25 111.69
c (Å) 100.23 100.4 100.45 100.85 100.13
α 90 90 90 90 90
β 92.41 96.49 95.15 95.84 96.01
γ 90 90 90 90 90
Resolution (Å) 1.6 2.01 2.42 2.2 2
Highest resolution bin (Å) 1.50 - 1.60 2.01 - 2.11 2.42 - 2.49 2.2 - 2.26 2.0 - 2.05
Observed Reflections 325473 136379 74187 93598 114623
Unique Reflections 308888 129513 70373 89824 108886
% completeness 94.9 98.9 91.91 97.9 82.5
R (merge) 0.049 0.067 0.0809 0.057 0.127
<I/σI> 13.1 10.12 10.52 13.06 8.36
Vm (Matthew s Coefficient) 2.51 2.44 2.48 2.48 2.48
% Solvent 50.92 49.49 50.41 50.42 50.41
Refinement
Free R value, random, 5% 23.77 26.35 23.25 28.45 33.11
R value 20.04 21.2 21.21 21.19 26.02
protein residues 495 495 495 495 495
w ater molecules 1066 450 721 676 370
Rmsd bond length (Å)a 0.01 0.02 0.01 0.03 0.014
Rmsd bond angle (Å)a 1.38 1.88 0.83 2.42 1.63
Rmsd betw een subunits (Å) 0.1 0.23 0.31 0.27 0.22
Overall coordinate error (Å)b 0.099 0.19 0.35 0.27 0.32
RSCC (Refmac5 )c 0.95 0.951 0.948 0.947 0.893
Residues phi-psi angles
Most favored (%) 91.3 90.7 89 89.5 89.4
Allow ed (%) 8.5 8.9 10 10.1 10
Generously allow ed (%) 0.2 0.2 0.3 0.4 0.4





SAHH shares 90 % sequence homology between Mtb and Mycobacterium 
smegmatis. M. smegmatis has a shorter doubling time of approximately two to three 
hours compared to Mtb and has been used as a surrogate for Mtb 111. Therefore M. 
smegmatis cells were used to study the MIC values for the inhibitors using whole cell 
inhibition assay. All inhibitors were dissolved in water to a concentration of 256 mg/L. 
First, 100 L of Middlebrook 7H9 media (Difco) was dispensed into all 96 wells of a 
microtiter plate. Then 100 L of the 256 mg/L stock inhibitor solution were dispensed 
into column # 2. Two fold serial dilutions were carried out for each column up to column 
# 10, giving inhibitor concentrations from 256 mg/L to 0.5 mg/L. Column # 11, 
containing only media served as a negative control. M. smegmatis mc2155 112 cells, 
diluted in 7H9 media, were added to all the wells to a final O.D600 of 0.001. Cells were 
grown at 37˚C for 72 hrs. After this period, the wells were measured visually for cell 
growth. MIC values were determined where the wells had no visible bacterial growth. 
 
Fragment-Based Screening for Lead Discovery 
High-throughput screening (HTS) initiatives in the late twentieth century were 
designed to boost the rate of drug discovery rapidly and in a cost effective manner. The 
first HTS techniques were pioneered by industries to cope with their fast paced drug 
discovery process. The original screening libraries contained natural products in 
fermentation broths, which soon translated to dimethyl sulfoxide stocks of small 




compounds had an average mass of five hundred daltons with hydrogen bond acceptors 
≤ 10, hydrogen bond donors ≤ 5 and a cLogP ≤ 5. To satisfy the properties aspired in a 
hit molecule and at the same time efficiently cover the compound chemical space 
required the synthesis of large number of compounds. The hit rates were typically low at 
about 0.5 – 1 % of the screening libraries which further required the screening of tens of 
thousands of compounds to identify statistically significant number of hits to proceed to 
the next step in the lead development. It has also been observed that the quality of the 
hits are crucial to the success of a HTS program as the lead compounds go through 
relatively minor chemical changes before they are launched as drug candidates 114. The 
observation that despite a large increase in the number of screening compounds in the 
HTS libraries over the years, there has been no corresponding increase in the launch of 
new drugs suggests that the HTS methods are limited in their effectiveness. Better 
screening methods were pursued to increase the effectiveness of the screening while at 
the same time reducing the time and cost involved in the process. 
 In the past decade a fragment based approach has emerged as a viable alternative 
to HTS methods utilizing large number of compounds. The fragment-based lead 
discovery approach uses compounds with molecular weight less than three hundred 
daltons and contains a reduced number of functional groups with a lipophilicity value 
(ClogP) of < 3 115. The smaller size of the molecules makes it easier to sample the 
chemical space more efficiently while keeping the size of the compound library 
relatively small at hundreds or at the most thousands of compounds 116,117. The leads 




studies of the target protein in complex with these fragments give valuable information 
about the interactions of the small molecules with the active site residues. Such 
interactions can be used as starting points for structure guided chemical synthesis of 
larger lead compounds that have higher binding affinities, thus increasing ligand 
efficiency and selectivity 118. The building up of a lead molecule from fragments, also 
called tethering, has been shown to be an effective method for designing structure based 
inhibitors of target enzymes 119. 
 A 760 fragments library was used to screen against the Mtb SAHH enzyme. The 
fragment library was built using molecules with core structures that were consistently 
observed in lead compounds that exhibited drug like properties. This library was 
constructed in collaboration with the Prof. Chris Abell’s laboratory at the University of 
Cambridge. 
 
Differential Scanning Fluorimetry 
A quick, easy and inexpensive method to perform fragment-based screening 
against a purified protein is by using the differential scanning fluorimetry (DSF). DSF 
typically uses a real time polymerase chain reaction (RT-PCR) to monitor the 
temperature-dependent unfolding of the protein and determine its melting temperature 
120. The protein is incubated with a SYPRO® orange protein stain and subjected to a 
gradual increase in temperature. As the protein begins to unfold, SYPRO® orange reacts 
with exposed hydrophobic patches in the protein increasing its fluorescent intensity, 




interactions of the protein with small molecules cause a shift in the Tm (ΔTm), which 
indicates protein: ligand complex formation (Figure 3). While the shift in the melting 
temperature of the protein is indicative of a binding event of a ligand to the protein, the 
amount of shift in Tm is not an indicator of the binding affinity of the ligand. Other 
methods like saturation transfer difference NMR or isothermal calorimetry are employed 





Figure 3: Representative thermal shift assay showing a shift in melting temperature ΔT 






As mentioned above, the DSF experiment was performed using an RT-PCR 
instrument to gradually increase the temperature of the reaction mixture consisting of 
Mtb SAHH and SYPRO® Orange dye in a suitable buffer while the protein unfolding 
event was monitored at the excitation and emission wavelength of the dye. First step in 
the experiment was to optimize the buffer. A wide selection of buffers covering their 
optimal pH range was used as controls to optimize the melting temperature of the 
enzyme. The different buffer solutions used in the experiment were; citric acid (pH 2.2 – 
3.8), sodium acetate (pH 4.0 – 4.8), sodium citrate tribasic (pH 5.0 – 5.8), sodium 
cacodylate (pH 6.0 – 6.8), sodium salt of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (Na HEPES) (pH 7.0 – 7.8), Tris (pH 8.0 – 8.8), 3-(Cyclohexylamino)-2-hydroxy-
1-propanesulfonic acid (CAPSO) (pH 9.0 – 9.8) and 3-(Cyclohexylamino)-1-
propanesulfonic acid (CAPS) (pH 10.0 – 11.0) 
The experimental set up was as described in the protocol suggested by Niesen et 
al., 121. To optimize the buffer conditions, Mtb SAHH at a final concentration of 4 µM 
was aliquoted into each assay well of a 96 well PCR plate. The different buffer 
concentrations were maintained at 0.2 mM final concentration. 1 µL DMSO was added 
to each well, which was replaced by the same amount of a fragment solution in DMSO 
during the actual fragment screening. SYPRO Orange dye which is obtained as a 5000 X 
concentrated solution was diluted in distilled water 500 times to a 10 X stock 
concentration. The 10 X dye solution was aliquoted to yield a 2.5 X final concentration 
in a final assay volume of 20 µL per well. The PCR plate was firmly sealed with a 




down the assay components and to eliminate any bubble formed during the pipetting 
steps. The RT PCR temperature settings were set to increase from 25 °C to 99 °C at the 
rate of 0.5 °C per minute. The excitation and emission of the SYPRO Orange dye was 
monitored at 492 nm and 610 nm respectively. 
Once the suitable buffer was established the same experiment was run in the 
presence of the fragment library, while keeping the buffer constant. 1 µl of the DMSO 
was replaced by 1 µL of the fragment solution which was maintained as a 100 mM 
DMSO stock in a storage plate. Thus the final concentration of the fragment in the 20 µL 
assay volume was 5 mM. 
 
Saturation Transfer Difference NMR 
Saturation transfer difference nuclear magnetic resonance (STD-NMR) has been 
effectively used to detect the enzyme – ligand interactions 122. In this technique the 
protein is selectively irradiated by Gaussian pulses causing saturation of the protein 
resonances, which is transferred to a bound ligand through intermolecular 1H – 1H cross 
relaxation. This is the on-resonance spectrum. Through exchange between bound and 
free ligand states the saturation is transported to solution and detected by subtracting a 





Figure 4: Principle of STD NMR. Cartoon depicting the transfer of saturation from 





The STD NMR was measured in a buffer solution containing 20 mM Tris pH 7.5 
and 50 mM sodium chloride. Mtb SAHH was pre incubated with ADO and NAD+. A 
master mix of the enzyme at ~ 220 µM stock concentration with the buffer solution was 
prepared containing 10 % deuterated water. The fragments were added at a concentration 
such that the enzyme: fragment concentration was maintained at a ratio of 1: 100. The 
fragment stock solutions were prepared in 100 % DMSO. The final assay mixture 
consisted of 20 mM Tris pH 7.5, 50 mM sodium chloride, 30 µM Mtb SAHH, 3 mM 
fragment molecule and 10 % D2O. In order to confirm the binding of a fragment to the 











keeping the fragment concentration constant. Accordingly molar excess of ADO was 
used at 10 fold, 100 fold and a 1000 fold concentration of the enzyme, while maintaining 
a 100 fold excess of the fragment. Thus, to an assay containing 30 µM Mtb SAHH, ADO 
was added at 300 µM, 3 mM and 30 mM concentrations, while the fragment was 
maintained at a final concentration of 3 mM. 
 
Results and Discussion 
Crystal structure of Mtb SAHH 
Mtb SAHH crystallized as a homotetramer in the space group P21.  Each subunit 
of Mtb SAHH (495 residues) consists of two  domains (Figure 5), as observed in 
previous structures, with domain I being a substrate-binding catalytic domain and 
domain II being a dinucleotide-binding domain (Rossmann fold). Each subunit is bound 
to one NAD+ molecule. Domain I consists of residues 11-247 plus 423-466 (281 total), 
and domain II consists of residues 248-422 (175 total). In addition, there is a C-terminal 
extension of 29 residues (467- 495) observed in SAHH from other organisms (except 
Archaea, where it is truncated by 8 residues) 123 that covers the NAD- binding site in an 
adjacent subunit. This interaction is complemented by the other subunit in a local two-
fold symmetry, making the tetramer a “dimer of dimers” (Figure 6). Upon a dimer 
formation (between chains A and B, for example (Figure 6)), ~5,700 Å of surface area is 
buried within each subunit, whereas a total of only ~3,440 Å of surface area is buried 
between chain A and the other two subunits (C and D) in the tetramer combined. The N-




extension found in Mtb and other prokaryotic sequences but not seen in eukaryotes; 
residues 11-19 form an additional -strand that packs against and extends the edge of the 





Figure 5: A single subunit of Mtb SAHH. The bound ADO and NAD+ are shown in 
stick representation with the atoms colored by elements. Molecular graphics images 
were produced using the UCSF Chimera package from the Resource for Biocomputing, 
Visualization, and Informatics at the University of California, San Francisco (supported 





Figure 6: A tetramer of Mtb SAHH. The bound ADO and NAD+ are shown in stick 
representation. Subunits A and B form a dimer and subunits C and D form a dimer, 




Mtb SAHH bound to NAD+ and Ado 
The Mtb SAHH was crystallized in the presence of the product Adenosine (Ado) 
and the cofactor NAD+ to look at the specific interactions of Ado with residues in the 
substrate binding domain. Comparison with the human SAHH, the crystal structure of 
which was also solved in complex with Ado, revealed no significant differences in the 





Figure 7: Superposition of Mtb and human SAHH active sites. The Mtb SAHH residues 
are shown in cyan and the human SAHH residues are shown in magenta. ADO is shown 




Mtb SAHH structure superimposes well on previously determined ligand-bound 
SAHH structures. The backbone C RMSD between the Mtb SAHH:ADO structure and 
the ADO-complexed structure from P. falciparum (PDB ID: 1V8B) (55% amino acid 
identity) is 0.84 Å (over 461 residues, or 94% of the sequence), as determined by SSM 
125. Similarly, the RMSD to the human SAHH (PDB ID: 1A7A) is 0.77 Å over 422 
residues, and the RMSD to the rat SAHH (PDB ID: 1KY5) is 0.90 Å over 415 residues. 
A superposition of the backbones of these four enzymes is shown in Figure 8.The 
domains are in a “closed” conformation, with the hinge between domains flexed by ~17 














four structures reported herein were complexed with a product or an inhibitor).There is a 
9-residue insertion (residues 109-117) that is unique to Actinobacteria 127, but this occurs 





Figure 8: Superposition of Mtb SAHH (violet) with human (red, 1A7A), rat (cyan, 
1KY5), and P. falciparum SAHH (yellow, 1V8B). The bound ADO and NAD+ from the 
Mtb structure are shown for reference. The 37- residue insertion in the Mtb and 
Plasmodium structures can be seen forming a strand-turn-helix at the surface (upper left, 





 Domain II binds NAD+ in a similar fashion to that observed in all previous 




Rossmann fold because of variation in the topological connections of the  core 89. 
Specific interactions with NAD+ include the side-chains of Thr20, Thr21, Asn253, 
Val286, Thr219, Thr220, Thr221, Thr338, Asn340, Thr304, Glu305, Ile306, Asn310 and 
Ile343, as well as numerous backbone atoms. All are conserved identically between 
human and Mtb SAHH, except Asn340 contacting the adenine ring, which replaces 
Cys278 in human SAHH. In addition, several residues from the C-terminal tail of an 
adjacent subunit make contact with the NAD+, covering over the binding site. These 
include Tyr493 and Lys489 (from subunit B), which hydrogen bond with the 
diphosphate and ribose moieties, respectively. 
 The Mtb SAHH structure has a 37-residue insertion (residues 167-203) that is 
observed in other prokaryotic but not mammalian sequences 127. The insertion extends 
helix 10 (human SAHH numbering 89) by two turns, and then forms an anti-parallel 
strand-turn-helix (see Figure 8) that packs on the surface of domain I, before re-joining 
helix 11. The insertion is similar to that observed in the P. falciparum structure (PDB 
ID: 1V8B 97). However, in 1V8B, helix 10 is extended by one additional turn before 
the strand begins, so they do not perfectly superimpose (Figure 8). The insertion 
structure lies on the surface of the substrate binding domain of a subunit and does not 
interact with adjacent subunits (i.e. does not influence packing of the tetramer). The 
insertion residues are far away from the active site (at least 12.7 Å away from the ADO 













The ADO-binding portion of the active site (Figure 9) looks similar to that of 
previous structures from other organisms complexed with ADO analogs. The active site 
is enclosed in a buried cavity approximately 14 x 9 Å in size, with the nicotinamide ring 
of NAD+ forming part of the boundary (packing against the substrate ribosyl ring, where 
it oxidizes and reduces C3’). All of the residues thought to be catalytically important are 
conserved, including Lys248 and His69 (equivalent to Lys185 and His54 in the rat 
numbering). The adenine ring is surrounded by hydrophobic residues: Leu68, Thr71, 
Gln73, Leu410, Met421, and Phe425. Ionizable residues Asp156, Asp252, Lys248 and 
Glu218 interact with the hydroxyls of the ribose. His69 and His363 form hydrogen-
bonds with the 5’ hydroxyl (2.82 and 2.69 Å, respectively). The only residue that is not 
perfectly conserved is a substitution of Glu58 (rat) by Gln73 in Mtb SAHH, both of 
which form a hydrogen bond with the N6 amino group on the adenine ring. In either case 
the carbonyl functional group on the side chain of Gln73 or Glu59 made hydrogen 
bonding interactions with the N6 amino group on Ado and did not represent an avenue 
for the design of a novel inhibitor specific towards the Mtb SAHH. 
 
Mtb SAHH bound to NAD+ and Inhibitors 
Mtb SAHH was crystallized with three known inhibitors of SAHH in other 
organisms to study their modes of inhibitory actions. These were Aristeromycin (ARI), 
2-Fluoroadenosine (2FA) and 3-Deazaadenosine (DZA) at resolutions of 2.01 Å, 2.42 Å, 
and 2.20 Å, respectively and all exhibited very similar binding-site geometry, with no 




Figure 10: Active sites of Mtb SAHH bound to the inhibitors ARI, 2FA, DZA and the 






structure had RMSD values of 0.18, 0.22, and 0.25 Å for complexes with ARI, 2FA, and 
DZA, respectively. 
The complex with ARI (Figure 10) is the first crystal structure of SAHH to be 
solved with 3’keto aristeromycin. The ribosyl ring oxygen is replaced with a carbon 
atom in ARI, which is in van der Waals contact with Leu410 (3.65 Å), as in the ADO 
complex. Thus no significant hydrogen bonds observed in the other crystal structures 
were disrupted by this substitution. His69 and His363 still form hydrogen bonds with the 
5’ hydroxyl group of ADO. Importantly, C3’ is observed to be planar, consistent with 
O3’ being oxidized to the keto form. This confirms the prediction based on the proposed 
mechanism of action for ARI (type-I inhibitor, activated by NAD+) 85. This abortive 
complex bears resemblance to the complex of rat SAHH with 3’-keto adenosine (PDB 
ID: 1KY5) 96, in which C3’ is also planar. O3’ nonetheless continues to hydrogen bond 
with the nearby Lys248 side-chain, which is close enough (3.23 Å) to abstract a proton, 
as well as Thr219 (2.82 Å). ARI strongly inhibits the Mtb SAHH enzyme, with an IC50 















IC50’s were determined by enzyme assay; MIC represents minimum inhibitory 
concentration against M. smegmatis MC2155 cells in a whole-cell assay. LogP values 
(estimated partition coefficients) were determined by the XLogP v2.0 method of Wang 




This is commensurate with inhibition activity reported for ARI against SAHH 
from other organisms (1.1 M vs. H. sapiens, 3.1 M vs. P. falciparum 97). The strong 
inhibitory activity of ARI can be explained based on the mechanism. The proton 
abstraction from C4’ of ADO is assisted by the presence of an electronegative keto 
group on one side (at the C3’) and the ribosyl oxygen on the other side, which makes the 
C4’ proton more acidic. In ARI, the ribosyl oxygen is replaced by a less electronegative 
carbon and hence the intermediate gets stuck in the 3’ keto form. ARI was the most 
potent inhibitor of the three with an in vitro IC50 value of 0.2 uM. 
Fluoroadenosine (2FA) was chosen for the crystallization studies based on 
reports of good enzyme inhibition by a similar molecule in the P. falciparum SAHH 
enzyme. The reported IC50 value for 2-Fluoro noraristeromycin in P. falciparum SAHH 
is 13 uM. The complex with 2FA (Figure 10) is similar to that of ADO, including the 
pucker of the ribose ring, and the position of the adenine ring (RMSD = 0.22 Å).  The 
Compound IC50 MIC logP 
Adenosine ~500 µM not determined -1.6 
Aristeromycin 0.2 µM >100 µM -1.0 
2-fluoro adenosine 66 µM 32 µM -1.4 




fluoro group fits snuggly into a hydrophobic pocket, surrounded by Phe425, Leu68, and 
the backbone carbonyl of His69 (all at 3.13 - 3.30 Å distance).  However, the closest 
contact is with the hydroxyl group of Thr74, to which the fluorine atom forms a 
hydrogen bond (2.48 Å). While not as potent as ARI, 2FA exhibits better inhibition (66 
M IC50) compared to ADO, which was only found to inhibit the enzyme at 
concentrations above 500 M (i.e. via product inhibition) (Table 2). Thus the fluorine 
atom, which is the only chemical difference, has a significant effect on binding affinity. 
A similar IC50 for 2FA has been observed for the human SAHH homolog (63 M) 97. 
However, in P. falciparum, polar substitutions at the 2-position have been found to have 
increased relative inhibition, which was attributed to the replacement of Thr60 (human) 
by Cys59, creating additional space in the ADO-binding pocket 97. Importantly, 
however, in contrast to ARI, 2FA was found to have bacteriocidal activity against M. 
smegmatis in a whole-cell assay (MIC of 32 M, whereas ARI and DZA had MICs 
greater than 100 M, Table 2). Fluorine substituted nucleosides are known to be better 
antibacterials 129. This may reflect differences in cell-wall permeability or uptake 
mechanism (e.g. by an active nucleoside transporter, which might not recognize 
carbocyclic compounds like ARI). 
The complex with DZA (Figure 10) superposes almost perfectly onto the ADO 
complex, with an r.m.s.d. of 0.25 A° between the ligands. The N6 amino group still 
hydrogen bonds with the carbonyl oxygen atom on Gln73 (3.02 A°). The C3 position of 
the adenine ring (substituted for N3) is 3.63–4.52 A° away from Phe425, Leu68, and 




activity, which again could be due to inability of DZA to exploit the same uptake 
mechanism as 2FA. 
 
Comparison with the Human and P. falciparum SAHH 
Although the three inhibitor molecules that the Mtb SAHH was crystallized with 
had their advantages, none of them represented a truly specific inhibitor of Mtb SAHH. 
The primary reason for this was that the product binding site was identical to the Human 
SAHH and offered almost no avenues for the design of novel specific inhibitors of Mtb 
SAHH. Hence the focus had to be shifted to other areas of the enzyme. 
When the Mtb SAHH active site was overlaid on top of the P. falciparum SAHH 
active site, a curious observation was made (Figure 11). The active site residue His345 
of P. falciparum SAHH was flipped out away from the 5’ hydroxyl group of Ado. The 
analogous residue in Mtb SAHH, His363, on the other hand was pointing towards the 5’ 
hydroxyl group of Ado and was within hydrogen bonding distance. This curious 
observation lead to the hypothesis that His 363 of Mtb SAHH may act as a gate, opening 
up to allow access to the substrate, SAH to enter and the product, homocysteine (Hcy) to 
leave the active site. If this were true, the definition of the active site would have to be 
expanded to beyond just the Ado binding region and to include the region occupying the 
Hcy moiety of the substrate SAH as well. The Hcy binding region may unveil 
differences in the architecture of the active site between the Human and Mtb SAHH, 
thereby opening up avenues to exploit the differences and design more specific 





Figure 11: Superposition of the active sites of Mtb SAHH and Pf SAHH. The Mtb 
SAHH residues are shown in cyan and the Pf SAHH residues are shown in green color. 




Mtb SAHH bound to NAD+ and SAH 
To prove the above hypothesis, we crystallized Mtb SAHH in the presence of the 
substrate SAH. Since SAHH catalyzes the hydrolysis of SAH to Ado and Hcy in the 
presence of NAD+, whenever Mtb SAHH was crystallized with SAH the crystal structure 
showed the presence of Ado bound in the active site. Hence to get SAH to bind and 
remain in the active site required the soaking of SAHH crystals with high concentrations 
of SAH for short periods of time. Even then the occupancy of SAH in the active site was 
low and part of the homocysteine moiety was visible. Thus, SAH was modeled into the 
His345 of pf SAHH 















active site as ethylthioadenosine. With the truncated SAH in the active site the binding 
mode of the substrate was apparent and clearly exposed the residues involved in the 
binding of the Hcy moiety of the substrate. Density corresponding to the covalently-
attached HCY was observed in an access channel (Figure 10 and 12), adjacent to the 5’ 





Figure 12: SAH bound Mtb SAHH showing the access channel from the SAH to the 
surface of the protein. Human SAHH is overlaid and represented in magenta ribbons. 
Mtb SAHH is represented in cyan ribbon. The arrow indicates the access channel from 
the surface of the enzyme to the active site. The region of the access channel contributed 
by the 37 residue insertion region is highlighted and the prominent residues displayed. 







The channel is formed by rotation of the peptide plane between C363 and 
C364 by nearly 180°, swinging the imidazole ring of His363, which was at 2.69 Å 
from the 5’OH of ADO (SAHH:ADO:NAD structure), to 8.3 Å away from the Sof 
SAH (SAHH:SAH:NAD structure). This rotation opens up an access channel to the 
buried ADO-binding pocket that can accommodate the HCY moiety of the SAH 
substrate (compare Figures 13A and 13B). The channel leads to the surface 
(approximately 20 Å away), and could permit release of the liberated HCY while the rest 
of the catalytic cycle continues (i.e. hydration at C5’, followed by reduction of keto at 
C3’). S of SAH makes a hydrogen bond with His69 (3.03Å). The C and C atoms 
make van der Waals contacts (3.66 - 4.09Å) with Gly362, Thr219, Leu407, and the 
2’OH of the NAD. Phe364 is also close-by (4.65Å), contributing to the hydrophobicity 
of the pocket. Density was not well-defined enough to accurately determine coordinates 
for the terminal amino and carboxyl groups (and C) of HCY. Therefore the ligand was 
modeled, refined, and deposited in truncated form as ethylthioadenosine (ETA), which 
was taken to partially represent SAH. The C atom of HCY occupies the same position 
as the imidazole ring of His363 in the other complexes (Figure 13A and 13B). 
Therefore, to accommodate the binding of SAH, His363 is forced to flip out of the 
channel, rotating approximately 180 degrees around the backbone. Importantly, binding 
of SAH clearly proved the hypothesis that His363 acts as a gate to allow the substrate to 
bind. The side chain of His363 in the Mtb SAHH:SAH complex was rotated about 180 





Solvent Access Channel of Mtb SAHH 
The “opening up” of the His 363 gate revealed an additional active site for the 
binding of the Hcy moiety. Additionally, a solvent access channel that leads from the 
surface of the enzyme to the active site was also discovered. Comparisons could now be 
made among the residues lining up this additional active site and the adjoining access 
channel between the Mtb and Human SAHH. The crystal structure of Mtb SAHH was 
superimposed with the human homolog (PDB ID: 1A7A; complexed with DHCeA 89), 
and the active sites were examined to look for differences that could be exploited for 
design of selective inhibitors. All of the residues lining the ADO-binding pocket are 
identical between Mtb and human, limiting the possibilities for inhibitor design. This 
even includes Thr74, which is equivalent to Thr60 in human, though is replaced by 
Cys59 in P. falciparum and has been investigated for design of selective anti-malarial 
drugs 97. The only exception is Gln73, which replaces Glu59 in the human enzyme, 
though both form hydrogen bonds with the N6 amino group of the adenine moiety. 
While the residues binding the Hcy binding site were conserved between the Mtb and 
Human enzymes, there were significant differences in the access channel architecture 
between the Mtb and Human enzymes (Figures 12, 13A and 13C). When this structure 
is compared with the human SAHH, many residues lining the putative access channel 
(HCY-binding region) are also found to be conserved, including Cys93, Asn94, Tyr133, 
Gly157, Asp159, Phe364, and Arg406. The residues corresponding to Phe364 (Phe 302) 
and Arg 406 (Arg 343) in the human SAHH were previously proposed to be involved in 




homocysteine 126. Upon analysis of the access channel, the importance of the 37 residue 
insertion region in the Mtb SAHH, which until now was unclear, became apparent. This 
insertion segment completely changed the architecture of the active site of Mtb SAHH 
relative to the Human SAHH. Most notably, the mouth of the channel is significantly 
more constrained in Mtb than in human (compare Figures 12 and 13A and 13C). 
First, there are several substitutions by large, bulky hydrophobic residues that 
build up the wall of the channel, including Trp134 (Leu111 in human), Met162 
(Asn137), Arg225 (Asn163), Phe190, and Trp187. The latter two are contributed by the 
37-residue insertion (surface helix) that is unique to Mtb (relative to the human 
sequence). While in the Human SAHH the access channel is more exposed to the 
environment being shallow and funnel like, the insertion residues transformed the access 
channel in the Mtb SAHH into a deep and narrow entry way (Figure 12 and 13). In 
addition, the insertion region projects the side-chain of Glu186 into the access channel.  
The distance from the carboxylate group on Glu186 to the 5’OH on ADO is 12.66 Å 
(Figure 13B). While this residue was not initially considered relevant 97, its proximity to 
the HCY portion of SAH bound in the channel (approximately 10Å from C, see Figure 
13A) makes it a potentially important residue in the design of competitive inhibitors. 
Such differences in the access channel architecture between the Mtb and Human SAHH 
could be exploited to design small molecules that could bind in the narrow hydrophobic 
channel of the Mtb SAHH and block access to the active site. Such molecules could 




A   
B   
C   
Figure 13: Differences in human and Mtb forms of SAHH enzyme near the entrance to 
the access channel / HCY-binding site. 
A)  Mtb SAHH bound to ETA and NAD showing a constricted solvent access channel 
lined by residues from the insertion region. Residues 167-203 from strand-turn-helix 
insertion are shown in cyan, with Glu186 highlighted. The figures were made using 
SPOCK 130. 
B)  Surface of Mtb SAHH binding site with access channel closed off by His363, and 
ADO enclosed in a buried pocket. 
 
 
C)  Human SAHH complexed with DHCeA and NAD showing a shallower solvent 
access channel compared to the Mtb SAHH. The surface of the active site has been 
drawn without His301 to simulate the open form of the channel. His301 would 
presumably flip out of the channel, allowing the SAH substrate to bind and HCY cleaved 







Fragment Based Screening 
In order to search for small molecules that could bind in the narrow hydrophobic 
Mtb SAHH access channel a fragment based approach was used. The advantage of the 
fragment based screening over regular high throughput screening (HTS) approach using 
large chemical compound libraries is that a relatively smaller library of compounds can 
be used to cover the chemical space. A fragment library consists of compounds with 
molecular weights of ≤ 300 g/mol and the molecules have at the most three functional 
groups. As a result the fragments are capable of making fewer interactions than a larger 
molecule with higher molecular weight and much functionality, which in turn results in 
lower binding affinities for the fragments. The advantage however is that the smaller 
size allows the fragments to sample many different orientations in the active site and 
bind in its most optimal orientation whereas a large molecule would have no such 
flexibility in sampling the active site. 
The fragment library consisted of 750 fragments ranging in molecular weights 
from 96 Da to 364 Da. Screening was performed using the differential scanning 




buffer for subsequent screening. The different buffer conditions that were tested 
included citric acid (pH 2.2 – 3.8), sodium acetate (pH 4.0 – 4.8), sodium citrate tribasic 
(pH 5.0 – 5.8), sodium cacodylate (pH 6.0 – 6.8), sodium salt of 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (Na HEPES) (pH 7.0 – 7.8), Tris (pH 8.0 – 8.8), 3-
(Cyclohexylamino)-2-hydroxy-1-propanesulfonic acid (CAPSO) (pH 9.0 – 9.8) and 3-
(Cyclohexylamino)-1-propanesulfonic acid (CAPS) (pH 10.0 – 11.0). Through 
comparison of the melting temperature curves with all the buffers, the Na-HEPES buffer 
at pH 7.0 was found to be the most consistent. Na HEPES buffer facilitated a sharp 
unfolding event at 43.6 °C, which corresponded to the melting temperature of the 
protein. Keeping this buffer constant, the fragment library was then screened at 5 mM 
fragment concentration, while the enzyme concentration was empirically arrived at 10 
µM. Since the aim of this experiment was to identify a fragment (or fragments) that 
bound to the narrow access channel leading up to the active site, the assay was set up in 
the presence of the natural substrates of the enzyme, namely NAD+ and adenosine. 
Incubating the enzyme with the natural substrates was an attempt to ensure that the 
active site of the enzyme would be inaccessible to the fragment molecules being 
screened. As the fragments typically bind with low millimolar affinity, they would also 
be unable to replace the natural substrates in the active site. The only other binding site 
accessible for the fragment molecules was the narrow access channel. The hydrophobic 
nature of the residues lining the access channel and the small surface area available to 
bind the fragments were in sync with the lipophilic nature of the fragments and their 




While a number of fragment compounds were able to produce between two to 
five degrees shift in the melting temperature, the curious observation was that none of 
the 750 fragments produced a positive shift in the enzyme melting temperature. A 
positive shift in the melting temperature suggests that the protein unfolding event takes 
place at a higher temperature, which is indicative of a stabilizing interaction between the 
ligand and the protein. This is usually observed when a fragment binds in the active site 
of the protein, thereby stabilizing the protein’s native conformation. On the other hand, a 
negative shift in the melting temperature suggests that the protein – ligand interaction 
has a destabilizing effect on the protein’s native conformation. This is usually observed 
when the protein has to adopt an unnatural conformation in order to accommodate the 
ligand binding. The following seven fragments summarized in Table 3 were identified 
by DSF experiment to have the most shifts in Tm with Mtb SAHH enzyme. The 
interactions with hit fragments were reasoned as destabilizing to the protein because they 
lowered the melting temperature of the protein in the DSF studies. The change in 
melting temperature was ≥ 5 °C. A closer look at the fragment identified through DSF 
studies revealed that all of the molecules contain two closed ring systems. All fragments 
contained at least one six membered aromatic ring with either one or no substitution. The 
closed ring systems were either fused together or separated by a single bond as in a 
biaryl system. The polar substituents included amide, chlorine, hydroxyl, tifluoro methyl 






Table 3: Fragment hits identified through DSF studies along with their molecular 
structures, molecular weights and the ∆Tm values. 

















































Table 3: Continued. 








175.2 34.6 9 
 
 
Saturation transfer difference nuclear magnetic resonance spectroscopy (STD 
NMR) technique was used to validate the hits obtained through DSF studies. Each hit 
fragment was tested using the protocol mentioned in the methods section. 500 mM stock 
solutions of the hit fragments were prepared in 100 % DMSO and added to the separate 
NMR samples containing the enzyme and buffer to a final concentration of 3 mM. Out 
of the seven fragments, five fragments displayed 1H chemical shift in the STD NMR 
experiment. The five fragments were (#1) 2-(piperidin-1-yl)benzamide, (#2) (2-(3-
chlorophenyl)thiazol-4-yl)methanol, (#4) (2-(4-(trifluoromethyl)phenyl)thiazol-4-
yl)methanol, (#6) 1-(pyridin-3-yl)-2-p-tolylethanone and (#7) N-(2,3-dihydro-1H-inden-
5-yl)acetamide (see Table 3). An example of the normal 1H NMR spectrum and the STD 














































































































































































































































































































































The aim of fragment based screening was to find small hydrophobic molecules 
that could bind in the narrow access channel of the Mtb SAHH enzyme and block the 
channel thereby inhibiting the enzyme function. Therefore the fragment based screening 
through differential scanning fluorimetry was conducted with the enzyme preincubated 
with NAD+ and ADO. While the natural substrates occupied the active sites, it was 
reasoned that the weak binding fragment molecules possibly will interact with the 
residues in the access channel. In order to confirm the independent binding event of the 
fragments and the natural substrate ADO, a control experiment was performed where the 
concentration of ADO was varied while the concentration of the fragment 2-(piperidin-
1-yl)benzamide was kept constant at 3 mM (Figures 16, 17 and 18). Three different 
concentrations of ADO were used, 0.3 mM, 3 mM and 30 mM. It was observed that 
while the NMR peak intensity of ADO increased at increasing concentrations, the peaks 
corresponding to the aromatic protons on 2-(piperidin-1-yl)benzamide were observed at 






































































































































































































































































































































































































This observation provided evidence that the binding of adenosine and the 
fragment were two independent events. Analysis of the active site and the access channel 
leading up to the active site shows that the binding site for the fragment was most likely 
in the access channel. The side chains of Pro184 and Phe364 could provide the 
hydrophobic environment for nonbonding interactions with the aromatic ring of 2-
(piperidin-1-yl)benzamide while the polar side chains of Glu186 or Asp183 could make 
hydrogen bonding interactions with the amide functional group on 2-(piperidin-1-
yl)benzamide. Attempts to soak the fragments into crystals of Mtb SAHH or to co-
crystallize the fragments with Mtb SAHH were unsuccessful. The fragments identified in 
this research represent a good starting point to build upon the chemical scaffold to 
develop a lead compound with tight binding affinities. 
 
Conclusion 
The crystal structure of the SAHH enzyme from M. tuberculosis, in complex 
with ADO, has been solved at 1.6 Å. The structure is largely similar to previously 
reported SAHH structures from human, rat, and malaria, exhibiting an  fold with two 
domains: an N-terminal substrate-binding domain bound to NAD+, and a C-terminal 
dinucleotide-binding domain. The protein is in a closed conformation, with the two 
domains rotated to enclose the ADO ligand in a buried pocket. The Mtb SAHH has a 37-
residue loop that forms a helix-turn-strand on the surface, similar to that found in the Pf 
SAHH, but not found in the mammalian structures. Complexes with three inhibitors 




expected interactions between the ligands and side-chains lining the pocket, as seen in 
previous structures. However, the ARI complex is the first reported structure of SAHH 
with ARI, and shows a 3’ keto group with planar carbon in the cyclopentanyl ring, 
confirming the prediction that it is oxidized by NAD+ as a mechanism-based inhibitor. 
While most of the residues lining the ADO-binding pocket are identical between Mtb 
and human SAHH, allowing few opportunities for design of selective inhibitors, less is 
known about the binding mode of the HCY appendage of the full substrate. We 
determined the co-crystal structure of SAHH with SAH. Contiguous density was found 
adjacent to the 5’ position of ADO and modeled as atoms in the body of covalently 
attached HCY. Binding of SAH forces a rotation of His363 around the backbone to flip 
out of contact with the 5’ position of ADO and opens up access to a nearby channel that 
leads to the surface. The structure, the first complex with the SAH substrate reported, 
suggests that His363 acts as a switch that opens up to permit binding of SAH, and closes 
down after release of the HCY appendage. While most of the residues in direct contact 
with the HCY are conserved between human and Mtb SAHH, the mouth of the access 
channel nearby is significantly different, with the Mtb SAHH having a much more 
enclosed entrance surrounded by hydrophobic residues, along with Glu186 (not found in 
human SAHH).  If the active site is expanded to include this HCY-binding access 
channel, these differences could potentially be exploited to design inhibitors that 
compete with substrate binding and moreover are selective against Mtb. 
An attempt was made to exploit this difference between the Mtb and Human 




could potentially bind in the Mtb SAHH access channel thereby blocking the channel for 
entry of the substrate or exit of the products of the hydrolysis reaction thereby inhibiting 
the enzyme function. Fragment-based screening presented an enticing opportunity to 
find lead compounds that could bind in the narrow access channel leading up to the 
active site. With its collection of small molecules with an average molecular weight ≤ 
300 daltons, and lipophilicity (ClogP) value ≤ 3, the fragment library was well suited for 
this investigation. 750 fragments were screened by the method of differential scanning 
fluorimetry. Through measuring the differences in the melting temperature of the apo 
enzyme and the fragment bound enzyme it was possible to identify eight candidates 
which had a melting temperature difference of 5° C or more. STD NMR technique was 
successfully employed to validate five out of the eight fragments as true binders of Mtb 
SAHH enzyme. The five fragments were; 2-(piperidin-1-yl)benzamide, (2-(3-
chlorophenyl)thiazol-4-yl)methanol, (2-(4-(trifluoromethyl)phenyl)thiazol-4-
yl)methanol, 1-(pyridin-3-yl)-2-p-tolylethanone and N-(2,3-dihydro-1H-inden-5-
yl)acetamide. 
The purpose behind the fragment based screening was to identify small 
hydrophobic molecules that could potentially bind in the deep and narrow access 
channel provided by the Mtb SAHH. Fragment screening was therefore conducted in the 
presence of the natural substrates, NAD+ and ADO bound into the active site of Mtb 
SAHH. STD NMR technique was used to prove the independent binding of the fragment 
and the natural substrates. Experiments were conducted using a fixed concentration of 




from 0.3 mM to 30 mM. Three different STD NMR measurements were taken at 0.3 
mM, 3 mM and 30 mM concentrations of ADO. The STD NMR peaks corresponding to 
the fragment were consistently observed with increasing concentrations of ADO, 
suggesting that the binding of the fragment was independent of substrate binding. In the 
absence of a crystal structure of Mtb SAHH in complex with the fragments it may be 
speculated that the fragments bind into the access channel of Mtb SAHH away from the 
active site. The access channel offers hydrophobic residues like Pro184, Ala185 and 
Trp187 that are unique to Mtb SAHH. 
 
Future Work 
Crystal structures of the Mtb SAHH in complex with the hit fragments would 
explain the mode of binding of the fragments and the specific interactions they make in 
the active site or the channel leading up to the active site. 
The goal of any fragment based screening is to identify fragments that can bind 
in the active site of an enzyme and then build up upon the fragments to exploit the 
surrounding active site residues available to make hydrogen bonding or hydrophobic 
interactions. Once the fragment binding position in the active site is confirmed through 
solving the crystal structure of the complex, medicinal chemistry efforts can be made to 
modify the fragment into a lead compound. Chemical modifications can be made to the 
hit fragments to either connect two or more fragments together to make a lead compound 











MTB NITROGEN REGULATORY PII PROTEIN 
 
Background and Introduction 
The PII family of small signal transduction proteins play a pivotal role as 
nitrogen sensors in microorganisms and plants 49,50. Nitrogen sensing is achieved by 
regulating the intracellular nitrogen to carbon ratio represented largely by glutamine and 
2-oxoglutarate (2OG) respectively. Intracellular nitrogen regulation is carried out by 
direct and indirect control of glutamine synthetase (GS) activity through PII proteins. E. 
coli has two homologues of the PII protein, GlnB (also referred to as PII), encoded by 
the glnB gene, and GlnK, encoded by the glnK gene. Under nitrogen limiting conditions, 
E. coli GlnB is uridylylated by a uridyl transferase (GlnD), and then interacts with 
adenyl transferase to directly activate GS through deadenylylation 47,131. Conversely, 
under nitrogen rich conditions, E. coli GlnB is deuridylylated by GlnD, and then 
interacts through the adenyl transferase to deactivate GS by adenylylation. GlnB has also 
been shown to form a direct complex with GS in its activation/deactivation cycle in 
Archaeal methanosarcina mazei 132.  
 
____________ 
* Part of this chapter is reproduced with permission from “Crystal structures of the apo 
and ATP bound Mycobacterium tuberculosis nitrogen regulatory PII protein.” Shetty 
ND, Reddy MC, Palaninathan SK, Owen JL, Sacchettini JC. (2010), Protein Science, 





In the indirect control system, E. coli GlnB interacts with the two component 
signal transduction system, NtrB and NtrC, to regulate the transcription of the gene glnA 
which encodes for GS 133,134. When GlnB is deuridylylated it can interact with a histidine 
kinase, NtrB, which regulates the phosphorylation state of NtrC, controlling the 
expression of glnA. Thus GlnB is indispensible to the pathway of nitrogen control in E. 
coli. 
GlnK is another PII homolog that also plays an essential role in the nitrogen 
control systems of several organisms including E. coli 56,135. In all known instances, the 
glnK gene lies in an operon immediately next to the amtB gene 136, which codes for an 
integral membrane protein, AmtB, that acts as ammonia/ammonium channel 58. Under 
nitrogen rich conditions in E. coli the GlnK trimer complexes with the AmtB trimer 
blocking the influx of ammonium into the cellular cytoplasm 59. GlnK is also implicated 
in the membrane sequestration of enzymes involved in nitrogen fixation. For example, in 
Azospirillium brasiliense GlnK binds to one of two different proteins depending on the 
nitrogen status. During nitrogen fixing conditions GlnK binds DraG, a glycohydrolase 
that switches on nitrogenases in Azospirillium 137,138, in conditions of nitrogen excess 
GlnK binds DraT, an ADP-ribosyl transferase, and switches off these nitrogenases. 
Binding of GlnK to DraG or DraT was found not to be competitive with the AmtB:GlnK 
complex suggesting that a ternary AmtB:GlnK:DraG/T complex exists 138,139. The 
formation of this complex defines a new regulatory role for GlnK: assisting in the 
membrane sequestration of the nitrogenases, DraG and DraT. Another ternary complex 




reported in Bacillus subtilis 140. Similarly, in the Gram-positive soil bacterium 
Corynebacterium glutamicum, GlnK interacts with the transcriptional repressor, AmtR 
141, and in Streptomyces coelicolor the GlnK:AmtB complex may interact with an OmpR 
type transcriptional activator, GlnR, that is involved in nitrogen metabolism 142,143. Thus 
the AmtB:GlnK complex is capable of functioning with many other protein partners like 
DraG, DraT, TnrA, AmtR, and GlnR to achieve nitrogen regulation.  
Crystal structures of GlnB and GlnK have been reported for organisms such as E. 
coli 144-146, Methanococuus jannaschii 147, Thermus thermophilus 148, Herbaspirillum 
seropedicae 149, Synechococcus sp. 150, and Arabidopsis thaliana 151; GlnB and GlnK 
have also been shown to form heterotrimers in solution 152,153. Mycobacterium 
tuberculosis (Mtb) has a single PII homolog, Rv2919c 30. The PII gene was found to be 
essential for survival in primary murine macrophages by transposon site hybridization 
(TraSH) in H37Rv 154. Its essentiality, the various roles that the protein is proposed to 
play in nitrogen regulation, and its absence in humans makes it an attractive drug target 
in Mtb, the causative agent of tuberculosis (TB). Despite its attractiveness as a drug 
target, the nitrogen regulatory system in Mtb is not well understood and no crystal 
structures of the apo or the substrate bound Mtb PII protein exists. 
The Mtb PII gene was annotated glnB based on its higher sequence homology to 
E. coli GlnB (www.webTB.org). However, it exists in an operon with glnD-PII-amtB 
(Rv2918c-Rv2919c-Rv2920c) leading to speculation that it might encode for a GlnK 
protein based on the operon organization observed in other microorganisms 50. The 




As part of the Mtb structural genomics consortium, the crystal structure of this protein 
was solved, both in the apo and ATP bound forms, with the aim of understanding its true 
identity (and hence its role) in Mtb, potentially opening avenues for inhibition studies 22. 
The crystal structures presented in this report provide important structural and functional 
insights into the role of Mtb PII as GlnK. 
 
Methods 
Cloning, Expression and Purification of Mtb PII Protein 
A 339 bp DNA fragment containing the PII gene (Rv2919c) was amplified by 
PCR with Mtb H37Rv genomic DNA as a template, using the following oligonucleotide 
primers: 
5' - GGG AAT TCC ATA TGA AGC TGA TCA CTG CGA TCG TGA AGC - 3' 
3’ - CCC AAG CTT TCA TAA CGC GTC GTG TCC GCG TTC AC – 5’. The 
amplified DNA fragment was digested with NdeI and HindIII restriction enzymes and 
subcloned into the corresponding restriction sites in a pET28b vector containing an N-
terminal His tag (Novagen). Following sequence confirmation, the plasmid was 
transformed into E. coli BL21(DE3) cells. Cells were induced with 1 mM isopropyl-1-
thio-β-D-galactopyranoside at A600 of 0.8, and grown for 15 hrs at 25 °C. The cells were 
harvested by centrifugation and lysed by French-press in a buffer containing 20 mM tris-
HCl, 500 mM NaCl, 5 mM β-mercaptoethanol (BME), pH 7.5 (buffer A), and a protease 
inhibitor (Roche Applied Science). The lysate was spun down and the supernatant loaded 




with a 100 mL linear gradient of 10 to 500 mM imidazole in buffer A. The peak fractions 
were collected and dialyzed in the presence of 20 mM tris-HCl (pH 7.5), 50mM NaCl, 
5% glycerol, and 5 mM BME and concentrated to 15 mg/mL using an amicon filter 
(Amicon) as measured by the Bradford protein assay (Bio-Rad). 
 
Crystallization 
Initial crystallization conditions were obtained at 289 K in 96-well plates by 
sitting-drop vapor diffusion. Crystals of the Mtb apo PII were obtained by mixing equal 
volumes of 15 mg/mL protein with a crystallization solution from Crystal ScreenTM 
(Hampton Research) containing 0.1 M sodium cacodylate pH 6.5 and 1.4 M sodium 
acetate as precipitant. The Mtb PII:ATP binary complex was prepared by mixing the 
purified 15 mg/mL protein solution with ATP (Sigma) at a final concentration of 5 mM 
and incubating on ice for 30 min. Crystals of Mtb PII:ATP were obtained in condition  
containing 0.1 M imidazole pH 6.0 and 1.0 M sodium acetate, also from Crystal 
ScreenTM. 
 
Data Collection, Structure Determination and Refinement 
X-ray diffraction data for Mtb PII and Mtb PII:ATP crystals were collected on 
APS beamline 19-ID and 23-ID respectively. For data collection, a single crystal was 
cryoprotected by brief soaking in N-paratone and then flash-frozen in a liquid N2 stream 




and PII-ATP complex structures. Crystals of the Mtb apo PII protein belong to the space 
group R3 with unit cell parameters a = b = 77.15 Å, c = 51.84 Å with one molecule per 
asymmetric unit and an estimated solvent content of 48.46%. Crystals of the Mtb 
PII:ATP belong to the space group P43212 with unit cell parameters a = b = 69.74 Å, c = 
146.68 Å with three molecules per asymmetric unit and an estimated solvent content of 
48.08%. Data collection details are summarized in Table 4. 
The structure of Mtb apo PII was solved by molecular replacement using Phaser 
156. The truncated E. coli PII structure (PDB ID: 1GNK) lacking the T-loop residues 38–
54, was used as search model to solve the Mtb apo PII crystal structure 146. The Mtb apo 
PII structure was used to solve the three positions of Mtb PII:ATP structure. After rigid 
body and restrained refinement using CCP4 – REFMAC5 102,157 the model building was 
carried out in COOT 105 and XTALVIEW 104 for both the structures; solvent molecules 
were subsequently added. Bias-minimized electron density maps were obtained using the 
Shake & Warp (SNW) protocol 158. Each subunit of the Mtb PII:ATP structure contained 
one molecule of ATP with clear electron density and were included in the Refmac 
refinement. The final R-factor for the Mtb apo PII crystal structure was 20.80% (Rfree = 
22.60%) at 1.4 Å resolution and for the Mtb PII:ATP structure it was 21.57% (Rfree = 





Table 4: Crystallographic and refinement statistics for Mtb PII protein. 
 Mtb apo PII Mtb PII:ATP 
PDB ID 3BZQ 3LF0 
Data Collection   
Space Group R3 P43 21 2 
Wavelength (Å) 0.96 0.98 
Temperature (K) 100 100 
a (Å) 77.15 69.74 
b (Å) 77.15 69.74 
c (Å) 51.84 146.68 
α (°) 90 90 
β (°) 90 90 
γ (°) 120 90 
Resolution (Å) 1.40 (1.40 – 1.44) 2.40 (2.40 – 2.46) 
Unique Reflections 21338 (1595) 14020 (982) 
% completeness 99.10 (100.0) 99.78 (97.92) 
R (merge) 0.06 (0.35) 0.07 (0.63) 
<I/σI> 23.94 (7.77) 12.20 (2.02) 
   
Refinement   
R value (%) 20.80 21.57 
Free R value, random, 5% 22.60 29.21 
Molecules per asymmetric unit 1 3 
Protein residues 99 312 
ATP molecules 0 3 
   
Rmsd bond length (Å)a 0.006 0.017 
Rmsd bond angle (Å)a 1.007 1.862 
Rmsd between subunits (Å) - 0.31, 0.39, 0.45 
   
Residues  -  angles   
Most favored (%) 98.80 96.60
Allowed (%) 1.20 3.40 
Generously allowed / Disallowed (%) 0.0 0.0 




Results and Discussion 
Crystal Structure of Mtb apo PII Protein 
The crystal structure of the Mtb apo PII protein was solved at 1.4 Å resolution by 
molecular replacement method using the E. coli apo GlnK structure (PDB ID: 1GNK) as 
a search model. The data collection and refinement statistics are in Table 4. The 
crystallographic asymmetric unit contains one subunit, however a homotrimer with 
identical subunits is formed in the crystal lattice (Figure 19 A). Size exclusion 
chromatography confirmed that Mtb PII protein exists as a trimer in solution (data not 
shown). 
The structural features of the PII family of proteins from different organisms are 
well conserved in the Mtb PII structure (Figure 19 A and B). The RMSD of a subunit of 
Mtb apo PII with E. coli GlnB (PDB ID: 2PII) is 0.78 Å (for 86 Cα atom pairs – 
excluding residues 36 to 55 and 109 to 112) 159 and the RMSD with E. coli GlnK (PDB 
ID: 1GNK - subunitA) is 0.70 Å (for 91 Cα atom pairs – excluding residues 26 and 36 to 
55) 146. Figure 19 B shows a subunit of the Mtb apo PII protein with the respective 
secondary features labeled. Each subunit of the Mtb apo PII structure consists of a 
double β-α–β (ferredoxin) fold that forms a β-sheet from four anti-parallel β-strands (β1 
to β4); helix α1 connects strand β1 to β2 and helix α2 connects strand β3 to β4. Helices 
α1 and α2 lie on one side of the β-sheet. Connecting strands β2 and β3 is a large loop 
region that extends out away from the main body of the molecule, designated as the T-






Figure 19: A) A ribbon diagram of the homotrimer of the apo Mtb PII protein looking 
down at the crystallographic triad. Molecular graphics images were produced using the 
UCSF Chimera package from the Resource for Biocomputing, Visualization, and 
Informatics at the University of California, San Francisco (supported by NIH P41 RR-
01081) 124. B) A single subunit of the Mtb apo PII protein colored by the secondary 




encompassing residues Gln39 through Val53, are disordered in the electron density map 
and therefore omitted from the final model of the Mtb apo PII structure. The rest of the 
molecule, including the smaller loop connecting helix α2 and strand β4 (consisting of 8 
residues, Arg82 to Gly89, referred to as the B-loop) which is oriented in the same 
direction as the T-loop, is fully ordered. The C-terminal residues extend out from β4 
strand to form a fairly large C-loop (Asp97 to Leu112). The C-loop has a 310 α-helix 
embedded within it between Gly108 and Ala111, consistent with the E. coli GlnK 
structure and in contrast to the E. coli GlnB structure 144. 
 
Crystal Structure of the ATP bound Mtb PII Protein 
The Mtb PII:ATP binary complex crystals were obtained by co-crystallization. 
X-ray data was collected to 2.4 Å resolution and the structure was solved by molecular 
replacement using the Mtb apo PII structure (PDB ID: 3BZQ) as the search model (Data 
collection and refinement statistics are presented in Table 4). Unlike the Mtb apo PII 
protein and the ATP bound E. coli GlnK, which have a single subunit in the asymmetric 
unit, the Mtb PII:ATP structure contained a trimer in the asymmetric unit with one ATP 
molecule bound per subunit (Figure 20). The molecular packing or binding of ATP to 
Mtb PII does not significantly change the overall structure of the protein. The trimeric 
Mtb PII:ATP structure is superposed onto the trimeric Mtb apo PII with an r.m.s.d. 
(between 94 x 3 Cα atom pairs) of 0.69 Å. The r.m.s.d. of Mtb PII:ATP with the E. coli 
GlnK:ATP trimer (PDB ID: 2GNK) is 0.80 Å (between 92 x 3 Cα atom pairs) 146, while 




subunit B of Mtb PII:ATP and the monomer of E. coli GlnB). The r.m.s.d. between the 
three subunits of Mtb PII protein is 0.31 Å between subunits A and B, 0.39 Å between 
subunits B and C and 0.45 Å between subunits A and C. The differences lie in the 
positions of the residues in the ATP binding region, while the rest of the molecular 





Figure 20: A ribbon diagram of the homotrimer of the ATP bound Mtb PII protein 
looking down the crystallographic triad. The three subunits of PII protein are represented 







loop of the apo PII structure is completely ordered in subunit B of the ATP bound Mtb 
PII trimer with the exception of Lys40 and the partially ordered Gln39. However, 
residues Gln39 to Val53 of subunit A and residues Gln39 to Glu50 of subunit C were 
disordered and were omitted from the final model of Mtb PII:ATP structure. 
 
Trimerization is Critical to the Function of Mtb PII protein 
The trimer has some distinct structural features that indicate the possible function 
of Mtb PII protein. In the trimer, the β-sheet from one subunit tilts toward the 
neighboring subunit at a shear angle that is typical of β-barrel structures 160,161. Three β-
sheets, one from each subunit, line the interior of the trimer and enclose a concave β-
barrel at the center of the trimer, while the α-helices of each subunit lie on the outside of 
the trimer (Figure 20). The β2 strands from the individual subunits form the mouth at 
the top of the β-barrel with Ser31 of each β2 strand making hydrogen bonding 
interactions with Gln34 of the neighboring β2 strand. Additionally, Glu32 from each β2 
strand comes closest to the center at the top of the β-barrel, lying symmetrically away 
from each other at a distance of ~ 9.1 Å and creating a negatively charged region at the 








Figure 21: Glu32 from β2 strands of each subunit of the homotrimer form the mouth of 




The inner lining of this β-barrel encloses a concave cavity with hydrophobic 
residues Leu3 from the β1 strand and Trp92 from the β4 strand. In addition to Glu32 at 
the mouth of the cavity, Arg60 and Glu62 from the β3 strands of each subunit insert the 
polar ends of their side-chains into the center of the cavity forming hydrogen bonds to 










 Finally, the β4 strand of each subunit bends inward at the bottom to close the 
base of the concave β-barrel. Pro95 residues from each β4 strand are brought into close 









The hydroxyl group of Ser94 in the β4 strand at the base of the β-barrel forms a 
hydrogen bond with the backbone carbonyl oxygen atom of Pro95 (of the same β4 
strand) through a water molecule. Furthermore, the presence of a network of ordered 
water molecules observed at the bottom of the β-barrel might also serve to stabilize the 
trimer. While the rest of the trimer interface is conserved between most other organisms, 
including E. coli GlnB and GlnK, the Pro95 residue of Mtb PII that occurs at the bottom 
of the β-barrel is not conserved across species. It is an Asp95 in E. coli GlnB, Klebsiell 
pneumoniae GlnB, Azospirillum brasilense GlnK, Herbaspirillium seropedicae GlnK, 




GlnK, and Herbaspirillium seropedicae GlnB. The amino group on Lys2 of Mtb 
PII:ATP is positioned closely to Pro95 at a distance of 4.7 Å within the subunit. The 
Lys2 forms a hydrogen bonding interaction with Asp97 of a neighboring subunit in the 
trimer of Mtb PII:ATP at 2.7 Å distance. In the case of E. coli GlnK, the Lys2 is 
involved in hydrogen bonding interactions with Glu95 (2.6 Å distance) of the same 
chain and hence is not available for interaction with the residue at position 97 of the 
neighboring subunit, which is Gln97 (6.7 Å). The functional significance of the 
hydrophobic and hydrogen bonding interactions involving Pro95, Asp97 and Lys2 at the 
bottom of the β-barrel in Mtb PII compared to E. coli GlnK/GlnB warrants further 
investigation in relation to trimerization. 
An important feature that becomes apparent in the trimeric state is that part of the 
long C-loop of one subunit lies parallel to the β4 strand of the neighboring subunit 
making several interactions. For instance, there are hydrogen bonding backbone 
interactions between Thr98 (C-loop of subunit C) and Val93 (β4 strand of subunit B), 
Val100 (C-loop of subunit C) with Val91 (β4 strand of subunit B) and Trp92 (β4 strand), 
Val102 (C-loop) with Lys90 (β4 strand). The backbone amide of Arg103 (C-loop) also 
hydrogen bonds with the backbone carbonyl of Gly89 (β4 strand) via a water molecule. 
The extensive intersubunit hydrogen bonds between the C-loop and the β4 strand could 
be the defining factor in the trimerization of Mtb PII. The C-loop of one subunit 
approaches the B-loop and the ATP binding site of the neighboring subunit which may 
also preserve the structural integrity of the functional trimer. For example, the backbone 




of Arg82 (B-loop of subunit B) at 2.8 Å distance. The C-loop also encloses a 310 helix 
turn at its C-terminal end, which contributes to the ATP binding site of the neighboring 
subunit and is partly stabilized by the hydrogen bonding of the carbonyl end of Ala111 
(C-loop) with the amino side-chain of Lys90 (β4 strand) (2.8 Å distance). The 
importance of the trimeric architecture is that the secondary structural elements involved 
in the trimerization also form part of the ATP binding pocket. In particular, the β2 and 
β4 strands of Mtb PII contribute key residues to the ATP binding pocket (vide infra) 
indicating that the trimerization is critical for its function. 
 
Comparison between the Apo and ATP Bound Mtb PII Protein 
The crystal structure of Mtb PII:ATP shows that ATP binds in three 
symmetrically equivalent positions in the trimer in a pocket formed by the base of the T-
loop, B-loop, the β4 strand of one subunit, and the β2 strand, β3 strand, and part of the 
C-loop of a neighboring subunit. In this structure the ATP exists in a C-3’-endo 
conformation with the adenine ring in the anti-orientation consistent with its position in 





Figure 24: ATP bound in the active site of Mtb PII protein. Residues contributed by the 
neighboring subunit are shown in tan color while the residues contributed by the ATP 




Conserved residues Gly87 (B-loop), Gly89 (B-loop), Lys90 (β4 strand), and 
Arg103 (C-loop) are also found in the active site of Mtb PII, all of which hydrogen bond 
with the polar phosphate groups of ATP. The adenine ring of ATP sits in a hydrophobic 
pocket surrounded by residues contributed by two neighboring subunits. Residues 
contributing to adenine binding include Ile7 of the β1 strand and Trp92 of the β4 strand. 
The residues of the neighboring subunit contributing to adenine binding include Leu26, 
Gly27, Met28 and Thr29 of the loop connecting α1 helix and β2 strand, Val64 of the β3 




itself has non-bonded interactions with residues from the neighboring subunit it helps to 
further stabilize the trimer as compared to the apo trimer. While all the hydrophobic 
residues move closer into the binding pocket upon ATP binding, two residues move 
away; Gly27 moves by 2.5 Å and lies at a distance of 3.4 Å from the adenine ring, and 
the amide linkage between Gly27 and Leu26 rotates by ~180˚ such that the carbonyl 
carbon of Leu26 is 4.4 Å away from its original position in the Mtb apo PII (Subunit B 
of Mtb PII with a complete T-loop was used to calculate all inter-atomic distances in the 
ATP binding pocket). The movement of Leu26 and Gly27 away from their positions in 
the Mtb apo PII structure makes space for the adenine ring of ATP.  
The protomer ATP interactions shown above can be viewed in reference to three 
important structural elements, namely the C loop (310 helix), the B loop, and the T loop 
(Figures 24). The C-terminal end of the neighboring subunit of Mtb PII (at the end of 
the C-loop), aided by a 310 helix, curls back to form part of the ATP binding pocket. The 
C-terminal residue Leu112 lines a hydrophobic pocket for the adenine ring of ATP, 
while the terminal carboxylic oxygen atom of Leu112 hydrogen bonds with Arg101 at a 
distance of 2.8 Å, which in turn hydrogen bonds with the phosphate of ATP (2.9 Å 
distance). The 310 helix must play a role in the binding of the ATP because it brings 
Leu112 into proximity with ATP. Furthermore, in the Mtb apo PII structure, the Cα atom 
of Leu112 moves away from the ATP binding site by 1.6 Å and loses its hydrogen 
bonding interaction with Arg101 although the 310 helix is conserved in the apo structure. 




Met1 (3.6 Å distance) of the same subunit. Upon binding ATP the Leu112 moves closer 
to ATP but still maintains the hydrophobic contact with the N-terminal Met1. 
The B-loop carries the conserved mononucleotide binding motif ‘Gly(84)-X-X-
Gly(87)-X-Gly(89)-Lys(90)’ and thus acts as the primary binding site for ATP 162. 
Compared to the Mtb apo PII structure, the B-loop in Mtb PII:ATP moves away from the 
ATP binding region, making space for the ATP to bind. The Cα atom of Lys85 at the tip 
of the B-loop moves away by 1.5 Å. The backbone nitrogen atom of Gly89 makes 
hydrogen bonding interaction with the oxygen atom of the β-phosphate at 2.9 Å distance. 
While the Cα atom of ATP-bound and unbound Lys90 are in identical positions, the 
side-chain moves in the ATP bound structure so that the N-Z atom of Lys90 is 5.3 Å 
away from its position in the apo structure and hydrogen bonds with the β-phosphate of 
ATP at 2.5 Å distance. 
Arg38 extends out from the base of the T-loop and hydrogen bonds with the 
oxygen atom of the γ-phosphate at 3.0 Å distance (Figure 24). The binding of ATP is 
involved in stabilizing the side-chain conformation of Arg38, and therefore should partly 
stabilize the T-loop conformation. In the Mtb apo PII structure, the side-chain of Arg38 
is disordered (along with the T-loop) and is represented as alanine, which could result 
from a lack of stabilizing interactions in the absence of ATP. Indeed, the Cα atom of 
Arg38 in the Mtb apo PII moves away from the active site by 8.3 Å compared to the 
ATP bound structure, to open this cavity to solvent. This effectively changes the 
flexibility of the T-loop conformation in Mtb apo PII. Comparing the apo and ATP-




γ-phosphate is the reason the base of the T-loop moves back into the active site (Figure 
25). While Arg38 forms one part of the enclosure for the phosphates of ATP, Arg103 
from the C-loop of the neighboring molecule forms another part of this enclosure 
forming a hydrogen bond with oxygen on the γ-phosphate (2.8 Å distance). Similarly, 
the C-loop also contributes Arg101, which further stabilizes the ATP binding site. 
Arg101 of subunits A, B and C hydrogen bond with the bridge oxygen between the β- 





Figure 25: Superposition of the base of the T-loop of the three subunits of Mtb PII 




While Arg38 moves in closer to the active site upon ATP binding, Tyr36 moves 
away (the C-α atom of Tyr36 moves by 2.9 Å distance) compared to its original position 
in the Mtb apo PII structure. In the ATP bound structure, the back bone nitrogen atom of 
the Tyr36 forms a hydrogen bond with the 3’ hydroxyl group of ATP (3.2 Å distance). 
Therefore, in the ATP bound PII structure, the Tyr36 orients its side chain more closely 
to the side chain of Phe55 (at 3.5 Å distance).  Since Tyr36 is the first residue and Phe55 
is the last residue of the functionally important T-loop, ATP binding can be said to partly 
influence the orientation of the T-loop itself. Thus Tyr36 along with Gly37, Arg38 and 
Phe55 plays a role in the stability of the base of the T-loop. It is clear from the positions 
of residues leading up to the missing section of the T-loop in subunit C that the loop has 
a very different conformation compared to subunits A and B (Figure 25). While Tyr36 
and Phe55 at the neck of the T-loop are in equivalent positions in subunit B and C, the 
Cα atoms of the functionally crucial Tyr51 are positioned 12.4 Å away compared to each 
other. Crystal packing might play a role in the solvent exposed part of the alternate T-
loop conformation observed in subunit C of Mtb PII:ATP structure (as discussed below). 
Taken together, the binding of ATP along with the positions of Tyr36, Arg38, and Phe55 
might contribute to the stability of at least the base of the T-loop of Mtb PII and point it 
in the right orientation to form a complex with the target proteins of PII, like AmtB or 
GlnD. 
 Although the residues at the base of the T loop including Arg38 is fully ordered 
in all subunits of Mtb PII: ATP (Arg38 is disordered in the apo structure), only subunit B 




residues of symmetry related molecules on the stability and conformation of the visible 
T-loop of subunit B in Mtb PII:ATP structure, we observed that part of the T-loop of 
subunit B packs inside a groove created by two symmetry related molecules (Mtb PII’ 
and PII’’) (Figure 24). Tyr51 of the T-loop makes hydrophobic interactions with Val53’ 
(3.8 Å distance) of the T-loop from the symmetry related molecule. Tyr46 makes 
hydrophobic interactions with Ser52’ (3.7 Å distance). Glu50 makes a hydrogen bond 
interaction with Thr98’’ (2.5 Å distance). The backbone amide group of Arg47 hydrogen 
bonds with the carboxylic acid group of Asp71’’ (3.0 Å distance), and the Cα atom of 
Arg47 makes a van der Waal’s interaction with the side-chain of Val70’’ (3.8 Å). 
Overlaying subunit B on subunit A reveals that the T-loop of subunit A is exposed to 
solvent without any stabilizing interactions; and overlaying subunit B on subunit C of 
Mtb PII revealed clashes of the T-loop with the T-loop from a neighboring symmetry 
molecule, requiring drastic changes in the T-loop conformation in subunit C to avoid 
these clashes. Because of this the T-loops in subunits A and C of ATP-bound Mtb PII 
were only partially ordered. Collectively, the interactions of the T-loop of subunit B with 
symmetry molecules help stabilize the flexible part of the T-loop, which would 
otherwise need to be stabilized by forming a complex with a target protein or an effector 
molecule such as 2OG 59. The crystal packing effect upon stabilization of subunit B’s T-
loop of Mtb PII protein mimics the formation of a complex with a target protein which 
indicates that the T-loop requires additional stabilizing interactions mediated through the 
binding of a target protein to Mtb PII (Figure 27 A). However, the present conformation 




physiological binding partners like AmtB (the GlnK:AmtB homology model is presented 
in a later part). 
 
Role of Mg2+ in the ATP Binding Site 
Analysis of available crystal structures of GlnB and GlnK in the RCSB Protein 
Data Bank revealed that all GlnK structures solved to date enclose a 310 helix at their C-
termini in contrast to GlnB structures (Figure 19 B). This includes the E. coli GlnK 
(PDB ID: 1GNK), Thermus thermophilus GlnK (PDB ID: 1UFL), M. jannaschii (M. 
jann) GlnK1 (PDB ID: 2J9C). Since both apo and the ATP bound Mtb PII proteins 
enclose a 310 helix at their C-termini it might be implied that Mtb PII functions as a 
GlnK protein. It is unclear what causes the formation of the 310 helix at the C-terminal of 
the GlnK protein since there is no conservation in the four residues – Arg107, Gly108, 
His109, Asp110 – that are involved in the formation of the 310 helix among different 
organisms like Mtb PII, E. coli GlnK and M.jannaschii GlnK1. It is possible that the 
micro heterogeneity observed in the sequences of GlnB and GlnK might have resulted in 
the difference in propensity for 310 helix formation. The 310 helix brings the terminal 
residue, Leu112 in proximity with the adenine moiety of ATP. While the side-chain of 
Leu112 helps to maintain a hydrophobic pocket for the adenine ring of ATP, the 
carbonyl end of Leu112 hydrogen bonds with Arg101, which in turn hydrogen bonds 
with the γ-phosphate of ATP, similar to the interactions observed in E. coli GlnK:ATP 
structure. Thus the significance of the 310 helix is that it contributes Leu112 towards 






Figure 26: Active site of the M. jannaschii PII protein with the bound ATP shown in 
pink stick representation and Mg2+ ion shown as a green sphere. The coordinated water 




The M. jannaschii (M. jann) GlnK1 crystal structure has also been solved in 
complex with ATP, and 2OG molecules 147. Out of three possible binding sites, only one 
2OG molecule was bound per trimer and it bound next to Tyr51 of the T-loop which 
adopts a significantly different conformation with respect to the unbound T-loops. 
Binding of 2OG did not, however, influence the conformation of the rest of the 
molecule, including the C-terminal, which still accommodates a 310 helix. Like the Mtb 




r.m.s.d. of 0.74 Å with the Mtb apo PII (between 95 Cα atom pairs from chain A of Mtb 
PII and M. jann GlnK1) and an r.m.s.d. of 0.87 Å with E. coli GlnK (between 95 Cα 
atom pairs from chain A of each). In addition, the crystal structure of the M. jann GlnK1 
shows a Mg2+ ion bound next to ATP which coordinates with all three phosphate oxygen 
atoms 147 (See Figure 24 and 26 for a comparison of the Mtb PII and M. jann GlnK1 
ATP binding sites). Yildiz et al. have argued that Mg2+ and ATP are necessary to change 
the T-loop conformation which then creates the 2OG binding site. In the case of Mtb 
PII:ATP protein, Arg38 of the T-loop occupies the Mg2+ binding site (Figure 26) to 
form a direct hydrogen bond with the γ-phosphate oxygen atom of the ATP (3.0 Å 
distance). Arg38 of Mtb PII is a Val38 in M. jann GlnK1 suggesting that a Mg2+ is 
critical for M. jann similar to many other ATP binding proteins. Binding of Mg2+ ion 
pushes the base of T-loop away from the ATP phosphates in M. jann GlnK1, while in 
Mtb PII:ATP structure it is observed that the base of the T-loop comes close to ATP (the 
main-chain amide group of Arg38 hydrogen bonds with the ATP α-phosphate at 3.1 Å 
distance). The same amide group of Val38 in M. jann GlnK1 is 4.7 Å away from the 
ATP α-phosphate 147. Therefore, it may be the case that a Mg2+ ion is not required by 
Mtb PII to change the T-loop conformation and create a 2OG binding site. Indeed, our 
attempts to crystallize Mtb GlnK in the presence of Mg2+ ions were unsuccessful. 
 
Comparison with the E.coli GlnK: AmtB Complex 
Mtb encodes a probable amtB gene (Rv2920c), which is next to the glnB gene 30. 




Mtb AmtB protein shows a 41% sequence identity. All essential residues involved in the 
interaction of AmtB with the T-loop of PII, specifically Phe107, His168, Phe215, 
Leu259, Ser263, Val299, Asp313, and His318 of the E. coli AmtB, were found to be 
conserved in Mtb AmtB 163. We constructed a homology model of Mtb AmtB and the T-
loop section of the Mtb PII protein based on the crystal structure of the E. coli 
GlnK:AmtB complex (PDB ID: 2NS1) (Figure 27 B) using the SWISS-MODEL 
program 164. Comparing the T-loops of subunit B of the Mtb PII protein with the 
homology modeled Mtb PII, we noticed that the region of the T-loop that sticks out from 
the main body of the PII protein swings away from the T-loop binding pocket of AmtB 
by ~ 45˚. The position of the T-loop observed in the crystal structure of Mtb PII:ATP 
could be due to crystal packing effects (vide ante). Thus, in order to bind Mtb AmtB, the 
T-loop would have to swing by ~ 45˚ with a maximum movement of ~ 11.0 Å (observed 
for the Cα atom of Arg47) to bring the T-loop inside the groove of AmtB (Figure 27 B). 
However, the base of the T-loop that forms and interacts with the ATP binding site does 
not move. This suggests that ATP binding stabilizes the base of the T-loop (residues 36-
39), but that the rest of the T-loop must be stabilized by a target protein. Given that PII 
proteins can bind a multitude of target proteins (particularly, AmtB, and GlnD of the 
same operon 165), it is logical to think that the T-loop exists in different conformations 
depending on the target protein it complexes with. For example, in the Arabidopsis 
thaliana PII:NAGK complex structure, the T-loop adopts a very different conformation 
compared to the E. coli PII:AmtB complex structure 166. The crystal structure of 




evidence for this protein-protein complex formation 167. Obviously other parameters 




A B  
Figure 27: Homology model of the Mtb PII protein in complex with Mtb AmtB protein. 
A) The figure shows the observed position of the T loop in the crystal structure of Mtb 
PII protein with the neighboring symmetry molecules shown in surface representation. 
B) Figure shows the movement of the T loop of the Mtb PII protein in a homology 
model of the Mtb PII protein in complex with Mtb AmtB protein. Part of the homology 







Looking into the T-loop binding pocket of the Mtb AmtB homology model, there 
are few differences when compared with the E. coli AmtB structure. The terminal 
hydroxyl group of Tyr51 of Mtb PII protein makes favorable hydrogen bonding 
interactions with the backbone amide of Phe224 of Mtb AmtB (2.6 Å distance). The 
phenyl ring of Tyr51 makes additional hydrophobic contacts with the side-chain of 
Leu223 (3.3 Å distance), which does not exist in E. coli AmtB, instead it is an Ala192. 
However some hydrogen bonding interactions observed in E. coli are missing in Mtb, 
such as the interaction of the backbone carbonyl of Arg47 with Arg253 of E. coli AmtB; 
in Mtb it is an Asp284 and is 5.9 Å away. There is also a 36 residue insertion at the C-
terminal of the Mtb AmtB that hangs on the cytoplasmic side of the membrane that was 
not included in the homology model, but will be involved in some form of interaction 
with the PII trimer. Thus Mtb PII protein would be expected to interact and form a 
complex with the Mtb AmtB. 
 
Annotation of the Mtb PII Protein 
 The gene encoding Mtb PII has been annotated glnB in the Tuberculosis 
Structural Genomics Consortium (TBSGC). Comparing the sequences of other PII 
proteins from across different species, the Mtb PII protein shows a 2 to 7% greater 
sequence identity with known GlnBs than with their respective GlnKs. (See Table 5 for 
comparison of percentage sequence identities with PII proteins from other organisms.) 
Thus, on the basis of sequence identity alone it could be termed Mtb GlnB. However, 




encoding glutamine synthetase, the glnK gene in most organisms is linked to an amtB 
gene forming an amtB-glnK or glnK-amtB operon (and may also contain a third gene, 
glnD). C. glutamicum and S. coelicolor are two other actinobacteria where the nitrogen 
regulation pathway has been studied in detail 168,169. Like Mtb they too encode a single 
homolog of the PII gene that lies between the amtB and glnD genes and the gene product 
has been annotated as GlnK in both microorganisms based on operon organization. As 
Mtb follows the same operon organization as C. glutamicum and S. coelicolor it is 
logical that the gene would also translate into a GlnK protein. Furthermore, it has been 
suggested that to be annonated  glnB, the protein product of these genes should consist 
of a conserved Lys3 and an Asp5 or Glu5 50. While the E. coli GlnB observes this rule, 
the Mtb PII protein has a Leu3 and Thr5, both consistent with E. coli GlnK. The Lys3 
and Asp5/Glu5 residues among GlnB proteins and the Leu3 and Thr5 residues among 
GlnK proteins are fairly conserved across species, suggesting that the Mtb PII gene is in 





Table 5: Percentage identity of Mtb PII protein with GlnB and GlnK of other organisms. 
 GlnB (% identity with 
Mtb PII protein) 
GlnK (% identity 
with Mtb PII protein) 
α Proteobacteria   
Azospirillum brasilense 60 56 
Rhodospirillum rubrum 57 60 
Azorhizobium caulinodans 59 57 
β Proteobacteria   
Herbaspirillum seropedicae 64 61 
γ Proteobacteria   
Escherichia coli 61 54 
Klebsiella pneumoniae 61 54 
Firmibacteria   
Bacillus subtilis -- 7 
Actinobacteria   
Corynebacterium glutamicum -- 68 
Streptomyces coelicolor -- 68 
Archaebacteria   
Methanococcus jannaschii -- 55 
Cyanobacteria   
Synechococcus 61 -- 
Plants   
Arabidopsis thaliana 46 -- 







The Mtb PII protein projects the Leu3 and Thr5 residues from each subunit into 
the central cavity of the β-barrel formed by the trimer, while E. coli GlnB has Lys3 and 
Asp5 residues in these positions. The significance of these hydrophilic versus 
hydrophobic residues at the center of the β-barrel in relation to the function of GlnB and 
GlnK is unknown and calls for further investigation. Apart from operon organization and 
sequence specific characterization, the crystal structure of the Mtb PII protein gives a 
clear indication of the nomenclature of the protein. The presence of a 310 helix at the C-
terminus of the Mtb PII protein is consistent with other known GlnK structures, while in 
GlnB this region is a loop that is positioned away from the ATP binding pocket. It has 
been proposed earlier that GlnK structures may differ from GlnB due to the presence of 
a 310 helix in the C-loop 145,146,150. For these reasons it was suggested that the gene for 
the PII protein in Mtb is glnK. 
 
Conclusion 
The operon organization of Mtb PII gene, the existence of GlnK specific 
structural features in both apo and ATP bound Mtb PII crystal structures, and the 
homology model of Mtb PII:AmtB complex, suggest that the PII homolog of Mtb can 
play a key role as GlnK in the nitrogen regulatory pathway. In fact the up-regulation of 
the PII, glnD, and amtB genes in response to low nitrogen conditions in Mtb 61 implies a 
possibility that the PII and GlnD proteins may be active in nitrogen regulation through 
AmtB and possibly in the transcriptional regulation of the genes involved in nitrogen 




transferase in the enterobacterial nitrogen regulation system 167. Alternatively, the same 
enzyme has been shown to act as an adenyl transferase on GlnK proteins in the 
actinobacteria – C. glutamicum and S. coelicolor 165,170. However, there is no evidence 
for the interaction between an adenylylated GlnK with GlnE in C. glutamicum and S. 
coelicolor 170,171; this is in contrast to E. coli, where the GlnE and GlnB proteins work 
together to regulate GS (ammonium dependent glutamine synthatase). While GlnE was 
shown to be essential for Mtb, affecting the adenylylation and deadenylylation activity of 
Mtb glutamine synthetase, this pathway was found to be independent of the 
PII/GlnD/AmtB proteins 61, suggesting that the GlnE dependant regulation of GS does 
not require a PII homolog.  
PII proteins have been implicated in the transcriptional regulation of genes 
involved in the nitrogen metabolism of actinobacteria 172. In S. coelicolor, an OmpR type 
transcriptional regulator, called GlnR, has been suggested to carry out the transcriptional 
regulation of genes involved in nitrogen control, including amtB, glnK, and glnD among 
others. A glnR gene was also identified and characterized in M. smegmatis (M. smeg) 
and shown to regulate the transcriptional activation of genes involved in nitrogen control 
in the organism 173, although a reduced number of the target gene sequences were 
identified in M. smeg compared to S. coelicolor. Mtb encodes a putative GlnR, which 
shares a 73% amino acid sequence identity (83% homology) with the M. smeg GlnR 
protein and 64% identity (78% homology) with the S. coelicolor protein. In vitro 
experiments with the S. coelicolor GlnR showed that it was able to bind the Mtb glnA 




might be a good candidate to regulate the transcription of genes involved in nitrogen 
control. It has also been suggested in previous studies that the C. glutamicum GlnK can 
complex with a TetR type transcriptional repressor, AmtR 141, which is considered a 
master regulator of the nitrogen metabolism genes, involved in the repression of 
transcription of at least 33 genes during nitrogen surplus. M. smegmatis was the only 
mycobacterium to have a homolog of the AmtR (42% identity), while the rest of the 
mycobacteria had no homologs of AmtR 174. Though M. smeg AmtR was considered to 
be an interesting candidate for a second nitrogen regulator 173, the exact role of the 
protein in the organism is unknown. 
The model for nitrogen regulation in Mtb can be proposed from previous studies 
in C. glutamicum, S. coelicolor and M. smegmatis 60,173,174 based on the identification of 
the homologous proteins in the bacterial genome sequence database (listed above), and 
from our structural data for Mtb PII protein (Figure 28). Under nitrogen limiting 
conditions PII protein is adenylylated by GlnD, preventing complex formation with the 
ammonium permease AmtB, permitting an unhindered flow of ammonium into the 
cytoplasm (Figure 28 A). During this event, adenylylated PII may bind GlnR, 
preventing it from functioning as a transcriptional activator of the amt operon and 
various other nitrogen metabolism genes (Figure 28 A) 172. At high intracellular nitrogen 
concentrations, GlnD is triggered to deadenylylate PII, freeing it to complex with the 
membrane bound AmtB and sequestering the PII protein to the membrane (Figure 28 
B). The uncomplexed PIIs in the cytoplasm are degraded by protein kinases. The 




nitrogen regulatory genes, however, the precise mechanism of PII/GlnR regulation needs 
be to be evaluated. Based on available data, the Mtb PII protein can interact with either 
AmtB (prevention of ammonium intake) or GlnR (transcriptional activation) to play a 
role as GlnK , guided by the adenylylation/deadenylylation by GlnD, in presence of ATP 
and possibly 2OG (Figure 28) 165,175. Taken together, the diverse association of Mtb PII 





Figure 28: The putative nitrogen control pathway in Mtb in the presence of A) low 









Our attempts to crystallize Mtb PII: ATP complex in the presence of Mg2+ ions 
were unsuccessful. However one cannot infer based on this observation that Mg2+ ion is 
not required for binding ATP. That a Mg2+ ion is not essential for binding of ATP or 
2OG can be confirmed by mutation studies, where the Arg38 of Mtb PII protein is 
changed to Val38 as in the case of M. jannaschii PII protein. If such a Arg-Val mutant 
Mtb PII protein is crystallized in the presence of Mg2+ and ATP and Mg2+ ion is 
observed in the active site coordinating with the ATP molecule, then it can be confirmed 
that Arg38 replaces the function of Mg2+ ion in the Mtb PII protein and that Mg2+ ion is 




The actual binding site of 2OG on PII protein is not clearly established. A crystal 
structure of Mtb PII in complex with ATP and 2OG would shed light on the binding 
mode of the effector molecule and also help establish the mechanism by which Mtb PII 
functions. 
Finally, while the homology model of Mtb PII: AmtB with the E. coli PII: AmtB 
suggests the possible role of Mtb PII as a GlnK protein, a crustal structure of such a 






NATURAL PRODUCTS DERIVED INHIBITOR CANDIDATES  
 
Background and Introduction 
The Role of Microorganisms in Drug Discovery  
Infectious diseases are caused by pathogenic microorganisms and are the leading 
cause of death worldwide. While such microbes were responsible for much of the 
suffering through the ages it was only recently that man was able to tap into the reserves 
provided by other nonpathogenic microbes to alleviate the pain caused by the former. It 
turns out that microbes are the best defense against microbes as microorganisms have 
contributed greatly in finding cure for the infectious diseases. Since the discovery of 
Penicillin in 1928, natural products derived from microorganisms like bacteria and fungi 
have played a major role in the treatment of infectious diseases. The discovery and the 
consequent application of streptomycin in the cure of tuberculosis exemplified the first 
instance where a major worldwide infectious disease could be controlled by the use of a 
naturally derived antibiotic and did much to raise the confidence of the scientific 
community towards natural products as an effective drug therapy. Streptomycin was 
isolated from Streptomyces griseus, an actinomycete, which subsequently proved to be 
the most prolific producer of antibiotics. New antimicrobials continue to be discovered 
from various strains of actinomycetes to this day, examples of which include the 
discovery of Abyssomicin from a rare actinomycete strain, Verrucosispora  176 and 




Microorganisms have traditionally been a good source of drugs and lead compounds to 
the pharmaceutical industry. There are many popular examples of antibiotics, which 
include vancomycin, cephalosporins and rifamycins 178. However, there is a continuous 
need to discover novel antibiotics. Antibiotics resistance among pathogens, evolution of 
new diseases like AIDS, Hanta virus and Ebola virus and the toxicity issues in some 
existing compounds make the process of drug discovery an ongoing effort. Fortunately, 
the metabolome of microorganisms contain a vast untapped reservoir of natural products 
that carry a wide range of structural diversity, of which many are yet to be discovered. It 
is fascinating to understand why microorganisms have evolved to produce such potent 
antimicrobial molecules. 
Nature consists of microscopic ecosystems where the microorganisms are in 
constant struggle for survival amidst limited resources. Under such conditions, 
microorganisms produce biomolecules with antibiotic properties to defend themselves 
from the competing microbes in their immediate environment. In most instances these 
natural product antibiotics are secreted into the environment. The small molecules act on 
the competing pathogens either by inhibiting enzymes involved in important metabolic 
pathways or by targeting bacterial cell wall or cell membrane. They may also have 
bacteriostatic effects by targeting the protein synthesis in pathogens. The same logic 
applies to the treatment of infectious diseases in humans, where the prospective drug is 
chosen to target proteins in the invading pathogenic microorganisms like Mycobacterium 
tuberculosis (Mtb) in TB and plasmodium falciparum (pf) in malaria. It has been 




molecule ligands are sought, and the small molecule space itself has been estimated to be 
in the range of 1014 to 1030 molecules 179. To cover such a large chemical space requires 
a library of small molecules that constitute a wide variety of structural and chemical 
diversity. This is the primary advantage of using natural products for random screenings. 
The novel structural scaffolds provided by natural products owing to the presence of 
many chiral carbon centers is greater than can be provided by any available collection of 
compounds synthesized using combinatorial chemistry. Natural products also have the 
desired ‘drug-like’ properties, i.e. they can penetrate the cell walls and membrane of 
microorganisms and they can get metabolized to leave little or no toxic by-products. 
Indeed, between 60 – 80 % of all approved antibacterial and anticancer drugs were 
derived from natural product screenings 180. It is believed that a large percentage of the 
world’s biodiversity remains unexplored in terms of testing for their bioactivity. 
Technical difficulties ranging from the extraction, isolation and purification of novel 
natural products from nature has made them unattractive targets to the drug discovery 
companies which look for rapid returns in their investments. However the rapid growth 
in sophisticated analytical techniques and instrumentation like high performance liquid 
chromatography, mass spectrometry, nuclear magnetic resonance spectroscopy and high-
throughput bioactivity assay methods in the recent years promises to considerably 
shorten the tedious and time consuming natural product extraction and identification 
procedures of the past. 
Natural products from microorganisms are preferred as antibiotics because they 




would be rather unwise to turn away from this vast treasure trove of biodiversity 
available from nature when seeking novel compounds to fuel the drug discovery 
programs. 
 
High-Throughput Screening Libraries 
Improvements in screening technologies like high-throughput screening (HTS) 
and the development of efficient assay conditions for screening natural products for their 
bioactivity meant that a constant supply of newly discovered compounds was required. 
For example, HTS methods allow 100,000 or more chemicals to be screened in a single 
day (ref). In order to meet the challenge of the large screening capabilities of HTS 
systems combinatorial chemistry technology were developed through the 90s and have 
contributed considerably to the compounds database 179. This approach involves the 
chemical syntheses of small molecules, largely based on the structural scaffold of natural 
products with drug like properties that are already known. While the synthetic 
procedures do afford chemical diversity to a given class of compounds, they are not a 
great source of structural diversity that is sought. ‘Metabolic engineering’ or 
‘combinatorial biosynthesis’ methods have been used with success to produce diversity 
in natural products by manipulating the microorganisms at the genetic level 181,182. The 
method was more target-specific and not capable of contributing to the natural 
compounds database at the desired rapid pace. 
Microorganisms remain unrivalled in their ability to produce bioactive 




structures of natural products possess advanced binding characteristics compared to 
purely synthetic compounds 183. Indeed about 40 % of the chemical scaffold found in 
nature are absent in today’s medicinal chemistry 184,185. New methods are therefore 
needed for discovering unique natural products with both structural and chemical 
diversity. 
 
Whole-Cell Bioactivity Screening of Natural Product Extract Libraries 
A vast majority of the antibacterials known today originate from the soil 
dwelling bacteria – Actenomycetes 186,187. Yet actenomycetes continue to be the source 
of novel natural products to this day 188. Continued discovery of novel natural products 
as lead candidates have sparked a renewed interest among the pharmaceutical industry to 
return to the field of natural product drug discovery 64. Success in finding a novel natural 
product antibiotic depends upon the size and bio-diversity of the microbial extracts 
library. Since larger libraries present a higher success rate, collaborations were initiated 
with institutions that could offer diverse source of extracts for bioactivity studies. Thus, 
in addition to the soil bacteria that were isolated (described in the previous section), bio-
activity guided fractionation were also performed on extracts obtained from different 
sources like the Vicuron library (FIIRV - Italy) and the Sarawak Biodiversity Center 
(SBC) (Malaysia). 
As discussed previously, a collection of compounds can be screened against 
pathogenic microorganisms in a blind whole cell bioactivity assay or they can be 




assay. Both methods have their advantages. The whole cell bioassay ensures that the 
compounds in the collection exhibiting poor cell permeability are removed from the 
priority list early in the screening process. However, the mode of cellular inhibition is 
unknown and compounds could be cytotoxic resulting in false positives. Also, in the 
case of a genuine inhibitor, the in-cell targets are unknown and the hit compounds 
present the possibility of reduced specificity towards the pathogen when tested in a host 
model. Cytotoxic compounds are usually easily identified and eliminated by performing 
simultaneous bioactivity assays with eukaryotic cells like yeast. 
Target directed in vitro assays are performed with enzymes / proteins that have 
been validated as a good drug target. These are enzymes playing important roles in key 
metabolic pathways, are essential for the cell survival or act as important virulence 
factors. While the target directed in vitro assay screening with a compound library does 
not demand the knowledge of the biophysical and biochemical properties of the selected 
target, the routine does require that the desired target be over expressed and purified for 
the purpose of the assay. An inhibitor of the target protein identified in this manner has a 
greater probability of moving along as a lead candidate if it performs well in the whole-
cell bioactivity assays as well. Natural products have an advantage in this regard since 
they are purported to have ‘drug-like’ properties, one of the criteria for which is good 
cell penetration power. 
The following sections will discuss the screening of natural products in a targeted 
in vitro enzyme assay. In this section, examples will be provided of two commercially 




assay. While the screening of the libraries is an ongoing process the section concludes 
with a discussion of the challenges encountered during the study, how they were 
overcome and the successful identification of a natural product inhibitor through the 
process of bioactivity guided fractionation of crude microbial extracts. 
 
Methods 
High Performance Liquid Chromatography Fractionation 
The Vicuron library consisted of ninety six extracts. 200 µg / ml worth of 
extracts were provided for each of the ninety six extracts. The dry extracts were 
reconstituted with 150 µL water. The extracts were fractionated by injecting on to a 
reverse phase C18 column on a Waters® high performance liquid chromatography 
(HPLC) with a photodiode array detector, a manual injector and a WFC III® fraction 
collector, also from Waters®. 100 µL of the solution was injected on to the HPLC while 
the remaining 50 µL were stored for later LC / MS analysis. Forty fractions were 
collected per extract by running a gradient between water, methanol and acetonitrile, 
each containing 0.1 % formic acid. (LCMS grade solvents were used). The LC gradient 
conditions were as described below: 
Column specification: 4.6 X 250 mm Waters Atlantis® T3, 5 µm (This column 
specification remains the same for all the subsequent LC fractionations on a semi 
preparative scale unless and otherwise mentioned) 
Flow rate: 1 ml / min 




Mobile phase: A = acetonitrile + 0.1 % formic acid, B = water + 0.1 % formic acid, C = 
methanol + 0.1 % formic acid. 
Gradient conditions: 10 % C, 90 % B to 100 % C in 25 minutes; 100 % C to 100 % A in 
10 minutes; 100 % A continued for 5 minutes. 
The HPLC fractions for each extract were collected directly into the wells of a 
ninety six well deep well polypropylene plate. While the photodiode array ultraviolet 
detector maintains a record of all absorbance in the Ultraviolet (UV) range between 200 
to 400 nm, the absorbance at 260 nm wavelength was extracted through the Empower® 
software for each of the ninety six LC chromatograms for the purpose of comparison. 
Out of the 1 ml fractions per well, 200 µL were aliquoted into a separate 96 well plate 
for later LC / MS analysis, while the remaining 800 µL fractions per well were 
evaporated and stock solutions made in DMSO to be used for whole-cell bioactivity 
assays. The ninety six extracts were grouped into similar UV chromatogram profiles, 
while taking into account the respective sources of the extracts. The UV data along with 
the bioactivity assay data was used to prioritize the active fractions of interest for further 
LC / MS analysis. 
Twenty nine crude butanol extracts from the Sarawak library were fractionated 
by Sarawak Biodiversity Center (SBC) and sent for testing the whole-cell bioactivity 
against M. smegmatis. 50 µL, equivalent to 1 mg of crude extract, was injected into a 
Zorbax Eclipse XDB-C18, 5 µm, 4.6 X 150 mm reverse phase column. The LC gradient 
for the HPLC fractionation was as follows; 10 % methanol to 100 % methanol in 15 




collected directly into 96-well deep well plates at the rate of 1 ml per fraction per 
minute. 800 µL from each fraction was dried and sent for testing, while the remaining 
200 µL were retained as reference. 
LC gradient conditions for the semi-preparative scale fractionations of the six 
prioritized extracts – 25061, 26071, 26072, 32010, 32022 and 67037 were as follows; 
Flow rate: 1 ml / min 
Injection volume: 20 µL 
Mobile phase: A = acetonitrile + 0.1 % formic acid, B = water + 0.1 % formic acid, C = 
methanol + 0.1 % formic acid. 
Gradient conditions: 10 % C, 90 % B to 100 % C in 25 minutes; 100 % C maintained for 
25 minutes; 100 % C to 100 % A in 10 minutes. 
LC gradient conditions for the preparative scale fractionation of the six prioritized 
extracts – 25061, 26071, 26072, 32010, 32022 and 67037 were the same as that for the 
semi preparative scale fractionation, except the flow rate was maintained at 5.0 ml / min. 
A 10 X 250 mm Waters Atlantis® T3, 5 µm preparative scale HPLC column was used 
for the fractionation. The fractions were collected directly into 16 x 100 glass fraction 
tubes at the rate of 5 ml per fraction per minute. 
 The bioactive fractions number thirty / thirty one of extract 67037 were further 
fractionated on the semi preparative HPLC column to isolate the active compound. A 
randomly selected inactive fraction number 26 was also fractionated to serve as a 
negative control. The gradient conditions for both bioactive and inactive fractions were 




for a period of 40 minutes at a flow rate of 1 ml / min. The forty fractions were collected 
in a 96-deep well polypropylene plate. 
 Upon testing the above fractions for bioactivity against whole cell Mtb and M. 
smegmatis, fraction number five was identified as bioactive. The remaining bioactive 
fraction number five was concentrated and subjected to further fractionation on the 
HPLC using the semi preparative C18 column. The gradient conditions for the 
fractionation were as follows; 
10 % A - 90 % B to 100 % A in twenty five minutes; 100 % A maintained for fifteen 
minutes; 100 % A to 10 % A – 90 % B in five minutes. Forty five fractions were 
collected in a 96 – deep well polypropylene plate. The generated fractions were again 
tested for their whole cell bioactivity against Mtb and M. smegmatis cells. The bioactive 
fractions from this set of fractions were analyzed by LC / MS. 
 
Whole-Cell Bioactivity Assay 
 An aliquot of each fraction was used for the M. semegmatis and Mtb whole cell 
bioassay. Yeast whole cell assay (against C. albicans) was tested as a surrogate for 
cytotoxicity assay. The bioactivity tests were performed in 384 well formats. 
Rifampicin, at concentrations ranging from 100 µM to 0.01 µM and an inhibitor, 
Vidya2, at concentrations ranging from 25 µM to 0.003 µM were used as positive 
controls against M. smegmatis and Mtb whole cells. Amphotericin, at concentrations 
ranging from – µM to – µM concentration was used as the positive control against C. 




were considered as positive controls. The 384 well plates containing the cells were 
incubated at 37 ˚C for 48 hours for M. smegmatis cells and 120 hours for Mtb cells. After 
this period, 1.25 μL of alamar blue (resazurin dye) was added to the wells and left for 
overnight in the incubator at 37 °C. The wells were then measured 
spectrophotometrically at 544 nm and 590 nm for cell growth. Wells with cell growth 
are able to reduce the alamar blue which then turns pink. The resazurin dye in the wells 
with no cell growth remained blue. Since the concentrations of the compounds in each 
fraction were unknown, an arbitrary value of 50 X was assigned to the active compound 
in each original extract dissolved in 150 µL solvent. Based on this arbitrary value and 
taking into account the dilution factors during the fractionation, evaporation of the 
fractions, resolubilization of the individual fractions and preparation of stock solutions 
from the fractions, the fractions were tested at a final concentration of 0.5 X. A 
representative layout of the fractions in a 384 well plate format along with the 


























































































































































































































































































































































































































































Liquid Chromatography / High Resolution Mass Spectrometry 
 The bioactive fractions in the original fractions received from SBC were 
analyzed by direct infusion into the high resolution micrOTOF-Q II® mass spectrometer 
from Bruker Daltonics Inc to help prioritize the extracts of further interest. Liquid 
Chromatography / Mass spectrometry (LC / MS) data was obtained for the active 
fractions from the prioritized extracts of the Vicuron extract library as well as the SBC 
collection of extracts on an Agilent 1200 Infinity series HPLC with temperature 
controlled autosampler and a photodiode array detector and the in-line micrOTOF-Q II® 
mass spectrometer from Bruker Daltonics Inc. The LC conditions were as follows: 
Column specification: 2.1 X 100 mm, Waters Atlantis T3®, 5 µm 
Flow Rate: 0.5 ml / min 
Mobile phase:  A = water + 0.1 % formic acid, B = acetonitrile + 0.1 % formic acid. 
Gradient conditions: 90 % A, 10 % B to 100 % B in 8 min; 100 % B continued for 4 
min; 100 % B to 90 % A, 10 % B in 2 min; 90 % A, 10 % B continued for 3 min. 
The high resolution mass spectrum (HRMS) was collected in electro spray 
ionization (ESI) positive mode in the mass range of 150 m/z to 2000 m/z. The ESI 
source settings were as follows; 
End plate offset = - 500 V 
Capillary = - 4500 V 
Nebulizer = 4.0 Bar 
Dry Gas = 11.0 L / min 




MS peaks of interest were identified by comparing the HRMS data for the active 
fractions with those of the neighboring inactive fractions and also from solvent (blank) 
runs to eliminate the insignificant MS peaks from consideration. Probable molecular 
formula was generated using the high resolution MS data for the MS peaks of interest. 
SmartFormula® prediction calculation available with the Data Analysis® software from 
Bruker Daltonics Inc. was used for the generation of predicted molecular formulas for 
the MS peaks of interest. 
 
Dereplication of Actives 
Dereplication is a process of screening the identified bioactive chemical entities 
against a database of previously discovered molecules to recognize molecules that 
already exist in the database 189. In the natural products drug discovery process repeat 
discoveries of bioactive compounds are a common occurrence and the dereplication 
process is used to eliminate such entities, unless the bioactive compound represents an 
activity that is different from the one published in which case it may be retained as a new 
activity. This is a method of data reduction to eliminate redundant data and concentrate 
on the unique MS data. 
The molecular formula generated for the MS peaks of interest from the bioactive 
fractions were subjected to a process of dereplication by matching the generated 
molecular formula and the HRMS data against the Dictionary of natural products (DNP) 
database. If the molecular weight, molecular formula, the biological source (where 




the results were retained as a plausible hit. The fractions for which no match could be 
found were considered unique, possibly novel compounds and hence worthy of further 
investigation to identify the active compounds. 
 
Results and Discussion 
Vicuron Extract Library 
Previously, a collection of 140,000 natural product extracts were obtained from 
FIIRV. The sources of these extracts were mainly rare actinomycetes, myxomycetes and 
fungi. 96 extracts were chosen from the total 140,000 extracts based on their previous 
bioactivity against gram positive bacteria. These were prioritized to enrich the collection 
with natural product extracts that were more likely to give anti mycobacterial hits. About 
200 uL worth of fermentation broth from the selected 96 extracts were acquired in one 
96 well microtitre plate to test their bio-activity against mc2155 strain of M. smegmatis 
and the mc27000 strain of Mtb. M. smegmatis is a fast growing generally nonpathogenic 
mycobacterium that is considered a surrogate for Mtb. The 96 extracts in the 
polypropylene plate were labeled according to their well positions. 
All 96 extracts were fractionated into forty fractions per extract. The LC 
condition was primarily a gradient between 10 % methanol and 100 % acetonitrile. The 
fractions were collected directly into the wells of a 96 well polypropylene plate. 100 uL 
of each fraction was aliquoted into a separate plate and saved for later LC/MS analysis 




in dimethyl sulfoxide (DMSO). Stock solutions were made for testing the whole cell 
anti-mycobacterial activity against strains of M. smegmatis and Mtb. 
Out of the 96 extracts, 33 extracts had fractions that were active against M. smegmatis 
and only three extracts had fractions that were active against Mtb. Given that the 96 
extracts were selected based on their previous activity against gram positive bacteria, the 
results of the whole cell bioactivity assay came as a surprise as all 96 or at least a 
majority of the 96 extracts were expected to have positive bioactivity against M. 
smegmatis and Mtb. However it is interesting to note that the previous activity in the 
parent collection came from testing the whole extracts and not the various fractions. This 
suggests that the previous activity could have originated from a mixture of compounds 
that acted in a synergistic or additive fashion. This is typically observed in most herbal 
and ayurvedic medicines where the activity arises from multiple components of the 
extract acting in combination. When the 96 prioritized extracts were fractionated it is 
likely that compounds that previously acted in synergy got separated on the column and 
thus the activity was lost when each fraction was tested individually. Reproducibility is 
always an issue in any kind of high-throughput or low-throughput screening. For reasons 
including human error or experimentally introduced error, it is not always possible to 
exactly reproduce a screening assay. Such unforeseen errors in reproducibility may have 
also caused the extracts to stop showing whole-cell bioactivity. In either case, the 
number of extracts showing activity was considered significant and it was prudent to 
focus on the active extracts to look for novel bioactive natural products. The statistics of 




extracts had bioactivity on Mtb, M. smegmatis or Candida albicans. Cells with values 
that were considered significant for the purpose of prioritizing the extracts are colored 
(Table 6). 
Two of the Mtb active extracts overlapped with the M. smegmatis extracts. These 
were extracts at well positions B3 and E8. Apart from the M. smegmatis and Mtb activity 
the fractions were also tested against C. albicans for their antifungal activity. The 
eukaryotic whole cell activity was considered as a surrogate for cytotoxicity assay. 
While a significant number (16) of the 96 extracts displayed antifungal activity, 
activities for six of these extracts overlapped with M. smegmatis whole cell activity and 
two of them overlapped with the Mtb activity (Highlighted in Table 6). Although the 
primary aim of the experiment was to find natural compounds that had anti-
mycobacterial activity, out of curiosity the extracts showing antifungal activity were also 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































A general observation among the active fractions was that activity was observed 
beyond the 20th fraction in most of the cases with some exceptions. The gradient system 
for HPLC fractionation from polar solvent to the non-polar solvent meant that the polar 
components of the extract mixtures eluted first followed by the nonpolar components of 
the extract in that order. Thus the compounds eluting beyond the 20th fraction can be 
expected to have nonpolar characteristics with few polar functionalities. It has been 
observed that compounds from a compound collection with good inhibitory activities 
that make it to the drug discovery stage are typically lipophilic (non-polar) molecules 190. 
Thus the later fractions from the HPLC separations would be more desirable as 
possessing anti-mycobacterial activity. 
After a high-throughput or low-throughput screening, the next step is to prioritize 
the compounds or extracts to be taken to the next level for further investigation. Thus the 
33 M. smegmatis active extracts were narrowed down to the few most promising extracts 
that could potentially allow the identification of a novel anti-mycobacterial or antifungal 
compound. Since the collection of 96 extracts consisted of rare actinomycetes, 
myxomycetes and fungi, it was possible that one or more of the extracts belonged to the 
same species and strain of microbe. In such cases it would be unintuitive to select two or 
more extracts that belong to the same strain for further investigation. Thus an additional 
step in the prioritization was to analyze the LC chromatograms of all 96 extracts and 
group them into extracts with similar biological origins. When the LC profiles of all 96 




the LC profiles of many extracts could be matched to other extracts in different well 





Figure 30: The LC UV profile chromatograms of two extract at well positions A6 and 
F5. The similarities in the LC profiles of the two are apparent. Both extracts were 













Figure 31: LC chromatograms of five different extracts sourced from myxomycetes. 




High resolution (HR) LC / MS data in the electrospray ionization (ESI) positive 
mode was collected for all bioactive fractions. The HRMS data was analyzed and 
compared with other active and inactive fractions and also with the blank solvent runs to 
identify MS peaks of interest. MS peaks that seemed to be unique to the active fractions 
and that could potentially represent the active component of the fraction were identified. 
The Data analysis® software on the Bruker micrOTOF Q-II MS instrument has a built-in 
SmartFormula® prediction program. The SmartFormula program was used to generate a 
list of predicted molecular formula for each MS peak of interest. High resolution MS 
data was used in the molecular formula prediction and in cases where the prediction list 
was greater than five, the results with the top five scores were retained. 
The next step in the identification of the active compounds was dereplication. 
Databases exist of all the previously identified, characterized and published natural 
products, like ChemBank, PubChem antiBase and Chapman & Hall’s Dictionary of 
Natural Products (DNP) 191. In natural products drug discovery it is common to 
encounter a previously discovered compound in a given fermentation extract. Different 
strains of the same species are known to produce the same antibacterial compounds 
under different environmental conditions. In order to save time and to prevent the 
rediscovery of known natural products, the dereplication process is a necessity. In this 
process preliminary information about the bioactive compound like their molecular 
weight, MS fragmentation pattern or LC-NMR 192 data are compared with those existing 
in the various databases to identify already known compounds and their analogs 193. The 




and was used as the basis along with the high resolution mass to perform dereplication 
against the database of over 200,000 natural products contained in DNP. No natural 
products with the same high resolution mass and the same elemental composition as 
those predicted were found. Hence it was concluded that the observed activity most 
likely came from a novel natural product or at least an analog of a known natural 
product. 
The UV absorbance data collected during the initial fractionation was also cross 
referenced with the activity data and the HRMS data on the active fractions to eliminate 
fractions that did not have any associated UV peak. Only the active fractions with an 
associated UV peak in the HPLC profile were considered because it would be easier to 
follow the bioactivity of compounds that exhibited a UV absorbance in the subsequent 
LC fractionation steps. As will be evident in the following paragraph, this feature was 
given much importance while prioritizing the extracts of interest for further 
investigation. 
Nine extracts were selected for further investigation and the reason for their 
selection is given below: 
B2 – This extract represented a unique biological source whose LC UV profile 
spectra did not match with that of any other extract in the collection. The extract had 
whole-cell bioactivity against M. smegmatis. The fractions that were bioactive also had 
strong UV peaks associated with them. The MS peaks of interest were in the range of 




B3 - This extract had fractions that were active against M. smegmatis as well as 
Mtb in the whole-cell bioassay. This is one of the three extracts that showed bioactivity 
against Mtb. The same fraction that was active against M. smegmatis was also active 
against Mtb. Further the activity was reproducible in both bioassays. Besides, the active 
fraction also had an associated UV peak. 
B5, B6 and B7 - These extract had fractions that were active against M. 
smegmatis with associated UV peaks for the fractions of interest. The active fractions 
were observed towards the nonpolar end of the LC gradient making the active compound 
or compounds possibly lipophilic in nature which is a desirable characteristic to have in 
a lead molecule. 
C4 - This was among the few extracts that had both M. smegmatis activity and 
anti-fungal activity against C. albicans. However it did not show any activity against 
Mtb whole cells. The active fractions had associated UV peaks. 
E3 - The extract had whole-cell bioactivity against M. smegmatis and strong UV 
peaks associated with the fractions containing activity. The active fractions of this 
extract also had the most number of unique MS peaks of interest with no matches against 
the natural products database during dereplication. 
E7, E8 – These were the other two fractions that were active against both M. 
smegmatis as well as Mtb in the whole-cell assay. Further the activities were 
reproducible. Extract E7 had intense MS peaks of interest, which might be easy to 
follow upon refermentation and fractionation. During the dereplication of the masses 




came up as one of the possible hits. This was an interesting find as antimycobacterial 
activity for this compound would be a novel activity. The source of the extract for E8 is 
known. It is a fungi and falls under the genus fusarium. 
  
Sarawak Biodiversity Library of Extracts 
29 extracts were short listed from a library containing a total of 145 microbial 
extracts, to test for their bioactivity against M. smegmatis. 17 of the extracts were 
sourced from different strains of the Streptomyces species. The sources for the remaining 
12 extracts were unknown.  The extracts were fractionated at Sarawak into 30 fractions 
per extract. The first 20 fractions were collected and the eluting solvents were removed 
by evaporation. The dry fractions were transferred into 96 well microtitre plates. The dry 
fractions were reconstituted into 20 µL per fraction and were assigned an arbitrary 
concentration of 50 X. The fractions were tested for bio-activity against M. smegmatis at 
a final concentration of the fractions of 0.5 X. The bioactive fractions were also tested 
for cytotoxicity against human cancer cell lines to eliminate the generally cytotoxic and 
nuisance compounds. Eight out of the 29 extracts had fractions that were active against 
M. smegmatis. The active extracts constituted 24 % of the total number of extracts 
tested. When the fractions were retested at double the concentration (1 X), 16 out of the 
29 fractions showed activity, which included the previous eight extracts. The active 
extracts from the rescreening constituted 55 % of the total number of extracts. When 
compared with the cytotoxicity data, it was observed that six of the M. smegmatis whole-




original M. smegmatis bioactive extracts (that tested positive for whole-cell bioactivity at 
low concentrations of 0.5 X). HRMS data was obtained for all bioactive fractions that 
were non cytotoxic, by direct infusion into the MS using an ESI probe in both positive 
and negative modes. 
The MS spectrums were compared with those of other bioactive fractions and 
with inactive fractions that were randomly picked. This was done to identify MS peaks 
of interest in the bioactive fractions that did not exist in the inactive fractions. If a certain 
MS peak appeared consistent in an adjacent bioactive fraction for the same extract but 
did not appear in an inactive fraction of the extract it was considered to be an MS peak 
of interest as it most likely corresponded to the bioactive component in the fraction. 
Likewise if an MS peak in a bioactive fraction was consistently observed in a 
neighboring inactive fraction it was most likely that the peak did not correspond to the 
active molecule. One possibility is that a bioactive compound may elute out of the HPLC 
column into two or more adjacent fractions, however, it may only be present in 
sufficiently high concentrations in one of the fractions to be able to respond to the 
bioactivity assay. A mass spectrometer with sufficiently high sensitivity can detect the 
mass of the active compound in all the fractions where it eluted even though it is at low 
concentrations. During analysis this phenomenon may cause a false negative data 
causing the MS peak corresponding to the active compound to be rejected as an 
uninteresting mass peak. In order to overcome this issue, random fractions that were far 




MS peak corresponding to the bioactive compound to occur in random fractions away 
from the bioactive fractions. 
SmartFormula® prediction calculation was used to generate molecular formula 
for the MS peaks of interest. Among other criteria, the SmartFormula® calculation uses 
the error (in ppm) in the high resolution masses of the predicted molecular formula and 
the experimentally observed mass to score the generated molecular formulas. Depending 
on how well the mass spectrometer is calibrated, the predicted molecular formula with 
the lowest ppm error has the highest probability of being the real molecular formula. 
Since calibration of a Time-of-Flight (TOF) MS can deviate marginally over time the 
experimentally observed masses cannot be relied upon as the real masses. An error of up 
to 10 ppm was allowed in the experimentally observed masses for the SmartFormula® 
program to accurately predict the molecular formulas. For this reason, molecular formula 
predictions with up to 10 ppm or the top five predicted molecular formulas calculated by 
SmartFormula® were considered. Another factor to be considered in scoring the 
predicted molecular formulas is the mean standard deviation or the ‘mSigma’ value, 
which accounts for the variation in the isotopic peak patterns between the experimentally 
observed set of peaks and the predicted isotopic peak pattern of a molecular formula. For 
the Bruker micrOTOF Q-II® MS instrument a variation of 20 ppm or less was 
considered to be within the acceptable range for the SmartFormula® calculation to 
accurately predict a molecular formula.  
The list of predicted molecular formulas thus generated and sorted for each MS 




discussed in the previous sections dereplication process is helpful to identify previously 
published compounds and eliminate them from the list of prioritized extracts. While 
most of the MS peaks did not match with the available natural products in the dictionary 
of natural products (DNP), there were a few hits such as Manzamine for extract # 26072 
that were interesting finds. They were of interest because Manzamine and its analogs are 
reported as inhibitors of Mtb 194,195, however this natural product is reported to be found 
typically in marine sponges. The source of extract # 26072 was Streptomyces 
misionensis and the genus Streptomyces are typically soil dwelling microorganisms. It 
would be an interesting find if Manzamine were indeed established to be the real source 
of the bioactivity as it would suggest a new source for the natural product. Natural 
products reported to be originating from certain marine sources like sponges have 
occasionally been corrected to be originating from other symbiotic and epiphytic 
microorganism that reside inside the sponges 196. Examples of these exist in the 
dictionary of marine natural products like Swinholide A, which was originally believed 
to be produced by the sponge, Theonella Sinhoei 197. This alkaloid was later isolated 
from the cyanobacterium Aphanocapsa feldmanni that exists inside the sponge 198. 
The available LC / UV profiles were also compared to each other and with their 
respective activity profiles. Extracts with bioactive fractions that had associated UV 
peaks were desirable as these would be easy to follow through subsequent purification 
steps. Six extracts were selected for further analysis either because they presented the 




published compound having a new bioactivity. These were extracts # labeled as 25061, 
26071, 26072, 32010, 32022, and 67037 and will hence be referred to by their labels. 
Large scale crude extracts were obtained for the six prioritized extracts. An 
aliquot consistent with the amount previously analyzed was processed in the same 
manner as before, then fractionated and the bio-activity tested to confirm that the activity 
was reproducible in the refermentation. Upon confirmation of activity, a preparative 
scale fractionation was performed using a preparative reverse phase C18 HPLC column 
at a flow rate of 5 ml/min. The same gradient of mobile phase solvents was used as for 
the small scale extracts. However the length of the gradient was expanded to cover 60 
fractions. Stock solutions of the fractions were prepared so that they could be tested in 
the whole cell bioactivity assays at 0.5 X like the previous batch of small scale extracts. 
Two out of the six extracts – 26071 and 67037 had whole cell activity against M. 
smegmatis and 26071, 32022 and 67037 had whole cell activity against Mtb. The 





Table 7: A summary of the 29 Sarawak extracts and their bioactivity
 
The extracts prioritized for further study are marked red. The fractions of the extracts 
that were bioactive against M.smegmatis in the original screen are shown in the blue 
cells. The cytotoxic extracts are shown in the grey cells. Fractions of the prioritized 
extracts that were refermented, refractionated and tested positive for bioactivity in the 
whole-cell assay against M. smegmatis cells are shown in the purple cells. Fractions that 
tested positive in the bioactivity assay against Mtb cells are shown in maroon. The last 
row colored dark red represents the active fractions of extract # 67037 that were further 
fractionated and tested for M. smegmatis and Mtb bioactivity. 
 
 










New M.smeg  activity 
(sm scale fractn.)
New M. tb 
activity (sm 
scale fractn.)
Prep M. smeg 
activity
Prep M. tb  activity
Streptomyces  sp. SXY66 8050 No No _
Streptomyces parvulus 8062 16, 17 16-19 _
unknown 8065 No No _
unknown 9020 No No _
Streptomyces seoulensis 9050 No No _
unknown 13067 19, 20 16, 19, 20 _
unknown 14056 17-19 15-19 _
Streptomyces  sp. M4032 25049 17 13-18 _
Streptomyces  sp. M4032 25054 17, 19 13-19 _
unknown 25061 18, 19 No Yes 36, 38, 40-43, 47-59 No 32, 33 33 (doubtful)
Streptomyces  sp. 210801 26008 No 19
Streptomyces  sp. L-2-14 26071 4, 14-18 No Yes 12-21, 30, 33-41, 45-
57, 59
4, 12-23 4, 5, 8, 9, 14 6, 9, 10, 12, 13, 14, 15, 16
Streptomyces misionensis 26072 4 No Yes 24, 34, 38, 40, 45, 47, 
48, 51, 53, 55-56
No No
unknown 31059 19 19
unknown 32010 10 No Yes 38, 40, 42-44, 47, 49-
57, 59-60
No No
unknown 32011 No No
Streptomyces  sp. SXY66 32022 12 No Yes 28-30, 34, 39-40, 44-
45, 49-52, 54-57
40 No 15-16, 32, 47
Streptomyces  sp. SXY66 32031 16, 19 No
Streptomyces Chromofuscus 32033 No No
Streptomyces Chromofuscus 33059 No No
Streptomyces Chromofuscus 33068 No No
Streptomyces  sp. IM - 7464 49045 No No
Streptomyces  sp. ACT - 0095 50025 No No
unknown 51054 13 No
unknown 54066 No No
Streptomyces  sp. TA 4 - 8 65055 No No
unknown 65067 19 No
unknown 67026 16 No
Streptomyces Chromofuscus 67037 11 No Yes 33-35 33-34 21, 30, 31, 46, 49, 
50, 52 
30, 14, 56-60




The Story of Extract 67037 
The activity profile of extract 67037 will be followed in this section. The 16s 
rDNA sequence of extract 67037 revealed the strain to belong to Streptomyces sp. 
SXY66. A butanol extract was shown to have positive antimicrobial activity against 
Micrococcus luteus and Pseudomonas aeruginosa. Further the crude extract was shown 
to have no inhibitory activity towards Aspergillus niger, Bacillus subtilis, Escherichia 
coli and Saccharomyces cerevisiae. Fractionation of the small scale extracts were 
conducted by S.B.C. and the dried fractions were sent for further testing against M. 
smegmatis and Mtb.When the fractionated extract was tested for whole-cell 
mycobacterial activity, fraction number 11 was bioactive against M. smegmatis. An 
aliquot of fraction number 11 was injected by direct infusion into the Bruker 
micrOTOF® Q-II mass spectrometer. MS peaks of interest were manually picked by 
comparing the MS data with those of the neighboring inactive fractions. As there was no 
match for the MS peak of interest in the dictionary of natural products database, the 
extract was considered worthy of further investigation. Large scale extracts for 67037 
were obtained by refermentation on a large scale. An aliquot of the large scale 
fermentation was used to perform a small scale fractionation in order to check for 










When these fractions were tested in whole-cell assay against M. smegmatis 
bioactive fractions could be found, which confirmed the success of the large scale 
refermentation. The HPLC UV profile of the original and refermentation extract 
matched further confirming the reproducibility of the extract. The remaining extracts 












Fractions were collected directly into glass test tubes at the rate of 5 
ml/min/fraction. The large scale fractions were dried, reconstituted in dimethyl sulfoxide 
(DMSO) and retested in whole-cell bioactivity assay against M. smegmatis and Mtb. The 



























smegmatis (mc2 155) cells. Fraction numbers 30 and 31 from the preparative scale 
fractionation of extract 67037 was bioactive against M. smegmatis whole-cells. (The 
other fractions exhibiting bioactivity were not consistent with the bioactivity assay 








Figure 35: Whole-cell bioactivity profile of the 60 fractions of extract 67037 on Mtb 
(mc2 7000) cells. Fraction number 30 from the preparative scale fractionation of extract 




 As this bioactivity originated from a preparative scale fractionation, there was 
sufficient amount of material to go through further rounds of HPLC separation to further 
isolate the active component of the fraction. Fraction numbers 30 and 31 of extract 
67037 were bioactive against both M. smegmatis as well as Mtb cells. These two 
fractions were hence pooled together and refractionated on the semi-preparative HPLC 


























Figure 36: LC UV profile of fractions number 30 and 31 of extract 67037 on semi-prep 
C18 HPLC column. 
 
  
The generated fractions were dried, reconstituted and retested for whole-cell 






























31 of extract 67037 on M. smegmatis (mc2 155) cells. Fractions number five, six and 








Figure 38: Whole-cell bioactivity profile of the fractionation of fractions number 30 and 
31 of extract 67037 on Mtb (mc2 7000) cells. Fractions number five and six were active 




In the retesting, fractions number five, six and seven were active against M. 
smegmatis whole-cells while fraction numbers five and six were active against Mtb 
whole-cells. Thus it was confirmed that the activity could be reproduced through the 
further rounds of purification. An aliquot of fractions number five, six and seven were 



























As a control, a randomly picked inactive fraction number 26 from the preparative 
scale fractionation of 67037 was refractionated using the same LC method as that used 
for the fractions number 30 / 31 (Figure 39). Fraction number 26 represented a negative 
control as none of the fractions generated from the fractionation would be expected to 
show bioactivity against Mtb or M. smegmatis in the whole-cell assay. Indeed, when the 
fractions were tested for bioactivity none of the fractions showed bioactivity against Mtb 




Figure 39: LC UV profile of fraction number 26 of extract 67037 on semi-prep C18 
HPLC column. The UV profile of fraction number 26 is different from the UV profile of 




Since fraction number five from the refractionation of fractions 30 / 31 was 
active, fraction number five from the refractionation of 26 was also selected for LC / 




this negative control other randomly selected inactive fractions from the fractionation of 
fractions 30 / 31, fractions two and 11 were also used as negative controls. The LC / 
HRMS data for all the selected fractions were collected using electrospray as a source of 
ionization in the mass spectrometer and in the positive and negative modes. 
Manually sorting through the mass spectrum at every time point of the LC 
gradient is time consuming and introduces human error into the analysis. Metabolite 
Tools® suite of software package developed by Bruker Daltonics Inc. was used to 
simplify the data processing. The Metabolite Tools® software suite consists of two 
programs – Metabolite Detect® and Metabolite Predict®. The two programs were 
originally designed to analyze plasma, blood or serum samples and identify the 
administered drug molecules and metabolites thereof. The operating parameters of the 
Metabolite Tools® software package was modified to apply to the bioactive and inactive 
HPLC fractions of the extract 67037 and to identify MS peaks of interest in the bioactive 
fractions. The Metabolite Predict® part of the software is designed to predict metabolites 
of a known drug compound and was not considered useful in the context of the present 
research. Hence, the use of Metabolite Predict will not be discussed in this dissertation. 
Metabolite Detect® was a useful component of the software package as it can statistically 
compare the mass spectrum of a test sample with that of a reference (control) sample and 
subtract all the MS peaks occurring in the reference sample from the test sample. When 
applied to the HPLC fractions of 67037 with the appropriate operating parameters, this 
software could be used to quickly narrow down to the MS peaks of interest that existed 




obtained from the bioactive fractions five and six from the refractionation of fractions 30 
/ 31 was used as the test sample. The LC / HRMS data obtained from the inactive 
fractions five and six from the refractionation of fraction 26 as well as the HRMS data 
obtained from the inactive fractions two and 11 from the refractionation of fractions 30 / 
31 were used as reference samples. Upon subtracting all the MS peaks in the reference 
samples from the test samples, the MS data could be narrowed down to MS peaks of 
interest that could be followed through further rounds of purification. 
 The remaining amount of the bioactive fraction number five was concentrated 
and refractionated on HPLC to further isolate the bioactive component in the original 




Figure 40: LC UV profile of fraction number five from the refractionation of fractions 







The newly generated fractions were again tested for their whole-cell bioactivity 





Figure 41: Whole-cell bioactivity profile of the fractionation of fraction five of extract 
67037 on M. smegmatis (mc2 155) cells. Fractions 32 and 33 exhibited whole-cell 































Figure 42: Whole-cell bioactivity profile of the fractionation of fraction five of extract 
67037 on Mtb (mc2 7000) cells. Fractions 32 and 33 exhibited whole-cell bioactivity 




Fractions number 32 and 33 from the new set of fractions displayed consistent 
whole-cell bioactivity against both M. smegmatis and Mtb cells (Figure 41 and 42). LC 
/ HRMS analysis was performed for all the bioactive fractions through the successive 
rounds of fractionations starting from the crude extract to the semi purified fraction 
observed in Figure 40. The LC / HRMS data was analyzed to follow the MS peaks of 























Figure 43: LC / HRMS analysis of fraction number 30 from the first round of 
fractionation of the crude extract. The MS profile at 9.8 minute time point in the ESI 




Figure 44: LC / HRMS analysis of fraction number five from the refractionation of 
fractions number 30 / 31. The MS profile at 9.8 minute time point in the ESI negative 










































Figure 45: LC / HRMS analysis of fraction number 32 from the refractionation of 
fractions number five / six. The MS profile at 9.9 minute time point in the ESI negative 




 The LC / HRMS analysis of bioactive fractions through the rounds of HPLC 
fractionation showed that the MS peak at (m/z) 354.30 and 388.28 in the ESI negative 
mode appeared consistently through the rounds of purification suggesting that one of 
these two peaks might be the source of bioactivity against Mtb mc27000 and M. 
smegmatis mc2155 whole cells (Figures 43, 44 and 45). Smartformula calculation for 
the MS peak at (m/z) 354.30 gave a molecular formula prediction of C21H40NO3 [M-H]- 
with err [ppm] =  -6.0 and mSigma [ppm] = 12.2 and for the MS peak at (m/z) 388.28 
gave a molecular formula prediction of C24H38NO3 [M-H]- with err [ppm] =  -4.7 and 
mSigma [ppm] = 10.7. 
At this stage of purification there was less than 1 mg of the fraction remaining, 
which did not allow for the NMR spectroscopic analysis of the fraction to elucidate the 
















fermentation broth of the bacteria producing the bioactivity was conducted. The 
extraction of the fermentation broth yielded a total of 0.6747 gm dry extract. The extract 
was dissolved in a minimum amount (~1 mL) of methanol and the clear solution was 




Figure 46: LC UV profile of the preparative scale fractionation of extract 67037. The 





 Fractions were collected at the rate of 5 ml/minute/fraction. 100 uL of each 
fraction were aliquoted into the wells of a 96 well polypropylene plate and evaporated to 
dryness. The wells were then reconstituted in 20 uL DMSO. 1 uL from each well was 
tested against M. smegmatis whole cells in a 384 well polypropylene plate containing a 





Figure 47: Whole-cell bioactivity profile of the fractionation of crude extract 67037 on 
M. smegmatis (mc2 155) cells. Fractions 30, 31 and 32 exhibited whole-cell bioactivity 




 The bioactive fractions identified from the whole cell bioactivity assay against 
M. smegmatis matched the bioactivity profile of the fractions generated for the previous 
batch of the extract 67037. Thus the bioactivity was reproducible. The bioactive 
fractions were pooled together, dried and reconstituted in 200 uL methanol and injected 





























Figure 48: LC UV profile for the fractionation of fraction number 30 to 32 of extract 




 Fractions were collected at the rate of 1 ml/minute/fraction. 10 uL of each 
fraction were aliquoted into the wells of a 96 well polypropylene plate and evaporated to 
dryness. The wells were then reconstituted in 5 uL DMSO. 2 uL from each well was 
tested against M. smegmatis whole cells in a 384 well polypropylene plate containing a 








Figure 49: Whole-cell bioactivity profile of the fractionation of fractions 30, 31 and 32 
from the crude extract 67037 on M. smegmatis (mc2 155) cells. Fractions 24 through 28 




 Bioactivity was obtained against M. smegmatis mc2155 cells for fractions number 
24 through 28 (Figure 49). LC / HRMS analysis was performed for the bioactive 































Figure 50: LC / HRMS analysis of fraction number 27 from the refractionation of 
fractions number 30 to 32 from extract 67037. The MS profile at 10.0 minute time point 




 LC / HRMS analysis revealed that the same MS peak at (m/z) 354.30 and 388.28 
appeared in the bioactive fractions (Figure 50). A search in the dictionary of natural 
products (DNP) using the HRMS at (m/z) 354.30 [M-H]- and 388.28 [M-H]- and the 
generated molecular formula prediction revealed a single match for the 354.30 [M-H]- 
peak and showed no matches for the 388.28 peak. The natural product that matched the 
MS peak at 354.30 [M-H]- was N-Methyl-N-(1-oxooctadecyl)glycine with an accurate 
mass of 355.308644 and molecular formula of C21H41NO3. In order to investigate the 
molecular structure of the natural product MS / MS fragmentation data was obtained 

















Figure 51: Fragmentation pattern observed for MS / MS of (m/z) 354.30 [M-H]- in the 




 The fragmentation pattern showed distinct peaks at (m/z) 116.07, (m/z) 130.08 
and (m/z) 310.31. Molecular formulas were predicted for the fragment peaks using the 
SmartFormula® calculator and are shown in the figure 51. While a similar fragmentation 
pattern could be obtained for N-Methyl-N-(1-oxooctadecyl)glycine, the predicted 
molecular formulas of the fragments did not match with the molecular formulas for the 
predicted fragments of N-Methyl-N-(1-oxooctadecyl)glycine. Thus based on the HRMS 
and the predicted molecular formula of the observed fragments, a chemical structure was 
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Chemical structures could be assigned to the observed fragment peaks in the 




Figure 53: Fragmentation pattern observed for MS / MS of (m/z) 354.30 [M-H]- in the 


























 The bioactive fraction number 27 was dried and reconstituted with ~ 400 µL 
(CD3)2CO (deuterated acetone). NMR spectroscopic data was obtained for the sample to 
gain insights into the structural characterization of the natural product (Figure 54 and 
55). 
The NMR data correlated with part of the predicted chemical structure. The 
broad peak observed at δ 1.3 ppm in the 1H NMR and the cluster of peaks in the δ 10 – 




Vicuron Extract Library 
A collection of microbial extracts enriched for activity against gram positive 
bacteria were selected and taken through a process of fractionation, testing the fractions 
for whole-cell bioactivity followed by subsequent preliminary characterization of the 
active fractions. Nine extracts out of the 96 were chosen for further investigation based 
on the bioactivity data. The selected extracts had the highest potential for producing a 
natural product with novel properties. Preliminary characterization of the fractions 














































































 At the time of writing this dissertation the refermentation broths for the nine 
prioritized extracts were yet to be received. One of the biggest challenges in natural 
product drug discovery is reproducing the fermentation broth in an identical fashion so 
as to reproduce the biological activity present in the original fermentation. Many 
different parameter like the media composition, nutrient sources, temperature, time of 
incubation, etc., need to be strictly controlled in order to allow the reproduction of the 
bioactive component by the microorganism in sufficient amounts to be detected in an 
assay. Minor variations in the culture conditions can cause the microbe to stop producing 
the active secondary metabolite or to produce an inactive analog of the same. A way to 
determine the reproducibility of the fermentation broth is to perform a preliminary 
HPLC fractionation on an aliquote of the extract and compare the HPLC profile to the 
same fractionation carried out on the original extract. If the LC UV profiles of the two 
fermentation products can be matched then it can be concluded with confidence that the 
fermentation was reproducible. Other experimental challenges include appropriate 
sample preparation of the extracts for fractionation, optimization of the LC gradient to 
achieve the best possible separation profile and prompt handling of the LC fractions to 
prepare stock solutions for the whole-cell bioactivity assay. 
The process of screening for whole-cell bioactivity was similar to what would be 
typically performed in a high-throughput fashion in a natural product drug discovery 
company. While a large natural products company would process in the order of 100,000 
extracts simultaneously in a truly high-throughput fashion, the present study involved 




screening. However the methods and the number of steps involved in the process remain 
the same. The results obtained from this low-throughput screening effort are significant 
and suggest that even a low-throughput screening effort when performed with insight 
can yield positive results in a short amount of time. 
 
Sarawak Biodiversity Library of Extracts 
Fractions of extract 67037 had anti-mycobacterial activity against both M. 
smegmatis as well as Mtb. The further fractionation of the active fractions still contained 
the original activity. This indicated that the bioactive component of the extract was 
stable through the multiple steps involved in the HPLC purification. When tested against 
human cancer cell lines the crude extract showed no cytotoxicity indicating that the 
bioactivity was specific towards mycobacteria. Through the process of bioactivity 
guided fractionation the crude extract was purified and the potential source of bioactivity 
was isolated. The natural product likely to be active against Mtb and M. smegmatis was 
identified through HRMS and tandem MS as 2-methyl-2-[(4-
oxoheptadecanoyl)amino]propanoic acid. NMR spectroscopic data obtained for the 
bioactive fraction was used to further validate the chemical structure of the natural 
product. The bioactive compound consists of a 17 carbon long aliphatic chain and a 
carboxylic acid head group. Based on the fatty acid like structure of the compound it 
may be speculated that the natural product can be easily taken up by the thick cell wall 
of the mycobacteria. In order to investigate the bioactivity of known naturally occurring 




for bioactivity against both mycobacteria in identically performed whole-cell assays at 
concentrations ranging from 20 µM to 0.15 µM. Surprisingly, the simple fatty acids 
showed whole cell inhibitory activity against the mycobacteria. Palmitic acid and stearic 
acid inhibited Mtb whole-cells with an MIC of ~ 5 µM and oleic acid and linoleic acid 





Figure 56: Whole-cell bioactivity assay of naturally occurring fatty acids against Mtb at 
20 µM to 0.15 µM concentration. Palmitic acid and stearic acid inhibited whole-cell 






































Figure 57: Whole-cell bioactivity assay of naturally occurring fatty acids against M. 
smegmatis at 20 µM to 0.15 µM concentration. Oleic acid and linoleic acid inhibited 




Palmitic acid and stearic acid are long chain fatty acids with no unsaturations in 
the aliphatic carbon chain while oleic acid and linoleic acid are long chain fatty acids 
with one and two unsaturations in the aliphatic carbon chain respectively. The 
bioactivity of these simple fatty acids against the mycobacteria validates the conclusion 
that an atypical fatty acid like the one identified through the high-throughput screening 
process can also follow the same mechanism of cell uptake and inhibition. While fatty 
acids have been used as inhibitors of cholesterol and fatty acid biosynthesis 199 and in 
cancer therapy 200, the current findings may open new avenues for using synthetic or 




































The process of screening natural product extracts for antibacterial activity is one 
that began with the discovery of Streptomycin back in 1944. Streptomycin was isolated 
from an actinomycete, which to this day continues to be the most prolific producer of 
antibacterial agents. Confirmation of 2-methyl-2-[(4-oxoheptadecanoyl)amino]propanoic 
acid as the bioactive agent in extract 67037, which is sourced from Streptomyces 
chromofuscus, will also reaffirm faith that 70 years after the discovery of the first 
naturally occurring antibiotic, natural products research still holds potential for 
discovering novel antibiotics against the dreaded disease of TB. 
 
Future Work 
An important aspect of natural product research is the investigation of the 
biological target of the molecule. Hence experiments will need to be performed to 
narrow down to the most probable enzyme or the biological pathway that the molecule 
targets. This can be achieved by several methods. One way is to isolate resistant mutants 
of the pathogen in the presence of the bioactive molecule. DNA of the mutant 
microorganism can then be extracted. A comparison of the whole genome sequence of 
the mutant and the wild type DNA will give clues to the location of the presence of the 
mutation. The genes carrying the mutations may be the ones conferring resistance to the 
pathogenic organism. Recombinant enzyme of the unmutated gene can be added to the 
microbial fermentation growing in the presence of the bioactive molecule. An increase in 
the dosing of the antibiotic needed to kill the bacterial culture would validate the gene or 





Natural Product Inhibitors of the Mtb Malate Synthase Enzyme 
Once a whole cell active compound is identified from a natural product library, 
the next objective is to find the pathway or the enzyme in the pathogen that the natural 
product targets. This requires growing cells that are resistant to the small molecule and 
sequencing the genome of the resistant strain. A comparison of the whole genome 
sequence of the resistant strain with the wild-type strain is then performed to find the 
mutation sites. This process enables identification of the target for the active compound. 
In order to speed up the process of lead identification, an alternate approach was used 
where Mtb malate synthase was selected as the target and the natural products library 
was screened in an in vitro enzyme assay. Malate synthase was selected as the target 
because it functions in the glyoxylate shunt pathway which has been shown to be 
essential for survival of Mtb inside the macrophages201 and also due to the absence of a 
malate synthase homolog in the human. 
An important factor contributing to the world wide spread of TB is the persistent 
nature of the Mtb bacillus. Mtb can survive inside the macrophages under harsh 
conditions by metabolizing inadequate nutrient sources such as fatty acids 202. For 
example, when glucose is not available to Mtb as a carbon source, it can divert the acetyl 
CoA from β-oxidation of fatty acids into a glyoxylate shunt pathway 203,204. The shunt 
pathway uses isocitrate lyase as a branch point in the tricarboxylic acid (TCA) cycle to 
generate glyoxylate and succinate. The glyoxylate is converted by malate synthase 




virulence or persistence factor in different organisms 205 206 207,208 and as it is absent in 
mammals it is an attractive target for drug discovery. 
The vicuron library of natural compound extracts discussed in the previous 
sections was used as a screening library in an Mtb malate synthase enzyme assay 
targeted screening.  
 
Methods 
High-Throughput in Vitro Assay 
The enzyme master mix constituted the following: 1800 µL of 10 X enzyme 
buffer (200 mM Tris pH 7.5, 50 mM MgCl2, 0.8 mM EDTA), 6896 µL Milli-Q water 
and 4 µL of 2 mg / ml malate synthase enzyme. 
74 µL of the master mix was added to each well of a 384-well microtitre plate, 1 
µL of the natural products extract was added. (All solutions were added to the microtitre 
plate using the liquid handling robotic instrument, CyBio Vario®.) The mixture was 
incubated for 20 minutes. At the end of the 20 minutes, 5 µL of acetyl-CoA solution 
(12.5 mM) was added right before reading the plate on a plate reader. 
The enzymatic reaction was started by adding a solution of 5,5'-dithiobis-(2-
nitrobenzoic acid) (DTNB) / glyoxylate mixture. The DTNB / glyoxylate solution was 
prepared by mixing 5 mM DTNB / 6 mM glyoxylate in Milli-Q water. 
The liquid handling robot was used to dispense 20 µL of DTNB / glyoxylate 
solution to complete the reaction. Plate reader was set at 412 nm wavelength. The 




the addition of the DTNB / glyoxylate mixture. Another reading was taken, 20 minutes 
after addition of the DTNB / glyoxylate mixture. This was the end point reading. 
 
Results and Discussion 
A 640 extracts Mtb whole cell active hit plate generated from the 140,000 
Vicuron microbial extracts library was used in the in vitro screening against Mtb malate 
synthase enzyme. While the complete set of natural products extracts could have been 
used in a high-throughput assay, it was reasoned that a subset of the 140,000 extracts 
which had already been shown to have anti-mycobacterial activity against whole-cell 
Mtb had a greater chance of containing a natural product inhibitor of the Mtb malate 
synthase. The inhibition assay was performed in a high throughput fashion using the Cy-
Bio Vario® liquid handling robot. A dry run was first conducted using a compound, JSF 
1038 as a positive inhibitory control and no inhibitors as negative controls to ensure that 
the enzyme assay was functioning as expected. To calculate a hit, the readings at the 
zero minute time point were subtracted from the 20 minute time point reading. By 
comparing with the positive controls, a value of below 0.5 Au were considered as hits. 
Seven of the extracts showed inhibitory activity in the malate synthase enzyme assay. 
One of these seven extracts was also part of the 96 Vicuron extracts tested for their 
whole cell anti mycobacterial activity. It was in position E6 of the Vicuron plate. The 
remaining 633 extracts that did not have any inhibitory activity against Mtb malate 
synthase but originally showed whole-cell inhibition against Mtb were reasoned to be 




HPLC using a C18 reverse phase column. 40 fractions were generated for each of the 
seven extracts. The 40 fractions were tested again in the same in vitro assay against Mtb 
malate synthase enzyme using the same robotic setup as the first round of screenings. 
Fractions from four out of the seven extracts retested positive. The active fractions from 
the above four extracts were then retested in a dilution series ranging from 2 X to 0.02 X 
relative to their concentrations in the previous activity assay, again using the same 
robotic setup as the first round of screenings. Three extracts out of the four retested in 
the dilution series. The previously mentioned extract number E6 from the Vicuron plate 
was one of these three active extracts that retested in the dilution series. Thus the subset 
of 640 extracts was narrowed down to the three extracts that were likely targeting Mtb 
malate synthase enzyme. These three extracts and their active fractions were labeled 
597-B5 (fraction number 32 and 38), 1146-F11 (fraction number 38) and 734-E2 









Figure 58 (1-5): In vitro enzyme activity assay of the extract 597-B5 (fractions 32 and 
38), 1146-F11 (fraction 38) and 734-E2 (fractions 34 and 35) at dilution series of 0.2 X 








































































The active fractions were tested in a dilution series ranging from 2 X (most 
concentrated) to 0.02 X (least concentrated). Fraction number 32 of 597-B5 inhibited 
Mtb malate synthase at concentrations of up to 0.06 X. Fraction number 38 of 597-B5 
inhibited Mtb malate synthase at concentrations of up to 0.03 X. Fraction number 38 of 
1146-F11 inhibited Mtb malate synthase at concentrations of up to 0.03 X. Fraction 


















































The advantage of a target directed in vitro screening is that the target is already 
known. Malate synthase is an attractive drug target in Mtb due to its association with 
persistence factors in different organisms like Candida albicans, Brucella abortus and 
Rhodococcus fascians and the absence of the same enzyme in human beings. The only 
test that remains to be done for the enzyme inhibitor is to check for its cell permeability. 
As the subset of 640 extracts were selected based on their whole-cell bioactivity against 
Mtb, it is already known that the bioactive component of the extract is cell permeable.  
HPLC fractions of three extracts from the 640 extract library were shown to have in vitro 
inhibitory activity against Mtb malate synthase in a high-throughput enzyme assay. 
Active fractions from the three extracts were tested in serial dilutions and were found to 
exhibit in vitro activity at concentrations as low as 0.03 X. The absence of structural 
information on the in vitro active compounds in the extracts precludes the accurate 
determination of an IC50 value. The amount of material present in the extract mixture 
was not sufficient to perform NMR analysis. Efforts are currently underway to obtain 
more crude extracts for the active extracts. The isolation and purification of the natural 
products in the active HPLC fractions on a preparative scale will enable the accurate 
structural characterization of the natural products exhibiting the in vitro inhibitory 





NATURAL PRODUCT INHIBITORS OF THE PROTEASOME 
 
Introduction 
 The high-throughput or low-throughput screening of a collection of synthetic 
compounds generated by combinatorial chemistry in a whole-cell bioactivity assay can 
be used to identify lead molecules with desirable cell wall penetrating capabilities. 
Molecules synthesized to populate a high-throughput library of compounds are designed 
to represent chemical diversity in relation to the functionalities or structural features. 
However the structural and functional diversity may or may not assist in increasing the 
cell penetrating capability of the combinatorial compound libraries. Lipophilicity is part 
of the reason for the cell penetration power of a small molecule 209. However, the 
complete physico chemical properties of a desirable cell penetrating compound are not 
completely understood. Natural products have a built-in advantage in this regard since 
they are naturally built to traverse through cell membranes. Secondary metabolites with 
bioactive properties that are biosynthesized in the cytoplasm of the producing 
microorganism are through evolution perfected by nature to be secreted by one microbe 
and taken up by another. Since the ability to penetrate cell walls constitute one of the 
‘drug-like’ properties in a molecule, natural products have this natural ‘drug-like’ 
property built into them. Hence, whole-cell bioactivity tests, while necessary for 
synthetic molecules, may not be critical for natural products. A faster approach to 




this research instead of a whole-cell assay the high-throughput screening of the crude 
microbial extract libraries were directed in a target-based in vitro assay. The human 
proteasome was used as the target for the in vitro assay. 
 The proteasome serves as an important drug target due to its central role in 
degradation of misfolded proteins and in maintaining the cellular concentration of 
regulatory proteins involved in cell cycle regulation, apoptosis and angiogenesis 210. The 
degradation process is modulated by the ubiquitin-proteasome pathway and generates 
peptides and amino acids, essential raw materials for synthesizing new proteins 211. An 
increased activity of the human proteasome is shown in cancer cell lines owing to the 
increased rate of metabolism 212. Cancer cells also exhibit higher levels of proteasome 
expression than normal cells which may contribute to the higher susceptibility of cancer 
cells to proteasome inhibitors 213. Proteasome is an attractive drug target because the 
inhibition of proteasome results in the intracellular accumulation of proteins, which 
results in cell growth arrest and programmed cell death 214. A number of different classes 
of synthetic compounds have been tested for anti-proteasome activity, including peptide 
aldehydes like MG-132, peptide vinyl sulphones like NIP-Leu3-vinyl sulfone, peptide 
boronates like PS-341, peptide epoxyketones like epoxomicin and β-lactones like 
lactacyctones 215-218. Natural product inhibitors of proteasome have also been identified, 
like TMC-95A derived from Apiospora montagnei 219, gliotoxin deried from fungus 220 
and (−)-epigallocatechin-3-gallate (EGCG) found in green tea extracts 221. Velcade 




inhibitor to be approved by the food and drug administration for the treatment of 
multiple myeloma 222,223. 
 Proteasome inhibition studies were initiated by testing aliquots of the crude 
microbial extracts in in vitro proteasome inhibition assays. The activity was measured 
against the chymotrypsin-like and caspase-like activity of the proteasome. The activities 
of the extracts were narrowed down to the bioactive components in the extracts by 
successive rounds of HPLC purifications followed by in vitro assays and mass 
spectrometric analysis to follow the MS peaks of interest that appeared consistently in 
the fractions showing in vitro proteasome activity. Finally NMR spectroscopy and MS 
fragmentation data was used to elucidate the structure of the active molecule. 
 
Methods 
High Performance Liquid Chromatography Fractionation 
 Crude material was obtained from Ohr pharmaceuticals in vials and round 
bottom flasks. The vials had insufficient material inside them to conduct HPLC 
fractionations and test the individual fractions. The crude material inside the round 
bottom flasks were sufficient to conduct multiple fractionations, followed by LC / MS 
and possibly NMR spectroscopic analysis. Crude material from five round bottom flasks 
were selected for HPLC fractionation and in vitro enzyme activity assays against the 
human and yeast proteasome. An aliquot of the crude was taken into vials to prepare an 
approximate stock solution of 20 mg / ml for each extract. 20 µL of the stock solution of 




Waters® high performance liquid chromatography (HPLC) with a photodiode array 
detector, a manual injector and a WFC III® fraction collector, also from Waters®. The 
gradient conditions were as follows; 
Column specification: 4.6 X 250 mm Waters Atlantis® T3, 5 µm (This column 
specification remains the same for all the subsequent LC fractionations on a semi 
preparative scale unless and otherwise mentioned) 
Flow rate: 1 ml / min 
Injection volume: 20 µL 
Mobile phase: A = acetonitrile + 0.1 % formic acid, B = water + 0.1 % formic acid, C = 
methanol + 0.1 % formic acid. 
Gradient conditions: 50 % B, 50 % C to 100 % C in 15 minutes; 100 % C to 100 % A in 
20 minutes; then 100 % A maintained for 10 minutes. 
 45 fractions were collected directly into the wells of a 96-well deep well 
polypropylene plate through the WFC III® fraction collector. 100 µL of fractions from 
each well was saved for LC / MS analysis while the rest was concentrated to test for 
proteasome activity in the in vitro enzyme assay. 
 The active fractions of Prot-2 were pooled together, the solvent was evaporated 
and the dry material was reconstituted in methanol to 20 µL. The 20 µL solution was 
injected into the HPLC column for further fractionation using a shallow gradient. The 
mobile phase gradient conditions were as follows; 50 % B, 50 % C to 100 % A in 5 
minutes; 100 % A to 90 % C, 10 % A in 1 minute; 90 % C, 10 % A to 60 % C, 40 % A 




minutes. Similarly, the active fractions of Prot-4 were pooled together, the solvent was 
evaporated and the dry material was reconstituted in methanol to 20 µL. The 20 µL 
solution was injected into the HPLC column for further fractionation. The mobile phase 
gradient conditions were as follows; 50 % B, 50 % C to 15 % B, 85 % C in 5 minutes; 
15 % B, 85 % C to 100 % C in 30 minutes; 100 % C to 30 % A, 70 % C in 30 minutes; 
30 % A, 70 % C to 100 % A in 5 minutes; 100 % A maintained for 5 minutes.70 
fractions for Prot-2 and 75 fractions for Prot-4 were collected directly into the wells of 
96-well deep well polypropylene plates. 
 Preparative scale fractionation for Prot-2 and Prot-4 were performed by 
dissolving 12.5 mg of the crude material for Prot-2 and 38 mg of crude material for Prot-
4 in 200 µL of methanol. The stock solution was injected into a 10 X 250 mm Waters 
Atlantis® T3, 5 µm preparative scale HPLC column. A flow rate of 5 ml / min was used. 
The gradient condition for the preparative scale fractionation of Prot-2 was as follows; 
50 % B, 50 % C to 100 % C in 15 minutes; 100 % C to 100 % A in 50 minutes; 100 % A 
maintained for 5 minutes. 
The gradient condition for the preparative scale fractionation of Prot-4 was as 
follows; 
95 % C, 5 % B to 100 % C in 30 minutes; 100 % C to 100 % A in 30 minutes; 100 % A 
maintained for 10 minutes. 






In Vitro Assay 
The in vitro proteasome assay for Chymotrypsin-like activity was performed 
using a fluorogenic substrate Suc-Leu-Leu-Val-Tyr-AMC and the Caspase-like activity 
was performed using a fluorogenic substrate Z-Leu-Leu-Glu-AMC. 20S proteasome was 
isolated and purified from human red blood cells and used in the assay at a final 
concentration of 100 nM. The reaction buffer consisted of 20 mM Tris pH 7.5, 1 mM 
EDTA, 1 mM DTT and 0.03 % SDS. The proteasome was first incubated with the 
inhibitor at 37 °C for 20 minutes in the reaction mixture containing the buffer. 5 µM 
fluorogenic substrate was added to initiate the reaction. The increase in fluorescence was 
monitored for 30 minutes and the reaction rates were measured as slopes of fluorescence 
versus time. 2 % DMSO instead of the inhibitor was used as a control to determine the 
percent inhibition. 
 
Liquid Chromatography / High Resolution Mass Spectrometry 
 The bioactive fractions were analyzed by Liquid Chromatography / Mass 
spectrometry (LC / MS) using the high resolution micrOTOF-Q II® mass spectrometer 
from Bruker Daltonics Inc to help prioritize the extracts of further interest. LC / MS data 
was obtained for the in vitro active fractions from the extracts on an Agilent 1200 
Infinity series HPLC with temperature controlled autosampler and a photodiode array 
detector and the in-line micrOTOF-Q II® mass spectrometer from Bruker Daltonics Inc. 
The LC conditions were as follows: 




Flow Rate: 0.5 ml / min 
Mobile phase:  A = water + 0.1 % formic acid, B = acetonitrile + 0.1 % formic acid. 
Gradient conditions: 90 % A, 10 % B to 100 % B in 8 min; 100 % B continued for 4 
min; 90 % A, 10 % B in 2 min; 90 % A, 10 % B continued for 3 min. 
The high resolution mass spectrum (HRMS) was collected in electro spray 
ionization (ESI) positive mode in the mass range of 150 m/z to 2000 m/z. The ESI 
source settings were as follows; 
End plate offset = - 500 V 
Capillary = - 4500 V 
Nebulizer = 4.0 Bar 
Dry Gas = 11.0 L / min 
Dry temp = 200° C 
MS peaks of interest were identified by comparing the HRMS data for the active 
fractions with those of the neighboring inactive fractions and also from solvent (blank) 
runs to eliminate the insignificant MS peaks from consideration. Probable molecular 
formula was generated using the high resolution MS data for the MS peaks of interest. 
SmartFormula® prediction calculation available with the Data Analysis® software from 
Bruker Daltonics Inc. was used for the generation of predicted molecular formulas for 







Results and Discussion 
 Aliquots of five different crude extracts were weighed and concentrated stock 
solutions were prepared in DMSO.  The five crude extracts were labeled Prot-1 through 
Prot-5 and will be referred by this label henceforth. Serial dilutions were prepared from 
the stock solutions and tested for proteasome activity in in vitro enzyme assays against 
the human and the yeast proteasome. The starting concentrations for the serial dilutions 
were at 20 mg / ml. All five extracts were found to display in vitro activity against the 
human and yeast proteasome. The process of activity based separation was started by 
injecting 20 mg / ml solutions of the crude extracts in methanol into a semipreperative 
C18 column on a HPLC (Figure 59). Solvent gradient systems starting at 50 % methanol 





Figure 59: The LC UV profile for Prot-4 as a representative of the HPLC fractionation 




All fractions were collected directly into the wells of 96-well deep well 
polypropylene plates. An aliquot of each of the LC fraction for all five extracts were 





Figure 60: The percentage inhibition of human proteasome in an in vitro enzyme assay. 



























In vitro Proteasome activity for Extract # 1, 2, 3, 4 & 5 




 As the physical parameters like the molecular weight of the active component in 
the extracts were unknown it was not possible to estimate the concentration of extract 
solution. Therefore, the concentrations of solution were prepared empirically based on 
the in vitro activity of the fractions. The abundance of activity found in the fractionations 
of the five extracts in the figure above showed that a concentrated solution of extracts 
was injected into the HPLC column resulting in the spreading of the active component 
across a broad retention time range. The number of active fractions in each extract is 
shown below in figure 61. 
The activity profile for all five extracts suggested that Prot-1 and Prot-2 might 
belong to one type of extract while Prot-4 and Prot-5 might belong to another type of 
extract with Prot-3 showing overlapping activity profiles with both types of the extracts. 





Figure 61: The activity profile of 45 fractions for each of the five crude extracts (Prot-1 
through Prot-5). The active fractions are colored in the figure. 
 
Prot-1
1 2 3 4 5 6 7 8 9 10 11 12
a x 15 16 31 32 x
b 1 14 17 30 33 x
c 2 13 18 29 34 45
d 3 12 19 28 35 44
e 4 11 20 27 36 43
f 5 10 21 26 37 42
g 6 9 22 25 38 41
h 7 8 23 24 39 40
Prot-2
1 2 3 4 5 6 7 8 9 10 11 12
a x 15 16 31 32 x
b 1 14 17 30 33 x
c 2 13 18 29 34 45
d 3 12 19 28 35 44
e 4 11 20 27 36 43
f 5 10 21 26 37 42
g 6 9 22 25 38 41
h 7 8 23 24 39 40
Prot-3
1 2 3 4 5 6 7 8 9 10 11 12
a x 15 16 31 32 x
b 1 14 17 30 33 x
c 2 13 18 29 34 45
d 3 12 19 28 35 44
e 4 11 20 27 36 43
f 5 10 21 26 37 42
g 6 9 22 25 38 41
h 7 8 23 24 39 40
Prot-4
1 2 3 4 5 6 7 8 9 10 11 12
a x 15 16 31 32 x
b 1 14 17 30 33 x
c 2 13 18 29 34 45
d 3 12 19 28 35 44
e 4 11 20 27 36 43
f 5 10 21 26 37 42
g 6 9 22 25 38 41
h 7 8 23 24 39 40
Prot-5
1 2 3 4 5 6 7 8 9 10 11 12
a x 15 16 31 32 x
b 1 14 17 30 33 x
c 2 13 18 29 34 45
d 3 12 19 28 35 44
e 4 11 20 27 36 43
f 5 10 21 26 37 42
g 6 9 22 25 38 41




4 and Prot-5 were similar. The UV absorbance values of the peak fractions of Prot-2 
were about two and half times higher than the absorbance values of Prot-1. Similarly the 
absorbance values of the peak fractions of Prot-4 were about 15 times higher than Prot-5. 
Hence, Prot-2 and Prot-4 were taken to be representatives of the two types of extracts 
and were investigated further. The active fractions of Prot-2 were pooled together and 
evaporated to dryness. The dry extract was then reconstituted in methanol and another 
round of HPLC separation was performed using a shallower solvent gradient system 
(Figure 62). The gradient system is mentioned in the methods section above. Similarly, 
the active fractions of Prot-4 were pooled together and evaporated to dryness. The dry 
material was reconstituted in methanol and injected into the C18 column using a shallow 














After refractionation, the new fractions were retested for their in vitro 
proteasome activity. In the repeat fractionation, fractions number 12 and 13 were active 
for Prot-2 and fraction number 11 was active for Prot-4. The amount of material left in 
each fraction was not sufficient to conduct structural characterization studies. Hence, 
preparative scale HPLC fractionation was performed for Prot-2 and Prot-4 by injecting a 
concentrated solution into the preparative C18 column. Accordingly, 12.5 mg extract 
from Prot-2 dissolved in 200 µL methanol was injected and approximately 38 mg extract 
from Prot-4 dissolved in 200 µl of methanol was injected into the preparative scale C18 

















The fractions were collected into glass fraction tubes at the rate of 5 ml / fraction 
/ min. The active fractions were identified by performing the in vitro proteasome assay 
against all the fractions. Fraction number 18 for Prot-2 and fraction number five for Prot-




The active fractions were analyzed by LC / HRMS to identify MS peaks of 
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Two MS peaks of interest were observed for Prot-2 at (m/z) 545.14 and (m/z) 
1089.28 in the ESI positive while peaks at (m/z) 543.13 and (m/z) 1109.25 were 




























at (m/z) 459.18 and (m/z) 934.38 in the ESI positive while a major peak at (m/z) 457.17 
was observed in the ESI negative mode.  
 NMR studies were initiated on fraction number 18 of Prot-2 and fraction number 
five of Prot-4. The 1H NMR data for fraction number 18 of Prot-2 was not conclusive. 
The 1H NMR peaks suggested the presence of an impurity. The 13C NMR data suggested 
that the concentration of the active compound was not sufficiently high to carry out 
further NMR studies.  
 Fraction number five of Prot-4 extract had a single sharp UV peak at the 
retention time of five minutes. The UV absorbance was sufficiently high at 2.5 AU. 1H, 
13C, Distortionless Enhancement by Polarization Transfer (DEPT) - 135°, DEPT - 90°, 
COSY, HSQC, HMBC and NOESY experiments were performed on the active fraction 
to elucidate the chemical structure of the compound (Figure 72 – 79). 1H NMR spectra 
and 13C NMR spectra were recorded on a Bruker Avance III HD NMR system.  
(CD3)2CO was used as the solvent with tetramethylsilane as the internal standard.  
Proton signals were observed in the 1H NMR spectrum as follows; (500 MHz) 
((CD3)2CO): δ = 2.01 (s, 3H), 2.11 (s, 3H), 6.14 (s, 1H), 6.15 (d, J=2 Hz, 1H), 6.20 (m, 
1H), 6.35 (s, 1H), and 6.52 (d, J=2 Hz, 1H).  13C NMR chemical shifts were observed at 
(125 MHz), ((CD3)2CO), 20.2, 21.3, 103.6, 104.2, 111.4, 111.7, 112.2, 119.8, 140.6, 
140.7, 156.8, 157.7, 158.9 and 159.0.  The DEPT – 90° and 135° revealed that there 
were 10 CH groups, 4 CH3 groups, no CH2 groups and 14 carbons had no attached 
protons.  COSY, HSQC, HMBC and NOESY NMR experiments were performed to 










































































































































































































































































The HRMS in the ESI positive mode was observed at m/z = 459.1816 and in the 
ESI negative mode was observed at m/z = 457.1697. SmartFormula® prediction also 
calculated the molecular formula of the active molecule as C28H26O6, which has a 
theoretical accurate mass calculated at 458.18. Collision induced dissociation (CID) of 




revealed mass peaks that correlated with the fragmentation pattern of the derived 








Figure 82: Fragment peaks from the MS / MS of (m/z) 459.18 of Prot-4 (zoomed into 






































Figure 83: Fragment peaks from the MS / MS of (m/z) 459.18 of Prot-4 (zoomed into 




Chemical structures could be assigned to all the major fragments observed in the 
MS /MS of Prot-4 based on the polyphenolic structure of the parent molecule. Thus the 



























The IUPAC name for the chemical structure of Prot-4 compound could be 
derived as 2,2’-di(3-hydroxy-5-methyl phenoxy)-6,6’-dimethyl biphenyl-4,4’-diol. With 
the knowledge of the molecular formula and the molecular weight information available 
for the discovered active compound, it was possible to calculate accurate IC50 values for 
the compounds inhibitory activity against the human proteasome. The IC50 value was 
determined to be ~15 µM for the human proteasome against the chymotrypsin-like as 

















































Likewise, whole-cell bioactivity assay was also performed for Prot-4 against 
different cancer cell lines to establish an MIC value. The MIC against drug resistant 
ovarian adenocarcinoma cell line, drug resistant breast adenocarcinoma cell line, 
lymphoma cell line and drug resistant lymphoma cell line were found to be ~ 20 µM 
which was consistent with the in vitro activity. 
 
Conclusion 
 The process of fractionating a crude extract and screening the fractions for 
proteasome activity in an in vitro assay was followed through successive fractionations 
of the active fractions until a sufficiently pure fraction was obtained. The pure fraction 
was analyzed and characterized by LC / HRMS and NMR spectroscopic methods. A 
previously unknown compound was identified as the source of activity against the 
human proteasomes. 
 The characterized natural product is a polyphenolic compound with a molecular 
weight of 458.18 and molecular formula of C28H26O6. While polyphenols like EGCG 
have been investigated as inhibitors of proteasome, these polyphenols are commonly 
found in plants products like vegetables. The source of the extract from which the 
polyphenol was discovered in this research is unknown, except that the extract is of 
microbial origin. Polyphenols are generally found in plant products in nature. Microbial 
sources of polyphenols are rare. If indeed the source of the Prot-4 extract is microbial, 




 The IC50 values of the natural product against human proteasomes are modest at 
15 µM. However, this can be used as a starting point to synthesize analogs of the natural 
product and improve the activity against proteasome. Structure activity relationship 
(SAR) of the natural product with the human will provide valuable insights into the 
binding mode of the inhibitor and clues to functional modifications of the inhibitor to 










TB is re-emerging and threatens to become a pandemic unless new therapeutic 
solutions are found. The urgency of the situation demands that all available avenues for 
drug discovery approach be explored to discover new inhibitors of the pathogenic 
microorganism, Mtb. A two pronged approach was applied to finding inhibitors of Mtb - 
A structure-based approach and a whole-cell inhibition based approach. 
The structure-based approach involves the biophysical and biochemical 
characterization of important biological targets in the pathogen that are selected for 
inhibition studies. Enzymes involved in important biosynthetic and metabolic pathways 
or proteins required for virulence factors are considered good targets for the structure-
based approach. The proteins or enzymes for which it is possible to design substrate or 
product analogs that can act as inhibitors of the protein by blocking the catalytic site are 
called druggable targets. For example, protein kinases are shown to be druggble targets 
in pathogenic microorganisms 224. The knowledge of the three dimensional structure of 
the molecular target in the pathogen including the active site architecture, the domain 
organizations and protomer interaction surfaces are used to synthesize small molecules 
that are designed to fit in the active site or an allosteric site within the macromolecular 
structure of the protein target or at the interface of important protein complex formation 
sites with high affinity. Tight binding of the designed inhibitors is expected to interfere 




The whole-cell inhibition approach, on the other hand, assumes no prior 
knowledge of any intracellular protein or other molecular targets. This is analogous to a 
blinded study and involves the identification of any inhibitor that can arrest cell growth 
or cause rapid killing of the cells in a culture medium. At the outset, the intracellular 
targets of the inhibitor are not known, which precludes the knowledge of any biophysical 
and biochemical information about the possible intracellular target of the inhibitor. 
Hence the small molecule inhibitors cannot be designed a priori. Therefore, in order to 
increase the chances of finding an inhibitor the whole-cell inhibition approach works 
best when a large number of inhibitors comprising a wide range of structural and 
chemical scaffold are used in the inhibition assay. Whole-cell inhibition approach 
therefore requires collections of synthetic or naturally occurring small molecules that can 
cover the chemical space of a typical ‘drug-like’ molecule. A ‘drug-like’ molecule is 
expected to follow ‘Lipinski’s rule of five’ 190. As defined by the Lipinski’s rule of five, 
a drug-like molecule contains ≤ 5 hydrogen bond donors, ≤ 10 hydrogen bond acceptors, 
a molecular weight of ≤ 500, a lipophilicity factor (cLogP) ≤ 5. Combinatorial chemistry 
or parallel synthesis approach are used to synthesize a large number of analogs of 
molecules of a given structural scaffold. Being constrained by the structural scaffold, the 
synthetically derived molecules can cover a limited chemical space. Natural products, on 
the other hand, are secondary metabolites biosynthesized in organisms like bacteria, 
fungi, higher invertebrates like marine sponges and plants through pathways that have 
evolved over millions of years. Due to this evolutionary advantage, natural products 




synthetic chemistry. Further, since natural products are biosynthesized by organisms to 
communicate with their immediate environments, they are naturally adept at penetrating 
through cell membranes and cell walls. The feature of being able to pass through 
membrane barriers makes the natural products desirable because such features are part of 
a ‘drug-like’ molecule. In addition, many secondary metabolites are biosynthesized by 
microorganisms and plants as interspecies defense mechanisms where the molecules are 
secreted out to protect the species against competing microbes in the immediate 
environment. The presence of natural antimicrobial properties makes natural products 
desirable candidates to be included in a screening library of compounds that is used for 
testing the whole-cell bioactivity against pathogenic microorganisms. Thus, natural 
products have advantages over synthetic molecules in the application of whole-cell 
inhibition studies. 
Protein targets from two important pathways in Mtb were selected for the 
structure-based inhibition studies. These were the Mtb s-adenosylhomocysteine 
hydrolase (SAHH) in the methylation pathway and the Mtb PII protein in the nitrogen 
regulatory pathway of Mtb. The s-adenosylmethionine (SAM) based methylation 
pathway serves as an important metabolic pathway in all organisms including Mtb 
because methylation plays a central role in crucial intracellular processes like DNA 
methylation, amino acid biosynthesis, protein post translational modifications, 
phospholipid biosynthesis and intercellular processes like quorum sensing. The 
methyltransferase enzymes commonly use SAM as a donor of methyl group to methylate 




reactions are referred to as transmethylation reactions. After the transfer of a methyl 
group SAM is converted to s-adenosyl homocysteine (SAH). SAH is a potent feedback 
inhibitor of the methyltransferases and needs to be cleared from the cytoplasm in order 
to facilitate unhindered transmethylation reactions. 
SAHH is a ubiquitous enzyme that assists transmethylation by breaking down the 
product of transmethylation reactions, SAH into adenosine and homocysteine (Hcy). 
SAHH also plays important part in other pathway like purine salvage and amino acid 
biosynthesis by generating the substrates for these pathways. Adenosine is processed in 
the purine salvage pathway by other enzymes like adenosine deaminase and adenosine 
kinases to generate adenosine triphosphate (ATP). Hcy is used in the biosynthesis of 
cysteine and the regeneration of methionine. Mtb SAHH was targeted for inhibition 
because of the essentiality of the enzyme to Mtb as observed by in vitro studies 45. 
Human genome also encodes for SAHH and the amino acid sequence of human SAHH 
protein is 55 % similar to the Mtb SAHH amino acid sequence. Due to the high 
homology of the two proteins, it was essential to structurally characterize the Mtb SAHH 
and identify differences in the active site of the enzyme from the two species that could 
be used to design specific inhibitors of the Mtb SAHH. Mtb SAHH was crystallized in 
the presence of the product adenosine and the crystal structure solved by x-ray 
diffraction method to 1.6 Å resolution. Crystal structures of Mtb SAHH were also solved 
in the presence of known SAHH inhibitors like aristeromycin (ARI), deazaadenosine 
(DZA) and 2-fluoroadenosine (2FA) to 2.1 Å, 2.2 Å and 2.4 Å resolutions respectively. 




and confirmed the proposed mode of inhibition for ARI. ARI was observed in the active 
site of the crystallized Mtb SAHH in the form of 3’ keto aristeromycin. ARI is a 
mechanism based inhibitor of Mtb SAHH (0.2 µM) where it initiates the mechanism of 
hydrolysis similar to adenosine but gets trapped at the formation of the 3’ keto 
intermediate. A less acidic proton at the 4’ position of ARI compared to adenosine 
prevents the proton abstraction step and halts the further mechanism. 
When compared to the active site of the human SAHH no significant differences 
were observed in the active site of Mtb SAHH. However, upon comparing with the 
active site of Pf SAHH a curious observation was made. The homologous histidine (His) 
residue in Pf SAHH corresponding to the His 363 of Mtb SAHH was flipped up by 180 
°. The imidazole side chain of His 363 is proximal to the 5’ hydroxyl group of adenosine 
at 2.69 Å. It was inferred that movement of the imidazole side chain of His 363 away 
from the 5’ hydroxyl group of adenosine may be required for the binding of the Hcy 
portion of the full substrate, SAH, which is attached at the 5’ position of adenosine. In 
order to understand the binding mode of the full substrate, SAH, Mtb SAHH was 
cocrystallized in the presence of SAH. While density for the complete SAH molecule 
was not observed in the binding site, SAH was modeled as ethylthioadenosine in the 
active site of Mtb SAHH. The binding mode of SAH in Mtb SAHH confirmed the 
hypothesis and for the first time showed that His 363 residue flips up and acts as a gate 
to allow the binding of the substrate, SAH. More importantly, crystal structure of Mtb 
SAHH revealed the architecture of the extended active site for binding SAH and also 




When comparisons were made with the human SAHH protein, differences could be 
identified between the two enzymes. Whereas in the human SAHH protein, the access 
channel was wide and funnel-like, the presence of a thirty six residue insertion in Mtb 
SAHH converted the access channel into a narrow path lined by hydrophobic residues. 
This difference between the human and Mtb SAHH could be used to design inhibitors 
that could bind in the narrow access way and block the function of Mtb SAHH. A 
fragment-based approach was adopted to identify small molecule inhibitors of the Mtb 
SAHH. A 750 compound fragment library was used to screen against Mtb SAHH in an 
assay using differential scanning fluorimetry technique. The technique uses a real time 
polymerase chain reaction (RT-PCR) to gradually increase the temperature of the assay 
mixture containing Mtb SAHH and a SYPRO orange dye in buffer. As the enzyme 
begins to unfold the dye interacts with the hydrophobic core of the enzyme causing it to 
fluoresce. The temperature at which the change in fluorescence emission is the highest is 
recorded as the melting temperature of the enzyme. Binding of a ligand to the enzyme 
causes changes in the stability of the enzyme leading to a change in the melting point 
temperature. Since the aim of the experiment was to find fragments that could bind in 
the narrow hydrophobic access channel of the enzyme, the assay was performed in the 
presence of bound adenosine and NAD+, thus occupying the enzyme active sites. 
Through screening of the fragment libraries eight potential small molecule fragments 
were identified. Attempts to crystallize Mtb SAHH in the presence of the binding 
fragments were unsuccessful. Saturation transfer difference nuclear magnetic resonance 




identified and validated in this study consist of an aromatic ring functionalized with a 
polar substituent like an amide, chloride, oxime or trifluoromethyl group with the 
exception of 1-(pyridin-3-yl)-2-p-tolylethanone. In the absence of crystal structures it 
may be speculated that the fragments take advantage of the hydrophobic nature of the 
access channel to form hydrophobic interactions involving the aromatic rings while the 
polar substituents on the aromatic ring may form hydrogen bonding interactions with 
residues like Glu186 which protrudes into the access channel and was identified as 
unique to the Mtb SAHH. Further studies on the design of inhibitors specific to the Mtb 
SAHH can be conducted by tethering the small molecules identified through fragment 
based screening and STD NMR to ADO and performing in vitro assays with the human 
and Mtb SAHH. Ligands that exploit the unique features offered by the narrow access 
channel would be expected to be selective towards the Mtb SAHH. 
PII is a family of signal transduction proteins that act as nitrogen sensors in 
microorganisms and plants. The role of signal transduction is achieved by PII through 
complex formation with other proteins like ammonium transporter protein complex 
(AmtB), glycohydrolase (DraG), DraT and glutamine synthetase (GS) involved in the 
nitrogen regulation pathway. Mtb nitrogen regulatory PII protein was selected as a 
potential drug target because of the many role played by the protein in the direct and 
indirect regulation of intracellular nitrogen levels. The PII protein is functional through 
post translational modification of GS and through regulation of transcription of the gene 
glnA which encodes for GS. A functionally important T-loop on the PII protein 




in the protein-protein complex formations. Factors influencing the orientation of the T-
loop on the PII protein to facilitate the complex formation remain unknown. 
Crystal structures of Mtb PII protein were solved in the apo form and in complex 
with ATP to 1.4 Å and 2.4 Å resolutions respectively. Density for the functionally 
important T-loop was missing in the apo structure while at least one of the subunits in 
the ATP bound PII contained a completely ordered T-loop. Comparisons with the E. coli 
and M. jannaschii PII proteins revealed that the structural features of Mtb PII are well 
conserved across species. The binding mode of ATP molecule in pocket formed by the 
interaction of two neighboring subunits in the functional trimer was also consisten with 
that observed in E. coli PII protein. Upon analysis it was apparent that the interaction of 
the residues at the base of the T-loop, particularly Arg38 with the ATP molecule was 
partially responsible for orienting the loop region towards target proteins for protein-
protein complex formation. The presence of Arg38 in the position of Mg2+ in M. 
jannaschii PII protein and the interaction of side chain of Arg38 with the γ phosphate 
group of ATP also suggested the possibility that Mtb PII protein may not require Mg2+ 
ion for ATP binding. This observation was consistent with in vitro assay studies that 
showed that Mtb PII protein binds to ATP (Kd = 1.93 µM) and 2-oxoglutarate (2OG) in 
the absence of Mg2+ ions. Stabilization of the T-loop in subunit B of Mtb PII protein 
through crystal packing effect mimicked the formation of a protein-protein complex 
formation and suggested that while the base of the T-loop was partially stabilized by the 
ATP binding, additional stabilizing interactions mediated through the binding of a 




and Mtb PII proteins based on the E. coli GlnK: AmtB complex showed that Mtb PII 
protein would have favorable interactions and would form a complex with Mtb AmtB 
protein. Structural studies of the Mtb PII protein revealed important insights into the 
function of the protein and its mechanism of action. Based on structural features like the 
presence of a 310 helix at the C-terminal, the presence of Leu3 and Thr5 residues in the 
central cavity of the β-barrel formed by the trimeric assembly of Mtb PII protein and the 
operon organization of Mtb PII gene in between amtB and glnD genes suggests that the 
Mtb PII gene should translate into a GlnK protein. The biophysical and biochemical 
knowledge gained about Mtb PII protein will be useful in designing specific and 
selective inhibitors of the protein. Inhibition of Mtb PII protein can potentially disrupt 
the nitrogen regulation pathway in Mtb leading to cell death. 
Chapter IV dealt with the whole-cell inhibition based approach to find inhibitors 
of Mtb. Natural products based drug discovery has been steadily declining in the recent 
years for reasons ranging from the time consuming processes of extraction, isolation and 
identification of new natural products to high costs. Big pharmaceutical companies have 
dropped their natural products discovery pipelines and shifted focus to other areas like 
combinatorial approaches to synthetic chemistry and genomics. A declining trend in the 
number of approved drugs introduced into the market is a clear testament that the 
alternative approaches to drug discovery are not working as expected in spite of the large 
amounts of investments being made. This trend holds true for tuberculosis therapy as no 
new drugs have been introduced against TB in the last forty years and a majority of the 




inhibition based as well as a target-based in vitro enzyme assay approach was used to 
screen a collection of natural product extracts. Different available libraries of natural 
product extracts were screened against M. smegmatis and Mtb cells in an attempt to 
identify the most potent hits. The bioactivity based HPLC fractionation and isolation was 
performed with the collection of ninety six natural products extracts obtained from 
Vicuron and twenty nine natural products extracts obtained from Sarawak Biodiversity 
center (SBC). Whole-cell bioactivity data, HPLC UV profiles and LC / HRMS data were 
used to search for fractions with whole-cell or in vitro bioactivity. As is the case in any 
high-throughput screening experiment, a vast amount of data is generated and methods 
of data reduction to screen out the irrelevant data are necessary. LC / MS analysis 
resulted in a large amount of mass spectral data and methods were needed to narrow 
down to the promising MS peaks of interest that could lead to the identification of the 
natural product that was the cause of the bioactivity. A commercially available suite of 
software package called Metabolite Tools® developed by Bruker Daltonics Inc. was used 
to subtract LC / MS data of the inactive fractions from those of the bioactive fractions. 
Once the peak listings were narrowed down to the most interesting MS peaks, 
SmartFormula® prediction calculator, also developed by Bruker Daltonics Inc. was 
employed to generate molecular formula predictions using the high resolution MS data. 
A dereplication process was performed on the generated molecular formula and the 
associated HRMS data to identify the masses that corresponded to natural products that 
already existed in the available dictionary of natural products. The extract number 67037 




through multiple rounds of fractionation and isolation. The bioactive fraction was 
purified by HPLC to isolate the source of the bioactivity. Through the application of LC 
/ HRMS, tandem MS and NMR spectroscopy a compound with a fatty acid like core 
structure was identified. The molecule was named 2-methyl-2-[(4-
oxoheptadecanoyl)amino]propanoic acid. No matches were observed for the chemical 
structure of the fatty acid against the dictionary of natural products. Therefore the 
identified compound is most likely a novel source of bioactivity against Mtb and M. 
smegmatis cells. Fatty acids have previously been used in the inhibition of fatty acid 
synthesis, cholesterol biosynthesis and in the inhibition of cancer cells 199,200. The whole-
cell inhibition of Mtb by saturated fatty acids like palmitic acid and stearic acid at MIC ~ 
5 µM was an interesting find in this regard as it indicated that other long chain fully 
saturated fatty acids may also be able to inhibit the Mtb whole-cells. Palmitic acid and 
stearic acid have 16 and 18 carbon atoms long saturated aliphatic chains respectively. 
The identified natural product contains a saturated aliphatic chain that is 20 carbon 
atoms long. Based on the fatty acid like core structure it may be speculated that the 
natural product could be an inhibitor of enzymes involved in the fatty acid biosynthesis 
in Mtb. 
The collections of natural product extracts were used in an in vitro enzyme assay 
against known drug targets in Mtb and human. A six hundred and forty microbial crude 
extract library that was previously determined to exhibit whole-cell bioactivity against 
Mtb cells was also directed in a target-based high-throughput in vitro assay to identify 




glyoxylate shunt pathway. It is implicated as a virulence factor and represents an 
attractive drug target in Mtb. Screening of the extract library yielded three extracts that 
displayed reproducible in vitro inhibitory activity. The extracts were fractionated on 
HPLC to separate the components of the extract into forty fractions per extract. The 
individual fractions were then tested for in vitro inhibitory activity against Mtb malate 
synthase. The active fractions were then tested in serial dilutions of 2 X to 0.02 X 
concentrations in the assay. Five fractions in total originating from three different 
extracts were determined to exhibit in vitro inhibitory activity at as low as 0.03 X 
concentrations. The absence of structural information on the in vitro active compounds 
in the extracts precluded the accurate determination of an IC50 value. Efforts are 
underway to structurally characterize the natural products in the bioactive microbial 
extracts. 
The bioactivity guided fractionation coupled with in vitro enzyme assay was used 
to identify a novel natural product inhibitor of the human proteasome. HPLC purification 
followed by high resolution mass spec data and NMR spectroscopy guided structure 
elucidation resulted in the identification a polyphenolic compound – 2,2’-di(3-hydroxy-
5-methyl phenoxy)-6,6’-dimethyl biphenyl-4,4’-diol – that showed inhibitory activity 
against the human and yeast proteasome in an in vitro assay. The natural product had a 
modest IC50 value of 15 µM against the human proteasome. The natural product was 
active against the chymotrypsin-like as well as the caspase-like activities associated with 
the proteasome. The molecular structure of the discovered polyphenol is unlike any other 




binding mode and structure-activity relationship of the polyphenol can be better 
understood by crystallizing and solving the crystal structure of the polyphenol in 
complex with the human or yeast proteasome. The symmetric polyphenolic structure of 
the natural product affords an opportunity to create functional modifications to improve 
the binding affinity and therefore increase the inhibitory effect on the proteasome and 
hence represents a lead in the search for anticancer drugs. 
In conclusion it may be stated that natural products research holds great potential 
in finding novel therapeutics against not only TB but also many diseases like cancer and 
AIDS. While the ‘low hanging’ fruits like streptomycin, erythromycin and vancomycin 
were discovered during the golden years of natural products drug discovery, many as yet 
undetected biosynthetic pathways exist in microorganisms, which produce novel natural 
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Chemical Derivatization of Microbial Extracts  
Generating a sufficiently large collection of diverse natural products to feed a 
high-throughput screening effort in drug discovery requires the systematic extraction and 
isolation of natural products from a wide variety of sources, like soil bacteria, fungi, 
marine organisms and higher plant species. This can be a daunting process and consume 
a large amount of resources and time to accomplish. Since a single natural product 
extract mixture could contain potentially diverse set of structural scaffolds which is 
typically observed in secondary metabolites, such an extract mixture could be used as a 
starting point to introduce more chemical functionalities in a semisynthetic approach. 
Such an approach was successfully applied to a study conducted on the n-butanol extract 
of the plant Polygonum ferrugineum Wedd. (Polygonaceae) 225. This approach does not 
assume any previous knowledge of the constituents of the mixture to be functionalized, 
nor does it require the isolation of the individual constituents. A chemical modification 
reaction is directed to a select functional group. Different secondary metabolites present 
in the extraction mixture containing the select functional group can get modified and 
give rise to analogs. Depending on the number of molecules with the functional group 
existing in the mixture, this technique can simultaneously generate a large number of 
new analogs, which can contribute to a greater diversity of natural products. 
In the present study a similar approach has been applied to a mixture of 




advantage can be taken of the structural diversity already existing in nature by using the 
secondary metabolites obtained from microorganisms as basis and starting points for 
carrying out chemical derivatizations. Single step chemical derivatization / 
functionalization reactions carried out on entire crude extracts from microorganisms 
have the potential to simultaneously generate a large number of chemically modified 
natural product analogs, thus introducing even more diversity into the extracts. Such an 
approach can provide a rapid system of generating libraries of structurally and 




 The microorganisms used to generate pools of natural product extracts included 
E. coli, Mycobacterium smegmatis (mc2155) 112, Streptomyces griseus, Streptomyces 
sahachiroi and bacteria isolated from the soil. Each organism was grown independently 
in cultures containing a wide range of fermentation media recipes like Lysogeny broth 
(LB), terrific broth (TB), Middlebrook 7H9 media (Difco), pharmamedia, soybean meal, 
corn steep liquor. The common carbon sources were glucose, sucrose, mannitol, and 
glycerol. Salts like manganese chloride, calcium carbonate, copper sulfate, iron sulfate 
were used to help increase the secondary metabolite production. The cell culture 
volumes ranged from 50 mL – 2 L. The incubation temperatures ranged from 25 – 37 ˚C. 
The time period of incubation ranged from 5 – 7 days. At the end of the incubation 




pellets and the spent media were independently treated to extract pools of secondary 
metabolites. Alternately, the culture was treated to an extraction protocol without 
separating the cells from the spent media. 
 
Cell Lysis and Extraction 
The cell pellets were extracted using a previously described cold methanol 
extraction protocol that is shown to extract the maximum pool of secondary metabolites 
from the pellets 226. The spent media was extracted by equilibrating it with organic 
solvents in a separating funnel. The organic solvents used for extraction included 
dichloromethane, 1:1 dichloromethane / isopropanol or ethyl acetate. Extraction of the 
spent media was carried out at neutral pH, acidic (3 – 4) pH, and basic (10 – 11) pH to 
enrich the extracts with natural compounds containing either acidic or basic groups. 
 
High Performance Liquid Chromatography Fractionation 
The unmodified extracts were dissolved in methanol, fractionated on a reverse 
phase C-18 Atlantis T3® (Waters) HPLC column to generate an ultraviolet (UV) 
absorbance peak profile of the extract. An analytical HPLC system with a W600 pump 
and a Photo Diode Array (PDA) detector from Waters was used. A solvent gradient was 
run from 100 % water containing 0.1 % formic acid (FA) to 100 % acetonitrile. The 
gradient was linear with a 1% change per minute and a flow rate of 1 ml /min. (The 
chemically modified extracts were dissolved in methanol or methanol water mixtures 




1ml/min. The individual fractions were then dried out by lyophilization and reconstituted 
in water or methanol depending on solubility of the dried fraction. Thus stock solutions 
were made for each fractions and aliquoted into 96 well polypropylene plates. The plates 
were stored at 4 ˚C until further analysis. 
 
Chemical Derivatization 
 p-bromobenzoyl chloride was used to carry out acylation of basic amine groups 
present in the natural products. Other chemical modifications carried out on the extracted 
metabolites included – amide bond formation using phenyl silane, benzoylation using p-
trifluoromethyl benzoylchloride, chlorination using trichloroisocyanuric acid and 
fluorination using DAST and using Selectfluor reagents. Click chemistry was also used 
to generate derivatives of secondary metabolites in the natural product extracts. The 
reaction involved two steps; the first step was to react the nucleophilic residues like 
amines, hydroxyl groups and thiol groups on the secondary metabolites in the crude 
extracts with a bromomethyl alkyne to generate a propargylated species. The second step 
was to react the propargylated species with bromobenzyl azide to undergo a cyclization 
reaction and generate benzyl triazoles.  
 
Whole-Cell Activity Assay 
Whole-cell bactericidal activity was carried out on M. smegmatis (mc2155) 
grown on 7H9 and M9 media and independently on Mtb (mc27000) grown on 7H9 




0.001 were added to the wells of a sterile 96 well microtitter plate. 4 μL of the 
fractionated extracts were then added to each well. Rifampicin at concentrations of 2 μM 
to 250 μM was used as a negative control. Wells containing only 7H9 media served as 
another negative control, while wells with the M. smegmatis mc2155 at the above 
mentioned final O.D600 of 0.001 served as the positive control. The cells were grown in 
an incubator at 37 ˚C for 72 hours. After this period, 5 μL of alamar blue (resazurin dye) 
was added to the wells and left for a couple of hours in the incubator. The wells were 
then measured visually for cell growth. Wells with cell growth were able to reduce the 
alamar blue which then turned pink. The resazurin dye in the wells with no cell growth 
remained blue. 
 
Liquid Chromatography /Mass Spectrometry 
 Fractions showing whole cell activity against M. smegmatis and Mtb mc2 7000 
were subjected to further fractionation on HPLC using a shallow gradient of the same 
mobile phase solvents used previously to allow for a better separation of the individual 
components of the active fraction. Simultaneously an aliquot of the same fractions were 
analyzed using liquid chromatography /mass spectrometry (LC /MS) to determine the 
mass composition of the fraction mixture. For the purpose of LC / MS, two different 
types of instrumentation were employed – a supercritical fluid chromatography (SFC) / 
MS (Waters) and an analytical LC /quadrupole Time of Flight (Q-TOF) MS. The 




Daltonics. The Bruker microTOF-QII® is able to detect masses in high resolution 
(HRMS) and at an accuracy rate of 5 ppm. 
 The SFC / MS use a normal phase column and hence was useful for analyzing 
the nonpolar components of the mixture. However, due to the nature of the extraction 
procedure, which selected for mainly polar compounds to be extracted, the SFC/MS 
instrument had limited success in identifying nonpolar compounds. The regular LC / 
HRMS on the other hand was able to detect several masses in the mass range of 100 to 
1000 m/z (mass to charge ratio) which were representative of the active fractions. 
 
Nuclear Magnetic Resonance Spectroscopy 
 500 MHz NMR spectrometers were used to generate 1H NMR data for the active 
natural compounds, when the activity came from a sufficiently pure fraction. 13C NMR 
data were also obtained whenever possible to assist in the assignment of the structure of 
the bioactive natural compound. 
 
Results and Discussion 
The aim of this project was to generate diversity in any given crude extract 
derived from a microorganism by employing relatively simple chemical derivatizations 
on the crude microbial extracts. An example of the evidence for chemical modification 
of the extracts was the p-bromobenzoylation reaction. The reagent, p-bromobenzoyl 
chloride was used to react with primary or secondary amines present in the crude 




containing hydroxyl groups would also react with p-bromobenzoyl chloride to form the 
corresponding esters. Methanol extracts of Streptomyces griseus cells were used for the 
reaction. The cells grown in liquid media were harvested from the media and divided 
into two parts. While one part of the cells was subjected to the functionalization reaction, 
the other part was left unreacted and used as a reference. Both functionalized and the 
unfunctionalized extracts were fractionated on HPLC using the same solvent gradient 















Success of the derivatization reaction was confirmed by three different methods: 
SFC-MS runs of the before and after derivatization extracts were compared to 
look for characteristic bromine isotope peaks in the derivatized extracts. Indeed such 
isotope peaks were observed in the MS, which did not occur in the unmodified extracts, 









To check for the reaction of amines to amides, chemical methods were 
employed: 70 mg /ml stock solutions of the unmodified and p-bromobenzoylated extract 
were prepared in methanol. Equal amounts of both the solutions were spotted on a TLC 
plate next to each other with a spot of plain water acting as control. A drop of the freshly 
prepared ninhydrin reagent was added to the spots and the plate was heated. The spot 
corresponding to the unmodified extract developed a strong red-blue coloration, while 














p-bromobenzoylation reaction introduces a phenyl group in the product, which in 
turn introduces conjugation into the system. Such compounds would be expected to have 
higher absorbance in the UV region. 0.6 mg/ml solutions of the unmodified and p-
Unmodified S. griseus
extract (at 70 mg/ml)
P-bromo benzoylated S. griseus




bromobenzoylated extract were prepared and scanned for their absorbance spectra in a 
UV spectrophotometer. As expected, the p-bromobenzoylated extract showed a much 
stronger absorbance in the UV region of 200nm to 400nm than the unmodified extract 




Figure 91: The UV absorbance of unmodified and p-bromobenzoylated S. griseus 
extracts at a concentration of 0.6 mg/ml. The p-bromobenzoylated extract showed a 
stronger UV absorbance in the range of 200 – 300 nm than the unmodified extract. 





A method is described to increase the structural and functional diversity of 
secondary metabolites in a crude mixture of unknown microbial extracts. Model 
Benzoylated S. griseus extracts





organisms like E. coli, M. smegmatis and Streptomyces griseus as well as randomly 
picked soil microbes such as Bacillus thuringiensis and Bacillus megaterium were 
cultured in the laboratory to a sufficiently high optical density. After harvesting the cell 
pellets secondary metabolites were extracted out of the cells by rupturing the cell wall 
using organic solvents like, dichloromethane and ethyl acetate. Chemical modifications 
were introduced in the pool of the secondary metabolites by employing single step 
derivatization reactions like chlorination, fluorination or p-bromobenzoylation carried 
out on the crude extracts without any purification. Click chemistry was one of the tools 
used for the derivatization reactions as well. The aim of the experiment was to introduce 
single modifications randomly in the pool of metabolites, which could potentially 
generate bioactive molecules where none existed before. For this purpose, the 
derivatized extracts were fractionated on HPLC and the fractions were tested for their 
whole-cell activities on M. smegmatis and Mtb. The underivatized extracts were also 
fractionated and tested for activity for reference and to keep track of the activity profile. 
This was followed by an activity-based fractionation and isolation of the active chemical 
component from the extract. 
Characteristic bromine and chlorine isotope peaks were identified through LC-
MS analysis for the respectively halogenated extracts confirming the success of the 
functionalization reactions. Chemical functionalization of the extract was also confirmed 
through chemical reactions such as the ninhydrine test to seek the functionalization of 




the Bruker microTOF-QII® mass spectrometer, which enabled preliminary identification 
of derivatized metabolites. 
Secondary metabolites in a S. griseus fermentation extract were successfully p-
bromobenzoylated by chemical derivatization on the crude extracts. Although similar 
derivatization experiments have been successfully carried out by other groups on a 
selected pool of known secondary metabolites 227-229, this is the first instance where a 
completely random set of unknown metabolites was used in the form of microbial 
extract. This experiment was a proof-of-concept that such derivatizations can be applied 
to any randomly selected metabolite pool or microbial extracts to generate a library of 
functionalized natural products. This process can significantly increase the size of the 
library of natural products that are used in the high throughput whole-cell screening or 
for in vitro enzyme inhibition assays. A larger library consisting of wider structural and 
chemical diversity of natural products will increase the probability of finding a drug lead 
compound. 
